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Abstract 
Cerebral  ischaemia  is  a  major  cause  of  mortality  and  morbidity  globally.  Neural  stem  and 
progenitor cells (NPC) have the potential to contribute to brain repair and regeneration after an 
ischaemic event. Both endogenous and grafted NPC have been shown to migrate towards the 
ischaemic lesion, and differentiate into neurons. This thesis investigates methods of labeling and 
tracking the migration neural progenitor cells to a site of cerebral ischaemic injury, using magnetic 
resonance imaging (MRI) contrast agents and transgenic lineage tracing techniques.  
First, labeling of exogenous NPC populations was investigated, for use in cell tracking in grafting 
studies.  Cell  labeling  was  optimized  in  vitro  with  fetal  NPC  using  the  iron  oxide-based  MRI 
contrast  agent.  A  labeling  method  was  developed  using  the  FePro  contrast  agent,  which 
maximized  iron  oxide  uptake,  was  non-toxic  to  NPC,  and  did  not  interfere  with  NPC 
proliferation and differentiation. Labelled cells were then grafted into the brain after cerebral 
ischaemia, and imaged over four weeks using MRI. NPC migration was not observed in vivo, but 
an endogenous contrast evolved over time within the lesioned tissue, which presented a source of 
confounding  signal  for  cell  tracking.  Endogenous  ferric  iron  was  observed  in  the  lesion  on 
histological  sections.  Several  limitations  of  using  MRI-based  iron  oxide  contrast  agents  were 
highlighted in this study. To circumvent these limitations, we considered the development of 
gadolinium-based MRI contrast agents for cellular labeling and tracking, in collaboration with 
Imperial  College  chemistry  department.  Polymeric  Gd-DOTA  chelates  were  synthesized  and 
designed for maximal r1 relaxivity, and their relaxivity and effects on cell viability were assessed. 
Through this approach, we identified a number of candidate polymeric Gd-DOTA chelates with 
high relaxivity and low cytotoxicity for use in cellular imaging and tracking studies.  
Next, cell tracking of endogenous NPC was investigated, using MRI contrast agent and transgenic 
lineage  tracing  approaches.  A  method  of  in  situ  labeling  of  endogenous  NPC  with  the  MRI 
contrast agent FePro was developed. NPC were labeled with FePro in situ, and their normal 
migration to the olfactory bulb, where they contribute to neurogenesis, could be imaged in vivo 
and ex vivo. In a second study, the migration of NPC constitutively expressing green fluorescent 
protein (GPF) under the promoters of genes of two developmentally distinct cortical and striatal 
NPC  populations,  was  investigated  following  cerebral  ischaemia.  Both  cortical  and  striatal 
populations of NPC were observed to contribute to the migrating streams of NPC that were 
observed in the striatum after five weeks post-ischaemia.  
These studies demonstrate that MRI contrast agents offer the potential for in vivo, longitudinal 
tracking of NPC migration, in both grafted and endogenous NPC populations. Coupled with 
transgenic lineage tracing, and used in animal models of CNS injury such as cerebral ischaemia, 
labeling and tracking the  migration of NSC with MRI contrast agents can contribute to our 
understanding of NPC biology in pathological environments. 
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Introduction 
Cerebral  ischaemia  is  a  major  cause  of  mortality  and  morbidity  globally.  Neural  stem  and 
progenitor cells (NPC) are a promising therapeutic candidate for the repair and regeneration of 
the ischaemic brain. Both endogenous and grafted NPC have been shown to migrate towards the 
ischaemic lesion, and differentiate into neurons. Understanding of the mechanism of action of 
NPC in the ischaemic brain is hindered by the limited methods of in vivo tracking of their 
distribution and migration. MRI contrast agents for cellular imaging might be suitable for NPC 
labeling and monitoring in vivo following engraftment. Some studies have achieved labeling and in 
vivo monitoring. New contrast agents and labeling methods have been described that have the 
potential to improve labeling efficiency, cell viability and in vivo detection. The aim of the research 
in this thesis is to optimize NPC labeling with MRI contrast agents to increase in vivo detection 
without affecting cell viability and NPC biology, for both exogenously and endogenously labeled 
NPC populations. This thesis investigates methods of labeling and tracking the migration neural 
progenitor cells to a site of cerebral ischaemic injury, using magnetic resonance imaging (MRI) 
contrast agents and transgenic lineage tracing techniques.  
In the following chapters we will introduce the main topics discussed this thesis: cerebral ischaemia, 
neural stem cells, and magnetic resonance imaging (MRI). It is designed provide an overview of the 
literature, highlight important themes and issues relevant to the research chapters, and set the context 
within which we have approached our research aims. 
  
1.  Cerebral ischaemia  
1.1.  Overview 
Stroke is a cardiovascular disease that affects blood flow in the brain. The most common type of 
stroke is cerebral ischaemia, which occurs as a result of the reduction of blood flow in a cerebral 
artery, in most cases the middle cerebral artery, causing a decrease in oxygen and glucose availability 
to the brain, and ultimately leads to localised energy failure and cell death. Energy failure contributes 
to cytotoxic oedema and the breakdown of the blood brain barrier (BBB), leading to vascular oedema 
and  an  inflammatory  response.  Central  nervous  system  (CNS)  injury  from  cerebral  ischaemia  is 
characterised by a necrotic core surrounded by an ischaemic penumbra. Further delayed neuronal 
death can occur in the peripheral penumbra days to weeks following the initial ischaemic insult.  
The CNS has high oxygen consumption, a low level of antioxidants, little capability for glucose 
storage, and a high level of substrates for reactive oxidative species (ROS), in particular high iron 
levels  and  fatty  acid  membranes  (Hayashi  et  al.,  2003).  Together,  these  factors  make  the  CNS 
particularly sensitive to oxidative stress during cerebral ischaemia, and activate necrotic, apoptotic 
and inflammatory response pathways.   
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1.2.  Public health perspective  
Stroke is a major cause of mortality and disability worldwide: the third commonest cause of death 
after heart disease and all cancers, and the most common cause of disability. Cerebral ischaemia is the 
most  common  type  of  stroke,  comprising  70%  of  stroke  cases.  Other  types  of  stroke  include 
intracerebral haemorrhage (13%) and subarachnoid haemorrhage (6%), with approximately 10% of 
strokes of unknown cause (The Stroke Association, 2006b). In the UK more than 130 000 people 
suffer from a stroke each year, of which one quarter result in mortality, and one third in disability 
(National Audit Office, 2005). Furthermore, there is a high risk – between 30-43% – of recurrent 
stroke within 5 years after the first stroke event, as well as a high risk of myocardial infarction.  
In the past 30 years, stroke prevalence and mortality has decreased, but at a slower rate than for 
coronary heart disease. However, the risk of death from stroke has remained constant at 25%. The 
decrease in prevalence can be attributed to the reduction in smoking rates and saturated fat intake 
since the 1970s, both risk factors for stroke.  
The risk factors for stroke are similar to those of other cardiovascular diseases: older age, male sex, 
smoking, a diet high in saturated fat, high blood pressure and serum cholesterol levels, obesity, 
diabetes, alcohol and low physical activity levels. Blood pressure is a causal risk factor for stroke, and 
is associated with 50% of all ischaemic strokes.  Smoking accounts for 10% of strokes: smokers are at 
two  to four times  greater risk  of  stroke than  non-smokers,  cessation  of smoking  for five  years 
reverses this difference in risk (The Stroke Association, 2006a). Though these are preventable risks, 
in the UK the public awareness for these risk factors, and how to manage them, is low.  
A Western lifestyle might be associated with increased cardiovascular disease risk. A reduction in 
smoking  rates  and  saturated  fat  intake  has  contributed  to  the  declining  mortality  rates  from 
cardiovascular  disease  since  the  1970s,  however  a  reduction  in  physical  activity  and  increase  in 
obesity and diabetes over the same period may have slowed the decline, and may cause an increase in 
prevalence in the future (Mokdad et al., 2003). Japan has the lowest incidence of cardiovascular 
disease  of  high  income  countries. In  a study of Japanese  emigrants, Robertson et  al  found  that 
Japanese emigrating to the US were at increased risk of cardiovascular disease than those remaining 
in Japan (Robertson et al., 1977). Conversely, developing nations adopting Western lifestyle and 
dietary risk factors associated with economic development – such as urbanisation, tobacco use, a high 
fat diet, are experiencing an increase in cardiovascular disease prevalence, as well as diabetes, obesity 
and high blood pressure. For example, smoking rates are extremely high in China, where 60% of men 
and 4% of women smoke – over 300 million smokers. Globally, two thirds of stroke mortality now 
occurs in developing countries (The Stroke Association, 2006), and rates are higher in urban areas.  
Socioeconomic status is another strong indicator of cardiovascular disease risk. There is an inverse 
relationship  between  social  status  and  stroke risk,  where  risk  decreases  with  income  in  a  ‘dose- 
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dependent’ effect (The Stroke Association, 2006), which suggests that the social environment is a 
determinant  of  risk.  This  is  supported  by  the  Whitehall  study,  which  found  that  cardiovascular 
disease  risk  was  inversely  related  to  employment  grade  in  civil  servants  (Brunner  et  al.,  1993; 
Hemingway et al., 2000; Marmot et al., 1991). This health inequality has also been demonstrated in 
terms of the reduction in cardiovascular disease prevalence – while the prevalence of cardiovascular 
disease  has  decreased  since  the  1970s,  the  majority  of  the  decrease  has  occurred  in  higher 
socioeconomic groups, with almost no difference in prevalence in low socioeconomic class. Even at 
the global level, socioeconomic factors influence stroke risk. National per capita income is a strong 
predictor of stroke mortality and morbidity (Johnston et al., 2009). 
Of perhaps greatest concern is the increasing risk of stroke with advancing age. Over 80% of strokes 
occur in those aged 65 or above, and 56% occur over 75 years of age. The population of the UK is 
ageing, and life expectancy is also increasing. The Office of Health Economics estimates that by mid-
century, the percentage of UK citizens over 65 years of age will increase to 25% of the population, 
compared to 15.7% in 2006 and 15% in 1981. As life expectancy is also increasing, the growing 
number of people above 65 will live longer, and are therefore at greater risk of a number of diseases 
including stroke and other cardiovascular diseases for a longer period of life. The result is that the 
overall  health  burden  to  the  NHS  is  growing  quickly  as  the  population  ages.  Reducing  risk  of 
cardiovascular disease in the population, and maintaining health into old age, is therefore a major 
health priority, in order to reduce the health burden of stroke or even maintain it at current levels. 
But there are also great opportunities for the development of novel treatments for stroke patients, 
which is discussed in the following sections, and investigated further in this thesis.  
 
1.3.  Clinical perspective 
The health burden of stroke in the UK is already large. Approximately 450 000 people are living 
disabled from stroke in England (National Audit Office, 2005), and only 5-9% of stroke patients are 
fully independent one year after stroke. This represents a huge cost to the NHS and wider economy: 
£2.8 billion in direct costs to the NHS, and £2.4 billion in additional care costs, such as nursing 
home and community care, annually, or £15 000 per person for 5 years of direct care, rising to £29 
000 to include additional care costs. This is greater than the costs associated with coronary heart 
disease. One quarter of all long-term hospital beds, and one fifth of acute beds, are occupied by 
stroke patients – the largest of any patient group. The average length of stay in a hospital is 28 days 
after stroke, but there is high variability among hospitals across the UK (National Audit Office, 
2005).  
There is clear evidence that appropriate clinical management of stroke and effective care can improve 
stroke  outcome,  reducing  death,  disability  and  complications  from  stroke  (Royal  College  of 
Physicians, 2007). Access to an acute stroke services in hospitals is linked to recovery from stroke 
(National Audit Office, 2005), and increasing the number of stroke units in hospitals is estimated to  
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have saved the NHS £82 million (The Stroke Association, 2006). In the UK, 91% of hospitals have a 
stroke unit, and 50% have an acute stroke unit. However, only 65% of stroke patients are treated in 
stroke unit, and only 10% of patients are admitted directly to a stroke unit (within four hours of 
admission)  (Royal  College  of  Physicians,  2007). These  data  present  clear  implications  for stroke 
outcome, as the only effective intervention requires treatment within three hours of stroke onset. 
Furthermore, 75% of patients who experienced a mild stroke or transient ischaemic attack (TIA) 
were not treated in a stroke unit. Treating patients with minor stroke or TIA in specialist units has 
been  shown  to reduce  hospital  admissions  for recurrent  stroke,  patient  disability,  and  ultimately 
healthcare costs (Luengo-Fernandez et al., 2009). As this group is at high risk of having a recurrent 
stroke, lack of access to a stroke unit may also miss opportunity for prevention.  
Clinical guidelines recommend that all patients with acute stroke should have a brain scan – magnetic 
resonance imaging (MRI) or computed tomography (CT) – within 24 hours of onset of symptoms, 
for stroke subtype diagnosis before treatment (Department of Health, 2007). Currently, most patients 
wait 48 hours on average (National Audit Office 2005), and only 9% have access to MRI or CT 
within  three  hours  of  admission  (Royal  College  of  Physicians,  2007).  The  most  cost-effective 
management of stroke would include scanning all stroke patients immediately (National Audit Office, 
2005).  
Currently  the  only  approved  intervention  that  improves  outcome  for  cerebral  ischaemia  is  the 
thrombolysis drug tissue plasminogen activator (tPA), which requires diagnosis of cerebral ischaemia 
and rtPA treatment within 3 hours of the ischaemic event. This treatment option is not currently 
routine in the NHS, with fewer than 1% of patients receiving rtPA treatment. This is partly due to 
clinical management, access to imaging facilities and radiologists, as well as a lack of public awareness 
of stroke as a medical emergency. In Australia, 9% of stroke patients are treated with rtPA, of which 
40% make a full recovery from stroke, which represents a saving of £16 million in rehabilitation and 
care costs.  
The middle cerebral artery (MCA) supplies a large portion of the cortex, including the frontal, parietal 
and temporal lobes, as well as the basal ganglia, posterior and anterior internal capsules. As such, 
occlusion  of  the  MCA  and  resulting  cerebral  ischaemia  leads  to  diverse  neurological  sequelae. 
Disability from stroke includes paralysis, speech impediments, aphasia, dysphagia, reduced mobility 
and  locomotion,  reduced  motor  control  including  hemiplegia  or  hemiparesis,  memory  loss  and 
dementia,  urinary  incontinence,  and  depression.  Long  term  care  for  stroke  is  focussed  around 
rehabilitation, and can include physiotherapy; speech therapy; and occupational therapy. Dieticians 
and psychologists may also be involved in long term care, to reduce lifestyle and diet risk factors 
associated with recurrent stroke, and to address mental health issues, respectively.  
There is an urgent need for improved stroke care. A coordinated approach of stroke risk prevention, 
improved clinical management, and drug development will be required to reduce the health burden 
of stroke. Stroke prevention and reduced exposure to risk factors will lower stroke incidence in the  
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population, and integrated clinical and social care management can improve outcome, reducing death 
and disability. There is also huge scope for development of treatments that will improve neurological 
outcome  after  stroke,  however  to  date  there  have  been  few  successful  drug  developments. 
Regenerative medicine may provide an alternative approach to neuroregeneration, which is discussed 
in the following sections.   
 
1.4.  Acute ischaemia 
In the brain, reduced cerebral blood flow (CBF) leads to energy failure and necrosis in neurons. The 
necrotic core of an ischaemic lesion develops via acute excitotoxic events, accumulation of toxic 
metabolites  and  mitrochondrial  dysfunction  (Durukan  and  Tatlisumak,  2007).  In  neurons, 
excitotoxicity  occurs  as  energy-dependent  functions  fail  in  the  absence  of  glucose  and  oxygen 
(Sugawara  et  al.,  2004).  Energy  failure  leads  to  the  abnormal  depolarisation  of  the  neuronal 
membrane, activation of voltage-gated calcium channels, and release of neurotransmitters into the 
extrasynaptic  space.  Extrasynaptic  glutamate  accumulates  and  can  activate  AMPA  and  NMDA 
receptors on adjacent neurons and glia, causing further Ca2+ influx into cells. This influx causes a 
disruption  in  ion  homeostasis  in  the  cell,  and  activates  intracellular signalling  pathways,  such  as 
further neurotransmitter release; activation of proteolytic enzymes to degrade the cytoskeleton and 
extracellular  matrix  (ECM);  and  the  production  of  free  radicals  such  as  superoxide,  hydrogen 
peroxide, the hydroxyl radical and nitric oxide. The disruption in ion homeostasis also results in an 
influx of water into the cell, causing cytotoxic oedema and osmotic lysis of cells. Together, these 
pathways lead to necrosis in neurons (Lai and Todd, 2006).  
Mitochondrial dysfunction in the absence of oxygen also leads to cellular necrosis. Oxidative stress 
results in the overproduction of the free radicals hydrogen peroxide and superoxide in mitochondria, 
which is normally scavenged by the superoxide dismutase (SOD) antioxidant. The free radicals can 
react with cellular components such as DNA, phospholipids, amino acids and carbohydrates, causing 
the rupture of mitochondria, release of proapoptotic molecules (Mergenthaler et al., 2004), and at 
high concentrations cell disintegration (Sugawara et al., 2004). Free radical production is an important 
contributor to CNS damage following ischaemia: in transgenic mice, overexpression of SOD has 
been shown to be neuroprotective in cerebral ischaemia, whereas SOD deletion increases ischaemic 
infarct size (Sugawara et al., 2004).  
 
1.5.  Inflammatory mediators in ischaemia 
A  number  of  pro-inflammatory  cytokines,  chemokines,  growth  factors  and  extracellular  matrix 
(ECM) proteins are upregulated and activated following cerebral ischaemia. These can persist for 
hours to days, and contribute to the change in CNS environment following stroke. As such, they may 
mediate  endogenous  or  engrafted  neural  stem  and  progenitor  cell  (NPC)  behaviour  following  
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ischaemia, which will be discussed further in Chapters 4 and 7.  
Pro-inflammatory  cytokines  are  upregulated  during  ischaemia,  and  are  associated  with  neuronal 
death. Interleukin (IL)-1β, IL-6 and TNF-α are upregulated, stimulating upregulation of P- and E-
selectin  cell  adhesion  molecules  in  endothelial  cells  (Huang  et  al.,  2006).  P-  and  E-selectin  are 
initiators  of  the  peripheral  inflammatory  cascade,  and  promote  leukocyte  adherence  to  the 
endothelium and infiltration into the brain parenchyma (Huang et al., 2006). Membrane proteins of 
the integrin family modify the basal lamina and ECM, disrupting the BBB and further promoting the 
inflammatory cascade (Huang et al., 2006; Nawashiro et al., 1997). Endothelial cells express vascular 
cell  adhesion  molecule  VCAM-1  and  ICAM-1,  with  which  β-integrin-expressing  leukocytes  also 
interact  (Mergenthaler  et  al.,  2004).  Pharmacoogical  inhibition  of  ICAM-1  blocks  leukocyte 
infiltration, and reduces ischaemic infarct volume (Soriano et al., 1996). Overexpression of TNF-α 
can  exacerbate  ischaemic  damage,  whereas  pharmacological  inhibition  decreases  infarct  volume 
(Wang et al., 2007a).  
Anti-inflammatory cytokines involved in the acute inflammatory response include TGF-β, IL-10 and 
MCP-1, which downregulate inflammation and are neuroprotective (Mergenthaler et al., 2004).  
Infiltration of leukocytes, such as neutrophils and monocytes, across the vascular endothelium into 
the  brain  parenchyma  occurs  as  early  as  30  minutes  following  ischaemia  (Huang  et  al.,  2006). 
Leukocytes contribute to microvessel obstruction, edema, tissue infarction and necrosis, independent 
of  neuronal  excitotoxicity and  mitochondrial  dysfunction.  Neutrophils  also  express selectins  and 
glycoproteins that mediate endothelial-leukocyte interactions. They release free radicals and matrix 
metalloproteases which contribute to tissue infarction (Huang et al., 2006).  
Chemokines are cytokines that promote chemotaxis and recruitment of immune cells.  Following 
ischaemia, these are released by neurons and glia into the interstitial space and cerebrospinal fluid 
(CSF) and influence the recruitment of microglia and macrophages to the injury site (Lai and Todd, 
2006; Wang et al., 2007a). The neurotrophin brain-derived neurotrophic factor (BDNF) is transiently 
expressed in neurons and microglia following ischaemia, and exogenously administered BDNF can 
decrease infarct volume (Lai and Todd, 2006; Benraiss et al., 2001; Pencea et al., 2001b). Microglia 
upregulate epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), 
and platelet-derived growth factor (PDGF) following ischaemia, and exogenous administration of 
VEGF can rescue neurons from ischaemic damage (Kuhn et al., 1997).  
Matrix metalloproteases (MMP) are Zn2+ endopeptidases that primarily modulate ECM homeostasis 
(Gasche et al., 2006). Following ischaemia, MMPs are involved in the inflammatory response, BBB 
disruption, and ECM remodelling through enzymatic degradation of basal lamina and ECM proteins 
(del Zoppo et al., 2007; Asahi et al., 2001; Kamada et al., 2007; Tejima et al., 2007). MMP activity 
may also contribute to hemorrhagic transformation (Gasche et al., 2006) and regulation of neuronal 
death (Cunningham et al., 2005). Neurons and astrocytes produce pro-MMP that can be activated 
following ischaemia. MMP-2 is activated immediately during ischaemia, and its expression overlaps  
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the area of necrotic core, whereas MMP-9 is activated from 3-24 h post-ischaemia.  
Inhibition  of  MMP-9  following  ischaemia  exacerbates  infarct  volume,  reduces  neurovascular 
remodelling,  and  reduced  functional  recovery  from  ischaemia  (Zhao  2006).  Administration  of 
exogenous VEGF partially attenuates the increase in lesion volume from MMP inhibition (Zhao et 
al.,  2006).  ECM  remodelling  through  MMP  activity  may  contribute  to  tissue  regeneration  and 
neurogenesis, and facilitate cell migration.  
 
1.6.  Cellular responses to cerebral ischaemia 
Early  ischaemic  events  such  as  blood  brain  barrier  (BBB)  breakdown  create  a  hypoosmotic 
environment around the vasculature as water moves into the brain parenchyma, which is known as 
vasogenic oedema (Panickar and Norenberg, 2005). In vitro, hypoosmotic conditions are sufficient to 
induce reactive astrocytosis, which is characterised by astrocyte hypertrophy; fibrous morphology, 
proliferation (Faulkner et al., 2004), migration, and upregulation of the intermediate filament GFAP 
in astrocytes (Panickar and Norenberg, 2005). Proliferation and hypertrophy begins within minutes 
of ischaemia and peaks at two weeks post-ischaemia (Panickar and Norenberg, 2005).  
 
1.6.1.  Reactive astrocytes 
Reactive astrocytes contain the area of inflammation and prevent the spread of injury, by demarcating 
and surrounding ischaemic tissue, separating the inflammatory response from viable neural tissue. 
Reactive astrocytes form scar tissue with fibroblasts (Pekny and Nilsson, 2005). They release taurine, 
which reduces local tissue oedema, produce the antioxidant glutathione (Pekny and Nilsson, 2005), 
and  secrete  VEGF,  which  is  neuroprotective  following  ischaemia.  In  transgenic  models,  GFAP 
deletion prevents reactive astrocytosis, and increases infarct volume, decreases local cerebral blood 
flow (CBF) and increases cytotoxic oedema following ischaemia. There is no glial scar formation, no 
restoration  of  the  BBB,  and  no  containment  of  inflammation  These  data  suggests  that  reactive 
astrocytes have a protective role following cerebral ischaemia.  
However, reactive astrocytes may also exacerbate tissue damage and inhibit axon regeneration via the 
formation of the glial scar (Sofroniew, 2005). Hyper-reactive astrocytes contribute to inflammation 
by producing nitric oxide (NO) and reactive oxygen species (ROS). Gap junctions in astrocytes may 
also have the negative effect of propagating inflammatory damage though distal communication with 
astrocytes in non-ischaemic regions (Panickar and Norenberg, 2005).  
 
1.6.2.  Activated microglia 
Microglial activity may be both protective and damaging following cerebral ischaemia, and microglia  
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interact with neural stem and progenitor cells (NPC) in the normal and injured brain. Understanding 
microglial activity in the ischaemic brain is therefore central to understanding the NSC response and 
lesion progression over time. The microglial contribution to the evolution of the ischaemic lesion is 
investigated in Chapter 4.  
Microglia form part of the CNS immune system. Their developmental origin is the bone marrow 
mesenchyme, and they populate the CNS during development (Aloisi, 2001; Napoli and Neumann, 
2009). There is both an endogenous microglial and peripheral macrophage response to ischaemia 
(Ladeby  et  al.,  2005b;  Ladeby  et  al.,  2005a).  Activated  microglia  and  macrophages  are 
morphologically and immunologically equivalent, and behave as a single cell type following ischaemia 
(Ekdahl et al., 2009). Macrophages have been distinguished from microglia experimentally by bone 
marrow irradiation and GFP bone marrow transplantation, where repopulated peripheral blood cells 
express GFP and resident microglia do not (Tanaka et al., 2003). Priller et al estimate that peripheral 
macrophages account for 1/3 of the activated microglial population (Priller et al., 2001). Microglia 
represent  the  first  immune  response  against  injury,  preceding  the  infiltration  of  peripheral 
macrophages and leukocytes (Tanaka et al., 2003; Schilling et al., 2003). Microglia are activated within 
minutes of cerebral ischaemia onset, whereas macrophages infiltration peaks at 24-28 hours post-
ischaemia (Jander et al., 2007; Kleinschnitz et al., 2003; Schilling et al., 2003). Macrophage/microglia 
remain at the ischaemic boundary for weeks to months (Ekdahl et al., 2009).  
Activated microglia take on an amoeboid morphology, migrate to sites of injury and upregulate 
inflammatory markers in response to cerebral ischaemia. Their major role following ischaemia is the 
mediation of the local inflammatory response and programmed cell death (Lai and Todd, 2006). 
Activated  microglia  act  as  sensors  of  excitotoxicity  and  necrosis  through  the  upregulation  of 
glutamate transporter 1 and ATP receptor, and synthesise and release a combination of cytokines, 
chemokines and growth factors such as BDNF and GDNF (Shaked et al., 2005). Microlia proliferate 
after ischaemia (Flugel et al., 2001; Djukic et al., 2006; Ajami et al., 2007). They respond to soluble 
factors and the loss of neuronal input following ischaemia by migration toward the lesion (Ekdahl et 
al., 2009; Hanisch and Kettenmann, 2007).  
Microglia can also become overactivated in response to injury, and have been implicated in secondary 
delayed neuronal death in the penumbra (Block and Hong, 2007). Overactivated microglia increase 
nitric oxide (NO) and TNF-α secretion, thereby increasing inflammation at the injury site (Butovsky 
et al., 2006). Inhibition of the immune response exacerbates ischaemic damage (Lalancette-Hebert et 
al.,  2007),  but  inhibition  of  microglia  by  minocyline  has  been  shown  to  be  neuroprotective 
(Yrjanheikki  et  al.,  1999).  Upregulation  of  IL-10  or  prostaglandin  E2  suppresses  the  pro-
inflammatory funtion of microglia and is also neuroprotective (Cacci et al., 2008).   
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Figure 1.6.2.1 Schematic timeline of inflammatory and protective events after cerebral 
ischaemia (modified from Durukan et al).   
 
Both  microglia  and  astrocytes  have  been  implicated  in  secondary  delayed  neuronal  death  in  the 
penumbra, which is discussed further in section 1.7, and is investigated in this thesis (Block et al., 
2007; Panickar and Norenberg, 2005). In the case of both astrocytes and microglia, a moderate, local 
inflammatory response from reactive astrocytes and activated microglia is protective in CNS injury, 
whereas  overactivation  of  astrocytes  and  microglia  propagates  the  injury.  However,  lack  of  any 
inflammatory response in the CNS also exacerbates the injury. Therefore, there is an intermediate 
level of inflammatory response that is optimal for neuroprotection. This may underlie the limited 
regenerative  capacity  of  the  mammalian  CNS,  where  the  severity  of  ischaemic  insults  leads  to 
overactivation of microglia and astrocytes, and prevents regeneration. Targeting pro-inflammatory 
cytokines and their cellular mediators may therefore have therapeutic potential. Cellular therapy may 
also  act  via  mitigating  the  inflammatory  response  and  creating  a  supportive  environment  for 
regeneration.   
 
1.7.  The penumbra and delayed neuronal death 
The penumbra can be defined as a region of ischaemic tissue peripheral to the necrotic core where 
viable neurons may be salvaged. It is therefore an important therapeutic target for CNS regeneration.  
The physiological profile of the penumbra has been characterised using a variety of methods. First 
defined in 1977 by Astrup et al, the penumbra is an area of ischaemic injury that experiences low CBF 
and residual circulation during the ischaemic event, but not the total membrane potential failure of 
neurons, where “neurons remain structurally intact but functionally inactive” and have the potential 
to be rescued with the restoration of perfusion (Astrup et al., 1977; Weinstein et al., 2004; Lo, 2008;  
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Fisher,  2004).  It  has  also  been  described  as  a  region  with  reduced  CBF,  oxygen  and  glucose 
consumption  (Ginsberg,  1990;  Powers,  1984),  ,  increased  excitotoxicity,  oxidative  stress  and 
apoptosis (Lo et al., 2005; Sharp et al., 2000). Neurons in the penumbra may become dysfunctional 
but do not undergo acute necrosis during ischaemia (Lo et al., 2005). The penumbra may later 
progress to infarction via delayed apoptosis hours to days after the ischaemic event, due to secondary 
cell damage from chronic inflammation and mild excitotoxicity (Mergenthaler et al., 2004). Therefore, 
a time window exists between the ischaemic event and latent neuronal death where cells in the 
penumbra are potentially salvageable.  
Cell protective programmes are upregulated within the penumbra (Mergenthaler et al., 2004). Heat 
shock  protein  70  (HSP70)  and  Hypoxia-inducible  factor-1  (HIF-1)  are  immediately  upregulated 
following ischaemia, and their expression overlap demarcates the penumbra(Weinstein et al., 2004b). 
The  penumbra  vasculature  is  characterised  by  vasoparalysis,  decreased  reactivity  of  vessels  and 
decreased autoregulation. There is a decreased metabolic response to neuronal activity, as well as 
decreased neuronal activity. Furthermore, reactive astrocytosis, expression of superoxide dismutase 
(SOD),  and  delayed  neuronal  death  from  apoptosis  peak  at  14  days  post  injury  (Girouard  and 
Iadecola, 2006). This indicates a slow degenerative process following the initial ischaemic insult and 
the onset of a chronic injury. 
Nestin expression is also upregulated in the penumbra, in GFAP+ reactive astrocytes (Li and Chopp, 
1999; Duggal et al., 1997; Lin et al., 1995), in a distinct GFAP- population of astrocytes (Burns et al., 
2007), and in infiltrating peripheral macrophages. Upregulation has been reported from 6 hours, 
peaking at 7 days, and persisting up to 4 weeks post-ischaemia (Duggal et al., 1997; Li and Chopp, 
1999). A small proportion of nestin+ cells have originated from the SVZ and migrated toward the 
penumbra (Burns et al., 2007). It is possible that nestin expression is linked to cell proliferation in the 
penumbra, though there are no BrdU co-labelling studies to date. Astrocyte proliferation occurs in 
the penumbra, and nestin expression may represent a recapitulation of developmental processes in 
the astrocyte population, as a mechanism of repair and regeneration (Wiese et al., 2004).  
 
1.8.  Animal models of  cerebral ischaemia 
Human stroke is typically a small vessel occlusion, or an arterial embolism. Distinctive features of 
human stroke are the presence of the ischaemic penumbra that progresses to infarction subsequent 
to the initial damage; reperfusion of the occlusion; and functional reorganisation of neuronal circuits 
affected by ischaemic damage. Animal models of cerebral ischaemia aim to mimic some or most of 
these features in mammals with similar cerebral physiology to the human.  
The Koizumi middle cerebral artery occlusion (MCAO) model is a model of focal ischaemia, which 
can be transient or permanent. It is presently the most common animal model of ischaemia(Koizumi 
J, 1986). It is this model that is used in chapters 4 and 7 to investigate cellular therapy and the  
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endogenous  neural  stem  cell  response  following  ischaemia.  To  perform the  procedure,  a  tipped 
suture is inserted into the carotid artery and advanced through the skull into the circle of Willis, 
where it occludes the MCA (Figure 1.8.1) (Durukan and Tatlisumak, 2007; Lythgoe et al., 2003). For 
a transient ischaemic injury with reperfusion, the suture occludes the MCA for a fixed amount of 
time, between 20 – 120 minutes, and is then withdrawn slowly to reperfuse and restore bloodflow to 
the occluded region. The procedure creates a volume of ischaemic injury in the ipsilateral hemisphere 
that encompasses the dorsolateral striatum and the anterior cortex, but excludes the hippocampus. 
Focal  ischaemia  requires  surgical  occlusion  of  the  MCA  because  the  circle  of  Willis  provides 
sufficient collateral blood supply to the MCA region via non-affected vessels.  
To date, most cerebral ischaemia studies are performed in the rat. The surgery is easier in a larger 
animal,  and  a  more  reproducible  lesion  can  be  achieved.  The  most  reproducible  lesions  can  be 
achieved between 60-90 minutes of occlusion, however with increasing occlusion time the volume of 
necrotic to penumbral tissue decreases, and less tissue is salvageable (Durukan and Tatlisumak, 2007). 
The MCAO surgery has also been developed in the mouse (Hata et al., 1998; Fujimura et al., 1999; 
Chen et al., 2005). While the surgery is more difficult in a smaller animal and lesion reproducibility is 
more difficult to achieve (Carmichael, 2005), the major advantage of performing surgery in mouse is 
the opportunity to study ischaemia by combining the MCAO surgery in transgenic animal models 
(Tureyen et al., 2005).  
The advantages of the Koizumi MCAO model are that it avoids the need for invasive craniotomy to 
access and occlude the MCA, it is a transient occlusion, and the animals can recover and survive 
weeks to months post-ischaemia. Many elements of the surgery can be modified: for example the 
suture width, length and coating material, and MCA occlusion time. The MCA occlusion model can 
also  be  modified  to  create  permanent  focal  ischaemia,  where  the  suture  is  not  withdrawn  after 
surgery, no reperfusion occurs, and the MCA region experiences a chronic decrease in blood flow 
(Lythgoe et al., 2003).  
The  disadvantages  are  that  the  infarct  size  can  be  variable  and  may  incorporate  the  thalamus, 
hypothalamus and substantia nigra. These structures are rarely infarcted in human, and hypothalamic 
injury may lead to hyperthermia (Durukan and Tatlisumak, 2007). Furthermore, the area of infarct in 
this model is significantly larger than in human stroke (Carmichael, 2005). Different rat and mouse 
strains have different cerebrovascular anatomy, and this may produce different infarct volumes, poor 
occlusions or subarachnoid hemorrhages, for example in the Fischer rat (Dittmar et al., 2006).  
The  Koizumi  MCAO  procedure  is  performed  under  anaesthesia,  and  this  may  itself  be 
neuroprotective (Kitano et al., 2007). Estrogen may also be neuroprotective, as female rats have 
smaller  stroke  volumes  than  male  or  ovariectomized  rats  (Alkayed  et  al.,  1998),  and  estrogen 
administration can reduce lesion volume in ovariectomized females (Rusa et al., 1999).  
A disadvantage common to all animal models of ischaemia is the lack of associated diseases which 
may  complicate  the  pathology,  which  are  common  in  the  clinical  setting:  surgery  is  typically  
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performed in young healthy animals. Apoptosis at the lesion is known to be increased in older (18 
months) rather than younger (3 months) ischaemic rats (Chen and Sun, 2007). Furthermore, this 
study  also  showed  that  post-ischaemic  neurogenesis  was  also  reduced  in  older  rats.  The  typical 
human stroke patient is of old age and may have other diseases such as atherosclerosis, diabetes or 
dementia, or conditions such as obesity and high blood pressure and cholesterol, all of which could 
complicate ischaemic pathology and patient recovery.  
Several other animal models of focal cerebral ischaemia exist. Photothrombotic ischaemia involves 
intravenous administration of a photosensitive dye – typically Rose Bengal – followed by selective 
irradiation over a specific area of cortex which activates the dye, causing endothelial damage, BBB 
disruption and ischaemia (Busza et al., 1992; Durukan and Tatlisumak, 2007). This procedure creates 
exclusively cortical lesions due to the limited penetration depth of the irradiation, and the infarct 
lacks a penumbra.  
Microembolic  and  thromboembolic  ischaemia  models  generate  heterogeneous  multifocal  lesions 
within the brain (Mayzel-Oreg et al., 2004; Papadopoulos et al., 1987; Vise et al., 1977). These models 
involve the intracarotid injection of microspheres, fibrin, fat or air emboli, silicone or collagen clots 
to produce embolism in intracranial arteries. The lesion volume and localisation is not reproducible, 
but the mechanism of infarction is similar to human stroke conditions. Following microembolism, 
the blood brain barrier breaks down immediately due to severe irritation of the vascular wall (Vise et 
al., 1977),(Vise 1977), in contrast to the human stroke where the blood brain barrier breaks down 
after several hours as a consequence of the ischaemic event.  
The  MCAO  occlusion  can  also  be  achieved  by  craniotomy  to  expose  the  MCA  and 
electrocoagulation of the artery to achieve occlusion (Clark et al., 1993; Tamura et al., 1981). While 
the reproducibility of this method is high, the occlusion is permanent, and the surgery introduces 
factors that are not common in human stroke such as exposure to air, local temperature change, and 
disruption of CSF homeostasis and intracranial pressure.  
The  spontaneously  hypertensive  rat  is  naturally  prone  to  stroke,  and  some  studies  have  been 
undertaken using this strain of rat (Nabika et al., 2004). In this rat the circle of Willis is incomplete 
and the system of compensatory collateral vessels is compromised.  
Characterisation of animal models of ischaemia and effectiveness of treatment can be assessed by 
several parameters. Lesion volume can be assessed by MRI (discussed further in section 3.5.6); TTC 
staining, or hematoxylin-eosin histology. Total lesion volume and lesion volume as a percentage of 
hemisphere volume can be expressed (Tatlisumak et al., 1998a; Tatlisumak et al., 1998b; Gerriets et 
al., 2004). The advantage of in vivo imaging modalities such as MRI is that no tissue processing or 
fixation is required prior to analysis, which can alter tissue volumes through dehydration, mounting, 
and removal from the skull.  
Ischaemic injury can also be assessed through behavioural tests such as skilled limb movements 
(Gharbawie  and  Whishaw,  2006;  Gharbawie  et  al.,  2006),  neurological  score,  beam  walking,  the  
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rotarod test or the sticky label test (Hunter et al., 2000) These tests assess the sensory and motor 
capabilities of animals and can be used as markers of functional recovery after ischaemia (Modo et 
al., 2002c).  
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Figure 1.8.1 The middle cerebral artery occlusion surgery (modified from Durukan et al.). ACA, 
anterior cerebral artery. MCA, middle cerebral artery. ICA, internal carotid artery. ECA, external carotid 
artery. CCA, common carotid artery. Green filament illustrates the tipped suture advanced to the MCA 
bifurcation, causing MCA occlusion.  
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2.  Stem cells  
2.1.  Definition 
A stem cell is a cell that has the capacity for unlimited self-renewal and the ability to terminally 
differentiate into multiple cell types. Thus, at each cell division the stem cell replicates itself; two cells 
are generated that will either commit to differentiation, or remain as stem cells. This pairing of 
continuous  cell  division  with  developmental  plasticity  is  what  defines  a  stem  cell,  and  is  the 
mechanism by which the developing embryo can give rise to a mature adult organism with multiple 
organs and cell types.   
Theories of stem cells and regeneration are historically linked. Regeneration has been observed in 
reptiles, amphibians and invertebrates for centuries, and was investigated with much interest in the 
eighteenth century at the height of the expansion of the biological sciences. Starfish limbs, newt tails 
and  eyes  were  severed  and  observed  to  re-grow  into  functional  units,  and  the  concept  of  an 
embryonal centre that could regenerate a missing limb was proposed. The isolation and study of stem 
cells  in  vitro  began  with  the  study  of  teratocarcinomas  in  the  mid-twentieth  century. 
Teratocarcinomas are spontaneously arising gonadal tumours  and are unique in that they contain 
differentiated cells as well as undifferentiated cells of all the embryonic germ layers. In vitro the 
teratocarcinomas can expand continuously. The study of these tumours gave rise to the concept that 
a single cell can proliferate and generate multiple mature cell types. The resemblance of teratomas to 
a disorganised embryo suggested a developmental origin of these cells and stimulated the search for 
the isolation of stem cells in the developing embryo (Friel et al., 2005a).   
The extent to which a stem cell can produce differentiated cells of any lineage in vivo is temporally 
and spatially regulated, and is determined by the developmental stage and the position within the 
embryo or adult organism. Stem cells derived from blastomeres can give rise to all 3 germ layers and 
placenta (Friel et al., 2005b). These cells are termed totipotent, for their capacity to generate all cells 
required for a new embryo. Cells of the inner cell mass (ICM) can give rise to endoderm, mesoderm 
and ectoderm but not placenta in vitro (Keller, 2005). These cells are termed pluripotent. Multipotent 
stem cells are somatic or adult stem cells that are developmentally restricted and can only generate 
cells of a specific lineage. Progenitor cells have a limited number of cell divisions before they will 
terminally differentiated, and are not considered true stem cells for this reason. 
Murine embryonic stem (ES) cells were first isolated and cultured from the ICM of the blastocyst 
(Friel  et  al.,  2005c),  and  only  relatively  recently  human  ES  cells  were  successfully  isolated  and 
cultured from the 8 stage pre-implantation embryo (Thomson et al., 1998). ES cells can give rise to 
endoderm, mesoderm and ectoderm in vitro, and develop into teratomas in vivo when implanted into 
immunodeficient adult mice, thus demonstrating their pluripotency (Trounson, 2005). ES cells can 
differentiate into specific lineages if prompted by specific genes, growth factors or if presented with  
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specific environmental cues. For example, ES cells transplanted into the subventricular zone of the 
normal adult brain migrate throughout the brain and differentiate into all neural lineages (Trounson, 
2005).  Developmental  pathways  regulating  cell  division,  differentiation,  and  lineage  have  been 
elucidated through the study of ES cells. Transcription factors such as Nanog, Oct4, Sox2 and BMP4 
have been identified as important regulators of self-renewal and maintaining an undifferentiated cell 
state (Friel et al., 2005d).  
Mature adult cells can also be reprogrammed to an embryonic state, to generate induced pluripotent 
stem cells. Takahashi and Yamanaka demonstrated that by introducing four key transcription factor 
genes  –  c-myc,  Oct3/4,  Sox2  and  Klf  –  to  adult  mouse  fibroblasts,  the  cells  returned  to  an 
embryonic-like state (Takahashi and Yamanaka, 2006). The authors could also create iPS cells from 
human fibroblasts (Takahashi et al., 2007). These cells are similar to ES cells, but do not require the 
destruction of an embryo for their generation. Other groups have improved this protocol to exclude 
the oncogenic c-myc gene (Yu et al., 2007), and without the use of retrovirus (Kaji et al., 2009), 
successfully generating pluripotent iPS cells.  
Stem cells exist in many mature adult organs in the mammal, including the brain. Stem cells have 
been identified in other tissues such as muscle, kidney, heart, gut, blood and skin. Hematopoietic cells 
normally give rise to mature blood cells in the adult, and are positive for markers such as CD34, c-kit 
and CD133, but not mature myeloid, lymphoid or erythrocyte markers. They can be isolated from 
the bone marrow, peripheral blood or enriched in umbilical cord blood. Mesenchymal stem cells give 
rise to cell types of the mesenchyme, including bone, cartilege, muscle, and fat. They are also derived 
from the bone marrow, and are defined as the adherent fibroblast population of white blood cells 
from the bone marrow, capable of differentiating into mesenchymal cell lineages. 
 
2.2.  Neural stem cells and neurogenesis 
This  thesis  investigates  the  activity  of  neural  stem  and  progenitor  cells  (NPC)  after  cerebral 
ischaemia, and what follows is an overview of NPC biology in the adult brain. Neural stem cells 
(NSC) are multipotential stem cells with the capacity for unlimited cell division, but whose progeny 
are  restricted  to  producing  cells  of  neural  lineage:  astrocytes,  oligodendrocytes  and  neurons. 
Neurogenesis is the process of generating new neurons, from the cell division of stem or progenitor 
cells, to commitment to a neural lineage, the migration and differentiation of the newborn cells, and 
functional integration into CNS pathways.  
NSC exist in the developing embryo and give rise to the majority of cell types in the CNS.  More 
recently, newborn neurons have been identified in the adult mammalian brain, raising the question of 
the  persistence  of  NSC  in  the  adult  CNS.  Neurogenic  regions  have  been  identified  in  the 
subventricular zone of the lateral ventricles and the subgranular zone of the hippocampus (Merkle 
and varez-Buylla, 2006; varez-Buylla and Garcia-Verdugo, 2002; varez-Buylla and Lim, 2004; Gage,  
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2000). Cells originating from these regions contribute to cell replacement in the olfactory bulb and 
hippocampus, respectively (Lois and varez-Buylla, 1993; Merkle and varez-Buylla, 2006); (Gage et al., 
1998; Gage et al., 1995). Cell division has also been reported in brain regions that are not normally 
neurogenic: the retina, spinal cord, olfactory bulbs, cerebellum, striatum and neocortex. Cells from 
the cortex, striatum, retina, and spinal cord have been shown to proliferate in vitro, and could be 
multipotent (Palmer et al., 1995; Palmer et al., 2000; Lledo et al., 2006a).  
Postnatal neurogenesis was originally suggested by Hamilton in 1902, and again by Altman in the 
1960s. In 1977 Kaplan and Hinds demonstrated that newborn neurons in the dentate gyrus can 
integrate  into  the  hippocampal  neural  network  (Kaplan  and  Hinds,  1977).  The  occurrence  of 
neurogenesis begged the question of the presence of stem cells in the adult CNS.  In the early 1990s, 
retroviral  cell  labelling  and  the  development  of  bromodeoxyuridine  facilitated  cell  tracing,  and 
Reynolds  and  Weiss  successfully  isolated  adult  NSC  (aNSC)  from  the  adult  mouse  SVZ,  and 
expanded and characterised these cells in vitro (Reynolds and Weiss, 1992; Morshead et al., 1994b). 
Adult neurogenesis has also been confirmed in primates (Pencea et al., 2001a) and humans (Bernier 
et al., 2000; Sgubin et al., 2007; Bedard and Parent, 2004).  
The function of adult neurogenesis may be an adaptive response by the brain to changes in the 
external environment or the internal state of the animal.  
Neurogenesis also occurs at the hippocampus, in the subgranular zone (SGZ) (Kaplan and Hinds, 
1977). Newborn cells migrate into the granule cell layer of the dentate gyrus, where they differentiate 
into  mature  granule  cell  neurons  and  extend  projections  into  the  hippocampal  region  CA3  and 
receive synaptic input from the entorhinal cortex (van et al., 2002). Cell death in the granule cell layer 
occurs at the same rate as neurogenesis, which suggests a controlled feedback exists between the DG 
and SGZ (Gage, 2000).  
 
2.3.  Development of  adult neural stem cells  
Through lineage tracing studies, it has been suggested that the developmental origin of the SVZ, the 
main proliferative region in the adult mammalian CNS, is the neuroepithelium (Malatesta et al., 2003; 
Merkle et al., 2004; Noctor et al., 2002b). In the embryo, this sheet of cells committed to neural 
lineage  folds  to  develop  into  the  neural  tube,  creating  a  ventricular  space  in  the  centre,  and  a 
surrounding  germinative  ventricular  zone  (Bonfanti  and  Peretto,  2007a).  Cell  division  occurs  by 
nuclear translocation, where mitosis takes place at the ventricle, the nuclei migrate to the pial surface 
during interphase, and return to the ventricular surface during subsequent rounds of mitosis. NSC at 
the ventricle extend processes that contact the pial surface. Symmetrical cell division results in the 
generation of two stem cells and leads to an exponential increase in cells and growth. Asymmetrical 
cell  division  generates  a  daughter  cell  that  migrates  away  from  the  ventricle  into  the  CNS  and 
differentiates into a mature cell (Merkle and varez-Buylla, 2006).   
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Radial glia appear in the ventricular zone of the embryonic CNS during cortical neurogenesis, and 
have been identified as the neural stem cells that give rise to the majority of cells in the embryonic 
forebrain (Malatesta et al., 2003; Noctor et al., 2002a; Merkle et al., 2004). Like neuroepithelial cells, 
they also have projections to the pial surface and contact the ventricle. During cortical neurogenesis, 
radial glia support the migration of newborn neurons by providing a scaffold for radial migration 
(Ghashghaei  et  al.,  2007b).  Following  neurogenesis,  radial  glia  generate  astrocytes  that  migrate 
throughout the cortex (Merkle and varez-Buylla, 2006), and themselves differentiate into astrocytes 
postnatally (Figure 2.1.1.i). In addition, some radial glia persist into adulthood and give rise to the 
population of neural stem cells in the adult SVZ.  
It  has  recently  been  reported  that  SVZ  stem  cells  have  a  mixed  developmental  origin,  with  a 
population  derived  from  the  embryonic  cortex  and  a  population  derived  from  the  embryonic 
striatum  (Young  et  al.,  2007b;  Willaime-Morawek  and  van  der,  2008).  Stem  cells  derived  from 
embryonic cortex, expressing the Emx1 transcription factor, migrate ventrally and intermix with 
striatal stem cell population, expressing the Gsh2 transcription factor. In the adult, Emx1-derived 
NSC populate the dorsolateral corner of the SVZ, and Gsh2-derived stem cells reside in both the 
lateral wall and dorsolateral corner. The two populations contribute differentially to neurogenesis at 
the olfactory bulb, where Gsh2-derived NSC give rise to all calbindin-positive and the majority of 
tyrosine-hydroxylase-positive interneurons, whereas Emx1-derived NSC give rise to the majority of 
calretinin-positive interneurons (Young et al., 2007c). The contribution of these NSC populations to 
neurogenesis post-ischaemia is investigated further in Chapter 7.  
 
 
Figure 2.3.1 Development of adult neural stem cells (modified from Young et al (top) and Ihrie et 
al (bottom)). Top, transcription factor expression in the periventricular zone at embryonic stage 12, 
and anatomical localisation of adult SVZ stem cell populations derived from embryonic transcription 
factor regions. Bottom, neural crest neural stem cell (left); radial glial cell at embryonic stage 14  
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(middle), and adult subventricular zone (right). Blue, stem cell. Green, progenitor cell. Red, migrating 
neuroblast. Grey, ependymal cell. Yellow, astrocyte.  
 
2.4.  SVZ anatomy 
The cytoarchitecture of the SVZ bears resemblance to the ventricular zone of the developing CNS, 
and is likely to originate from this structure. Cell types in the SVZ have been well characterised. 
GFAP-expressing  astrocytes  (type  B  cells)  are  neural  stem  cells  that  generate  transit-amplifying 
progenitor  cells  (type  C  cells),  which  then  generate  postmitotic  migrating  neuroblasts  (type  A 
cells)(Fig 1.1.iii)(Merkle and varez-Buylla, 2006; Lim et al., 2007). 
Doetsch et al identified the population of GFAP-positive(+) astrocytes (type B) as the stem cell pool 
in the SVZ (Doetsch et al., 1999a). These cells have several characteristics in common with radial glia 
of the developing cortex. Type B cells extend processes that contact the ventricle, and both they and 
radial glia express GFAP and the intermediate filament protein nestin (Doetsch, 2003f; Doetsch, 
2003c). Type B astrocytes undergo asymmetrical cell division and generate daughter cells that are type 
C  transit-amplifying  cells  (Doetsch,  2003b;  Doetsch  et  al.,  1999a).  In  the  normal  brain,  this 
population is quiescent with a cell cycle of 15 days (Chiasson et al., 1999). Following ablation of 
rapidly-dividing cells in the SVZ by arabinofuranoside-C (Ara-C), type B cells are the only remaining 
proliferative cell type, and over the course of weeks the SVZ is repopulated with type C and type A 
cells (Doetsch et al., 1999a). Furthermore, genetic tagging of type B cells demonstrates that type C 
and type A cells are derived from type B stem cells (Doetsch et al., 1999a). While 12% of SVZ cells 
are GFAP+, only 1% of SVZ cells are capable of proliferating and generating neurospheres in vitro 
(Bonfanti and Peretto, 2007b). This suggests either that not all GFAP+ cells are stem cells, or that in 
vitro culture conditions are suboptimal for stem cell proliferation. Other markers expressed by SVZ 
NSC include nestin, vimentin, Sox2, Pax6 and CD133. 
Type C progenitor cells are a fast-dividing population (Noctor et al., 2004) with a 12hr cell cycle 
(Chiasson et al., 1999). They express the markers Dlx2 and nestin, but not GFAP (Doetsch, 2003e). 
They also express the EGF receptor (EGFR) and may therefore be important in regulating the rate 
of proliferation in the SVZ (Doetsch, 2003a). Type C cells generate type A migrating neuroblasts. 
Type A cells express Dlx2, doublecortin (DCX), and polysialated neural cell adhesion molecule (PSA-
NCAM)(Ming  and  Song,  2005).  Neuroblasts  migrate  away  from  the  SVZ,  through  the  rostral 
migratory stream (RMS) to the olfactory bulb (OB), where they differentiate into granule cells and 
periglomerular inhibitory interneurons, over 90% of which are GABAergic (Ghashghaei et al., 2007c; 
Lledo et al., 2008). In the normal brain, 30 000 neuroblasts are generated per day in mice (Lledo et 
al., 2006b). Neuroblasts can migrate to the OB in 6 days and fully differentiate within 14 days from 
their birth (Lledo et al., 2006c).  
Ependymal cells are derived from radial glia (Spassky et al., 2005), form a single layer of ciliated cells 
around the ventricle and express nestin, an early neural marker (Chiasson et al., 1999). Limited cell  
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division of this population in vivo, as well as limited expansion in vitro has been reported. However, 
ependymal cells are not multipotential and thus are not the source of stem cells in the SVZ (Chiasson 
et  al.,  1999).  Ependymal  cells  may  support  neurogenesis  in  the  SVZ  through the  expression  of 
Noggin (Lim et al., 2000). Inhibition of the Noggin antagonist BMP4 increases the GFAP+ stem cell 
pool at the SVZ, and overexpression of BMP4 increases glial differentiation (Bonaguidi et al., 2005).  
 
Figure 2.4.1 SVZ Anatomy. Top, sagittal section of rodent brain. Red areas denote regions of 
neurogenesis in the adult brain. LV, lateral ventricle. SVZ, subventricular zone. SGZ, subgranular zone. 
DG, dentate gyrus. RMS, rostral migratory stream. OB, olfactory bulb. Bottom, coronal section of the 
lateral ventricles (yellow), and SVZ cytoarchitecture (inset). B, GFAP+ SVZ stem cell astrocytes. C, 
transit-amplifying progenitor cells. A, migrating neuroblasts. E, ependymal cells.  
 
2.5.  The subventricular zone niche 
The SVZ has a unique capacity for neurogenesis in the adult CNS and has been identified as a 
neurogenic  niche  (Merkle  and  varez-Buylla,  2006;  Lim  et  al.,  2007;  Gage,  2000).  This  begs  the 
question  whether  there  is  a  unique  population  of  cells  in  the  SVZ  capable  of  neurogenesis,  or 
whether the environment is uniquely permissive for neurogenesis? It is likely that the answer is both, 
however there is strong evidence that the cytoarchitecture and extracellular environment of the SVZ 
play a critical role in enabling neurogenesis (Palmer et al., 2000; Palmer et al., 1995; Palmer et al., 
1999b; Song et al., 2002), as SVZ-derived aNSC transplanted into non-neurogenic regions in the 
adult CNS are gliogenic and incapable of neurogenesis (Gage et al., 1995).  
The  cytoarchitecture  of  the  SVZ  bears  resemblance  to  the  neurogenic  ventricular  zone  of  the  
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developing  CNS,  and  originates  from  this  structure  developmentally.  The  mammalian  SVZ  may 
represent a developmental artefact persisting into adulthood, with a quiescent population of neural 
stem cells of embryonic origin. In avians and reptiles, the ventricular zone persists into adulthood, 
and ventricular radial glia are capable of neurogenesis throughout adult life (Lindsey and Tropepe, 
2006).  
These neural stem cells (B cells) have been identified as being GFAP-expressing astrocytes (Doetsch 
et al., 1999a). Astrocytes in non-neurogenic regions can proliferate and generate new glia in the 
normal brain (Doetsch, 2003), and express SSEA-1, an early embryonic marker of cell proliferation 
(Doetsch, 2003). In vitro, astrocytes proliferate when exposed to growth factors. It is possible that the 
SVZ  provides  a  permissive  environment  for  astrocytes,  which  are  capable  of  proliferation  and 
gliogenesis in other brain regions, to undergo neurogenesis, rather than there being a subpopulation 
of astrocytes unique to the SVZ. 
The  non-NSC  astrocytes  in  the  SVZ  may  enable  neurogenesis  through  the  expression  of 
developmental genes and maintenance of a germinal niche. Some astrocytes span the SVZ and are in 
contact  with  both  the  CSF  and  vasculature,  suggesting  that  they  modulate  neurogenesis  by 
monitoring these environments. Wnt signalling by astrocytes promotes neuronal fate specification of 
NSC in vitro and in vivo (Lledo, 2006). Sonic hedgehog (Shh) is secreted by SVZ astrocytes, and 
stimulates  NSC  proliferation  (Jiao  and  Chen,  2008).  Application  of  exogenous  Shh  induces 
neurogenesis in the normally non-neurogenic cortex (Jiao and Chen, 2008). Astrocytes derived from 
the SVZ increase neurogenesis in cultured aNSC in vitro, whereas astrocytes derived from spinal cord 
do not (Doetsch, 2003).  
Some studies have found that ependymal cells are capable of cell proliferation, and suggest that this 
cell  type  may  be  a  candidate  neural  stem  cell  in  the  SVZ.  Johansson  et  al  demonstrated  that 
ependymal  cells  labeled  with  intraventricularly-injected  DiI  contributed  to  neurogenesis  at  the 
olfactory bulb (Johansson et al, 1999). The authors also demonstrated that the DiI+ ependymal cells 
could generate neurospheres in vitro. Some GFAP+ NSC are known to contact the ventricular 
surface, and may have incorporated the DiI label as well. Other studies have found that ependymal 
cells  express  the  stem  cell  marker  CD133,  and  demonstrate  that  CD133+  cells  contribute  to 
neurogenesis at the OB and can generate neurospheres (Coskun et al, 2008). However in this study 
the authors used CD133 and not an ependymal-specific marker, and other studies have found that 
CD133 is expressed in GFAP+ NSC (Mirzadeh et al, 2008). Other studies indicate that ependymal 
cells cannot generate neurospheres indefinitely, and that ependymal-derived neurospheres do not 
differentiate into neurons, oligodendrocytes and glia (Chiasson et al, 1999). Spassky et al did not find 
evidence of ependymal cell proliferation in the adult brain (Spassky et al, 2005). Not all ependymal or 
GFAP+ cells are SVZ NSC. Ependymal cells and GFAP+ NSC are both derived from radial glia 
developmentally, and SVZ NSC share many properties with radial glial cells. There is also evidence 
that ependymal cells respond to cerebral ischaemia injury by proliferation (Zhang et al, 2007).   
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A ‘vascular plexus’ exists at the SVZ, where blood vessels are in close association with astrocytes and 
neuroblasts (Shen et al., 2008). The blood brain barrier is partially open at the SVZ, where regions of 
vasculature  do  not  have  astrocytic  endfeet  and  small  molecules  (<400  Da)  can  enter  the  brain 
(Tavazoie  et  al.,  2008).  This  has  led  to  the  theory  of  a  neurovascular  niche  that  promotes 
neurogenesis  in  the  SVZ  (Palmer  et  al.,  2000);  (Lim  et  al.,  2007).  Endothelial  cells  promote 
neurogenesis in SVZ-derived aNSC in vitro (Lledo et al., 2006d). Endothelial cells secrete growth 
factors important for neurogenesis including fibroblast growth factor-2 (FGF-2), epidermal growth 
factor  (EGF),  vascular  endothelial  growth  factor  (VEGF),  brain-derived  neurotrophic  factor 
(BDNF), and p-derived growth factor (PDGF)(Doetsch, 2003i).  
A similar vasculature exists in the RMS, where blood vessels are oriented in parallel to the migratory 
neuroblasts (Shen et al., 2008), and the RMS may also be a neurogenic niche (Mendoza-Torreblanca 
2008). Astrocytes in the RMS have been shown to proliferate, migrate and differentiate into olfactory 
bulb granule and periglomerular interneurons (Alonso et al., 2008).  
The extracellular matrix (ECM) proteins in the SVZ and surrounding blood vessels can activate, 
cleave, and sequester signalling molecules and thus play a role in regulating neurogenesis.  Progenitor 
cells and migrating neuroblasts express the laminin receptor ab1-integrin and interact with ECM 
proteins including tenascin C and laminin (Ghashghaei et al., 2007d). Blocking αβ1-integrin inhibits 
NSC adherence to endothelial cells, and reduces cell proliferation, demonstrating the effect of the 
ECM and vasculature on SVZ neurogenesis (Shen et al., 2008). Tenascin C is implicated in niche 
maintenance through control of growth factor signalling and EGFR expression, and the modulation 
of sensitivity to growth factors(Garcion et al., 2004).  Heparin sulphate proteoglycans (HSPG) bind 
to growth factors and migratory guidance cues such as the slit proteins (Ghashghaei et al., 2007e), 
and thus play an integral role in regulating cell proliferation and migration. 
The  ECM  environment  outside  of  the  SVZ  may  be  anti-neurogenic.  The  oligodendrocyte 
transcription  factor  and  marker  Olig2  may  be  a  repressor  of  neurogenesis,  and  blocking  Olig2 
expression has been shown to enhance neurogenesis following injury (Buffo et al., 2005). Ephrin-A2 
and A3 is expressed in astrocytes outside of SVZ niche, and is inhibitory to neurogenesis. In Ephrin-
A2 and -A3 knock out transgenic mice, neurogenesis occurs throughout  the CNS (Jiao et al., 2008).  
 
2.6.  Neuroblast migration  
Neuroblast migration to the olfactory bulb (OB) is investigated in Chapter 6. Migration along the 
RMS occurs within 2 weeks of neuroblast generation at the SVZ, and differentiation at the olfactory 
bulb  between  15-45  days  (Petreanu  and  varez-Buylla,  2002).  Using  3H-thymidine  labelling  of 
newborn  neuroblasts, the  authors  also  observed  a  decrease  of  50%  of  newborn neurons  in  the 
olfactory bulb at 15-45 days, suggesting that apoptosis occurs at the differentiation phase.  
Type A cells orient themselves away from the SVZ, forming a leading process. Chains of neuroblasts  
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migrate within a glial tube through the RMS (Figure 2.4.1)(Lois et al., 1996; Lois and varez-Buylla, 
1994). While neuroblasts are primarily postmitotic, they are capable of proliferation when in contact 
with astrocytes in the glial tube (Gritti et al., 2002).  
DCX is a microtubule-associated protein required for migration along the RMS. Mutation in the 
DCX gene results in slow migration, but does not affect the orientation of neuroblasts or their 
responsiveness  to  cues  (Kappeler  et  al.,  2006).  Deletion  of  DCX  does  not  result  in  abnormal 
migration to the OB, suggesting that there may be some functional redundancy of structural proteins 
involved in migration (Ocbina et al., 2006). DCX deletion does result in morphologic defects in 
neuroblasts and delayed migration through the RMS (Koizumi et al., 2006). PSA-NCAM regulates 
the  organisation  of  chain  migration  and  contact  between  neuroblasts  (Ghashghaei  et  al.,  2007).  
Deletion  of  the  PSA-NCAM  gene  decreases  the  size  of  the  OB  through  a  decrease  in  cell 
replacement by neuroblasts (Gage, 2000b). In PSA-NCAM-mutant mice, odor discrimination but not 
odor detection was disrupted, indicating a functional role for neurogenesis at the OB (Gheusi et al., 
2000).  
Repulsive and attractive guidance cues are likely to influence neuroblast migration. Removal of the 
OB does not alter neuroblast migration (Kirschenbaum et al., 1999), therefore attractive cues from 
the OB are not the primary driving force for migration. Neurogenesis is not reduced or disrupted in 
anosmic mice (Petreanu and varez-Buylla, 2002). However, other studies have demonstrated that 
odor-enriched environments increase neurogenesis exclusively at the olfactory bulb, suggesting that 
cues from the olfactory bulb may be important in neurogenesis regulation (Rochefort et al., 2002).  
The long-distance repulsive cue Slit is expressed in the septum, striatum, choroid plexus and in type 
C cells (Ghashghaei et al., 2007f; Abrous et al., 2005), and regulate the motility and directionality of 
neuroblast migration (Ming and Song, 2005); (Zhao et al., 2008). Long distance gradients of repulsive 
cues  such  as  Slits  are  created  by  directional  CSF  flow  generated  by  the  movement  of  ciliary 
epithelium in the lateral ventricles (Sawamoto et al., 2006). Heparin sulphate proteoglycans in the 
ECM can modulate the Slit signal (Ghashghaei et al., 2007a). Neuroblasts express the Slit receptor 
ROBO and the netrin receptor DCC.  
The astroglial tube surrounding the RMS is a source of local repulsive cues and creates short distance 
gradients (Ghashghaei et al., 2007h). Neuroblasts express integrins on their cell membranes that 
interact with ECM proteins and receptors for migration guidance cues in the SVZ and RMS (Lledo et 
al.,  2006e).  Other  cues  implicated  in  neuroblast  migration  are  the  ephrins/Ephs(Conover  et  al., 
2000), GABA, and netrin (Ghashghaei et al., 2007i). At the OB, reelin causes neuroblasts to exit the 
RMS, re-orient their direction of migration, and migrate into OB granule cell layers where they 
differentiate(Ghashghaei et al., 2007; (Gong et al., 2007).  
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2.7.  Control of  neurogenesis and the potential of  NSC 
Various growth factors and neurotransmitters regulate neurogenesis.  FGF-2 is secreted by astrocytes 
and endothelial cells in the SVZ (Hagg, 2005), and exogenous FGF-2 increases neurogenesis and the 
number of type B stem cells (Wagner et al., 1999; Kuhn et al., 1997). Infusion of EGF into the lateral 
ventricles  increases  cell  proliferation  in  the  SVZ  (Kuhn  et  al.,  1997;  Doetsch  et  al.,  2002),  and 
infusion  of  EGF  into  the 4th  ventricle  stimulates neurogenesis  in  the  normally non-proliferative 
subventricular zone (Martens et al., 2002). VEGF induces neurogenesis and angiogenesis in the CNS, 
and can stimulate the release of BNDF (Hagg, 2005). BDNF promotes neuroblast survival and 
increases neurogenesis (Hagg, 2005). TGFα is a ligand of EGFR and increases neurogenesis (Hagg, 
2005). Type C transit-amplifying cells express growth factor receptors, NMDA receptors sensitive to 
glutamate  and  electrical  activity,  and  Ca2+  channels.  Extrasynaptic  GABA  levels  affect  both 
proliferation and the rate of migration in the RMS (Lledo et al., 2006f).  
Developmental  transcription  factors  are  also  implicated  in  neurogenesis.  Noggin  is  expressed  in 
ependymal cells (Ming and Song, 2005), and astrocytes in the SVZ express neurogenesin and wnt.  
Other developmental factors associated with neurogenesis are sonic hedgehog (Ahn and Joyner, 
2005), bone morphogenic protein-4, notch1, pax6, and mash1 (Lledo et al., 2006a).   
Several environmental factors have been shown to influence neurogesis. Positive modulators include 
an odor-enriched environment, exercise, learning, and caloric restriction of diet (van et al., 1999; 
Gould  et  al.,  1999;  Gould  et  al.,  1997;  Mirescu  et  al.,  2004;  Lichtenwalner  and  Parent,  2006; 
Komitova et al., 2005; Naylor et al., 2005a; Lee et al., 2002; Hauser et al., 2000; Raber et al., 2004; 
Ekdahl et al., 2003; Lindqvist et al., 2006). Negative modulators include stress, depression, drug or 
alcohol abuse, a high fat diet, diabetes, inflammation and irradiation (Herrera et al., 2003; Gould et 
al., 1997; Malberg et al., 2000; Dranovsky and Hen, 2006; Powrozek et al., 2004; Mirescu et al., 2004; 
Beauquis et al., 2006). 
The potential of aNSC can be examined in vitro using cell culture systems.  aNSC are isolated from 
the SVZ, mechanically and chemically dissociated, and cultured in a defined medium that supports 
the  survival  and  proliferation  of  neural  stem  cells  but  not  other  cell  types,  or  that  induces  the 
differentiation of neural stem cells (Reynolds et al., 1992; Vescovi et al., 1993).This population is 
enhanced  and  enriched  over  subsequent  passages.  The  SVZ  stem  cell  population  is  capable  of 
proliferation, and can differentiate into all neural lineages. Clonal analysis through lineage tagging 
with  a  genetic  marker  establishes  that  a subset  of  differentiated  cells  are  derived  from  a  single, 
original stem cell (Morshead et al., 1994a). Together, these techniques establish the potential of aNSC 
to proliferate and differentiate.  These in vitro techniques are applied to assess the effects of MRI 
contrast agents on NPC behaviour in Chapter 4.  
Transplantation studies can demonstrate the potential of NSC in vivo.  Embryonic NSC transplanted 
into embryonic CNS migrate extensively and follow endogenous migratory routes (Brustle et al., 
1997; Brustle et al., 1998). Similarly, embryonic NSC transplanted into the adult CNS migrate and  
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differentiate into all neural cell types (Wichterle et al., 1999). Adult NSC transplanted into embryonic 
CNS have limited potential and do not migrate extensively (Lim et al., 1997). Adult NSC transplanted 
into non-neurogenic regions of the adult CNS are gliogenic and do not generate neurons (Gage et al., 
1995; Seidenfaden et al., 2006), and adult NSC transplanted into the SVZ or SGZ follow normal 
migratory routes and differentiate appropriately (Herrera et al., 1999; Suhonen et al., 1996). -derived 
NSC  can  also  differentiate  into  cerebellar  interneurons  after  cerebellar  transplantation,  which 
indicates that their neurogenic capacity is not restricted to the SVZ (Milosevic et al., 2008). These 
studies suggest that adult NSC are more committed and lineage-restricted than embryonic NSC, but 
also emphasize the role of the neurogenic niche in determining neurogenic potential. 
 
2.8.  Oligodendrocyte precursor cells 
Oligodendrocyte precursor cells (OLPs) represent an additional population of proliferating cells in 
the adult brain, and are known to proliferate throughout adult life. We investigate the fate of OLPs 
following ischaemia, alongside the fate of NPC, in Chapter 7, and an overview of OLP biology is 
summarised below. The majority of mature oligodendrocytes are generated from OLPs between 
postnatal  day  7  and  14.  The  developmental  origin  of  OLPs  is  in  the  ventricular  zone  of  the 
developing brain, but they migrate and are distributed throughout all regions of the brain, including 
white matter, the cortex and striatum, by postnatal stages.  
Following the postnatal burst of oligodendrocyte production, a population of OLPs persists into 
adulthood  (Wolswijk  and  Noble,  1989).  OLPs  coexpress  platelet-derived  growth  factor  receptor 
alpha (PDGFRα) and NG2 proteoglycan (Nishiyama et al., 1997). PDGF is a chemoattractant for 
OLPs in vitro and in vivo (Noble et al., 1988; Zhang et al., 2004a), and PDGFRα  expression in OLPs 
is required for proliferation and differentiation (Woodruff et al., 2004; Pringle et al., 1992; Richardson 
et al., 1988). PDGF has been shown to maintain OLP cell cycling (Bogler et al., 1990). Loss of 
PDGF results in loss of PDGFRα+ OLPs and hypomyelination (Fruttiger et al., 1999). PDGFRα  
expression can lead to neural tube defects, gliomas and hypomyelination (Fruttiger et al., 1999; Li et 
al., 1996; Payne et al., 1997).NG2 can also be expressed in vascular smooth muscle cells (Ozerdem et 
al., 2001), and blood-borne macrophage (Dawson et al., 2000; Bu et al., 2001). Other lineage markers 
–  transcription  factors  SOX10  and  Olig2  –  are  expressed  all  cells  of  oligodrendroglial  lineage, 
including both OLPs and oligodendrocytes.  
OLPs contribute to mature oligodendrocyte generation and myelination (Bu et al., 2004; Franklin et 
al.,  1997;  Zhu  et  al.,  2008).  Upon  differentiation,  OLPs  downregulate  PDGFRα    and  NG2 
proteoglycan, upregulate myelin and myelinate axons (McTigue and Tripathi, 2008). The number of 
oligodendrocytes in the brain is determined by the number of axons. During development, more 
oligodendrocytes are generated than required. Those that are not in contact with axons undergo 
apoptosis within 2-3 days, due to lack of survival cues from axons (Barres et al., 1992; Raff et al., 
1993).   
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In vitro, adult OLPs can differentiate into oligodendrocytes and astrocytes (Wren et al., 1992; Engel 
and Wolswijk, 1996; Yoo and Wrathall, 2007). In vivo, OLPs do not contribute to astrogliogenesis in 
the normal brain (Groves et al., 1993), but when transplanted into a glia-depleted environment are 
capable of differentiation into both oligodendrocytes and astrocytes (Franklin et al., 1997). OLPs 
have also been shown to differentiate into astrocytes in vivo after injury (Alonso, 2005). 
NG2+ OLPs may also receive synaptic input, and can form synapse-like connections with neurons. 
OLPs express AMPA, NMDA and GABA receptors (Bergles et al., 2000), and AMPA-mediated 
currents  have  been  described  in  OLPs  (Kukley  et  al.,  2007;  Ziskin  et  al.,  2007),  as  well  as 
electrophysiological action potential-like ‘spiking’ (Karadottir et al., 2008). This OLP responsiveness 
to synaptic activity results in activity-dependent intracellular signaling pathway activation, which may 
be involved in the regulation of OLP proliferation, differentiation and migration (Nishiyama et al., 
2009). OLPs may be vulnerable to excitotoxicity due to their expression of glutamate receptors.  
It has recently been reported that OLPs can also generate forebrain neurons in the normal adult 
brain in the piriform cortex (Rivers et al., 2008), and postnatal OLPs can generate neurons in vitro 
(Kondo and Raff, 2000; Belachew et al., 2003; Aguirre and Gallo, 2004). can also differentiate into 
neurons when grafted into neurogenic brain regions (Windrem et al., 2004). the normal brain, OLP 
contribution to projection neurons in the piriform cortex was found to be approximately 1.4%, 
however the function of these cells is unknown (Rivers et al., 2008). 
Following an injury involving demyelination, such as EAE, remyelination can occur and is mediated 
by  OLPs  (Nishiyama,  1998;  Nishiyama,  2007).  OLPs  respond  to  injury  through  proliferation, 
differentiation  and  remyelination  (Levine  and  Reynolds,  1999).  NG2+  cells  may  be  a  diverse 
heterogeneous population, as only a subset respond to cerebral injury (McTigue and Tripathi, 2008). 
2.9.  Neurogenesis and cerebral ischaemia 
2.9.1.  Cell proliferation at the subventricular zone 
Expansion of the SVZ and neural stem cell proliferation ipsilateral to the lesion has been reported 
following cerebral ischaemia in several rodent models (Parent et al., 2002; Arvidsson et al., 2002; 
Kokaia et al., 2006; Jin et al., 2001; Dempsey et al., 2003; Yan et al., 2006). Neurogenesis has also 
been reported following human stroke (Minger et al., 2007; Sgubin et al., 2007).  
Cell proliferation, as well as proliferation rate, increases within 24 hours of the initial insult, peaks at 7 
days(Zhang  et  al.,  2004c;  Zhang  et  al.,  2004b),  decreases  by  2-4  weeks  (Takasawa  et  al.,  2002; 
Dempsey et al., 2003; Zhu et al., 2003), but remains elevated relative to contralateral and baseline 
non-ischaemic SVZ for several weeks and up to a year post-ischaemia (Thored et al., 2006). Even a 
short period of ischaemia (15 minutes) is sufficient to increase neurogenesis at the SVZ, without 
causing inflammation or infarction (Naylor et al., 2005b).  
SVZ isolated from the ischaemic hemisphere generate more neurospheres than non-ischaemic SVZ 
(Zhang et al., 2004b). Furthermore, the same result is obtained following Ara-C ablation of type C  
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cells, suggesting that proliferation predominantly occurs from the stem cell pool following ischaemia. 
Asymmetric cell division increases from 40% in normal SVZ to 60% in ischaemic SVZ, reflecting an 
increase in proliferation in type B cells and expansion of the SVZ (Zhang et al., 2004c). Ependymal 
cell early proliferation, upregulation of CD133, and de-differentiation into radial glia-like cells has 
also been reported (Zhang et al., 2007a; Coskun et al., 2008; Carlen et al., 2009).  
2.9.2.  Factors influencing neurogenesis post-stroke   
A mechanism of early neural stem cell response to ischaemia may be glutamate sensitivity. Blocking 
NMDA receptors in the SVZ blocks an increase in neurogenesis following ischaemia, indicating a 
role for glutamate excitotoxicity in early activation of SVZ neural stem cells (Arvidsson et al., 2001).  
Growth factors also modulate neurogenesis post-ischaema. A number of experimental methods have 
been used to investigate the action of growth factors on neural stem cells. The effect of application 
of exogenous growth factors on neurogenesis can be assessed in vitro and in vivo after ischaemia. 
Growth factor expression can be upregulated locally by adenoviral transduction after ischaemia, or by 
overexpression in a transgenic mouse model.  
FGF-2 is known to influence the neural stem cell popultation in the normal brain (Kuhn et al., 1997), 
and  is  implicated  in  the neurogenic  response  after  ischaemia.  FGF-2  is  upregulated  at  the  SVZ 
following ischaemia for up to 14 days (Endoh et al., 1994; Yoshimura et al., 2001), coinciding with 
peak  SVZ  expansion  and  enhancing  neurogenesis  (Leker  et  al.,  2007;  Yoshimura  et  al.,  2001). 
Overexpression of FGF-2 enhances the neurogenic response after ischaemia by increasing SVZ cell 
proliferation and migration (Dayer et al., 2007). Gene profiling changes at 7 days post-ischaemia 
show upregulation of the FGF family genes and the FGF receptor 1 (as well as members of the Sox 
family  genes;  integrins;  MMP-2;  Hif-1α;  Notch  signalling  genes;  Bmp4  and  TGF-β  superfamily 
genes) (Liu et al., 2007a). Exogenous FGF-2 has been shown to enhance NPC proliferation (Ay et al., 
2001). Intranasal administration of FGF-2 from 2 hours post-ischaemia has been shown to improve 
neurological function and reduce infarct volume (Ma et al., 2008).  
Insulin-like growth factor-1 (IGF-1) promotes NPC proliferation in the presence of FGF-2, and 
neuronal differentiation in the absence of FGF-2 (Kalluri et al., 2007; Camarero et al., 2003; Otaegi et 
al., 2006). The IGF-1 receptor is expressed on SVZ NSC (Yan 2006). IGF-1 is also upregulated after 
ischaemic  injury  in  the  penumbra  (Yan  et  al.,  2006),  and  is  associated  with  neuronal  and 
oligodendroglial differentiation (Hsieh et al., 2004; McCurdy et al., 2005; Yan et al., 2006). Inhibition 
of IGF-1 by intraventricular infusion of IGF-1 antibody inhibits cell proliferation at the SVZ (Yan et 
al., 2006).  
The growth factor EGF can inflence the rapid amplification of cells by neural progenitor cells. 
Heparin-binding EGF (HB-EGF) is upregulated after ischaemia (Tanaka et al., 1999; Yan et al., 
2006),  and  the  EGF  receptor  (EGFR)  is  upregulated  in  neural  progenitor  cells  after  ischaemia 
(Ninomiya et al., 2006). HB-EGF has been shown to increase neural stem cell proliferation in vitro  
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(Jin et al., 2005), and injection of a HB-EGF adenovirus increases progenitor cell proliferation post-
ischaemia  (Sugiura  et  al.,  2005).  FGF-2  and  EGF  intraventricular  infusions  demonstrated  an 
increased cell replacement in the striatum following ischaemia (Tureyen et al., 2005). 
BDNF and GDNF upregulation has been reported following ischaemia, and increase neurogenesis 
(Takami et al., 1992; Kokaia et al., 1995; Kitagawa et al., 1999). BDNF adenoviral injection into the 
lateral  ventricle  results  in  increased  neurogenesis,  differentiation  and  functional  integration  into 
damaged  tissue  (Benraiss  et  al.,  2001).  A  similar  result  was  achieved  with  BDNF  infusion  after 
ischaemia (Hazell, 2007). GDNF has been shown to protect against neurotoxicity (Wong et al., 2005) 
and provide trophic support to cells locally (Kobayashi et al., 2006).  
Erythropoeitin  (EPO)  and  VEGF  expression  are  regulated  by  the  transcription  factor  hypoxia-
inducible factor-1 (HIF-1). HIF-1, EPO and VEGF are all upregulated after ischaemia (Jiang et al., 
2001; Hayashi et al., 1997). Erythropoeitin treatment increases neurogenesis after stroke (Jin et al., 
2002; Wang et al., 2004), and proliferation in the SVZ is reduced in EPO knock-out transgenic mice 
(Tsai  et  al.,  2006)  Exogenous  EPO  infusion  has  been  shown  to  increase  neuroblast  migration 
towards ischaemia and proliferation at the SVZ (Shingo et al., 2001). EPO has been shown to be 
protective after ischaemia, and its therapeutic effects is being trialled in the clinic (Ehrenreich et al., 
2002). VEGF increases neurogenesis in vitro and in vivo (Jin et al., 2002), and mice overexpressing 
VEGF show increased neurogenesis after ischaemia (Wang et al., 2007b). Roitbak et al demonstrated 
that the neuroprotective effect of VEGF was mediated via HIF-1α and VEGF (Roitbak et al., 2008). 
VEGF and the VEGF receptor 2/Flk-1 are expressed in adult NSC, and VEGF has been shown to 
promote neurogenesis in vitro, though not through increasing cell proliferation (Schanzer et al., 2004).  
BrdU studies also demonstrate an increase in neurogenesis in the striatum and cortex, normally non-
neurogenic brain regions, following ischaemia (Parent et al., 2002; Arvidsson et al., 2002). Cells from 
the SVZ may migrate into the striatum or cortex and differentiate into neurons, or cerebral ischaemia 
may activate a quiescent population of cells with proliferative capacity in the striatum and cortex to 
undergo neurogenesis. The origin of post-ischaemic neurogenesis is investigated further in Chapter 7.  
2.9.3.  Migration of  neuroblasts in response to ischaemia 
Neuroblast migration into the infarcted region has also been reported following cerebral ischaemia, 
from 24 hours to 16 weeks post-ischaemia (Kokaia et al., 2006). We investigate NPC subpopulations 
associated  with  post-ishaemic  neurblast  migration  in  Chapter  7.  Neuroblasts  exit  the  RMS  and 
migrate into the striatum towards the ischaemic infarct (Arvidsson et al., 2002). Lateral migration into 
the striatum from the SVZ has also been observed, with chains of DCX+ cells migrating out of the 
SVZ, in close proximity to astrocytes and blood vessels (Parent et al., 2002c), toward the ischaemic 
infarct (Magavi et al., 2000; Hicks et al., 2008; Wang et al., 2007b; Thored et al., 2006; Thored et al., 
2007). Most DCX+ cells colabel with BrdU (Kokaia et al., 2006), suggesting that they are generated 
post-ischaemia.   
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The origin of migrating DCX+ cells following ischaemia is thought to be the progeny of SVZ neural 
progenitor cells, and the identification of DiI+ DCX+ migrating neuroblasts in tracing studies after 
ventricular DiI infusion supports the SVZ origin (Jin et al., 2003) In the non-ischaemic SVZ, DCX+ 
cells co-express neural progenitor markers Sox2 and Nestin, but co-express the mature interneuron 
marker tyrosine hydroxlase following ischaemia, suggesting that they become committed to neuronal 
differentiation (Hou et al., 2008; Lai et al., 2008). However other studies have suggested that the 
DCX+ cells may originate from local progenitor cells. Hua et al observed DiI+ cells in the olfactory 
bulb and rostral migratory stream after intraventricular DiI injection in ischaemic mice, but did not 
observe DiI in DCX+ cells at the ischaemic lesion (Hua et al., 2008). The authors suggest that a local 
progenitor cell can give rise to neuroblasts and contribute to neurogenesis. In a similar study, DiI was 
injected intraventricularly in the nestin-EGFP transgenic mouse, and the authors report that only a 
subset of GFP+DCX+ neuroblasts was DiI+ (Burns et al., 2007) Cell labelling and longitudinal 
tracking of cell migration following ischaemia would help to elucidate the origin of DCX+ cells in 
the ischaemic brain, and a method of endogenously labelling and imaging SVZ NPC with MRI 
contrast agent for this purpose is developed in Chapter 6.  
 
Figure 2.9.3.1 Neuroblast migration following cerebral ischaemia (from Chopp et al, 2005). LV, 
lateral ventricle. CC, corpus callosum. Yellow, neural stem can progenitor cells. Red, migrating 
neuroblasts. 
 
It is likely that multiple attractive cues together with a permissive ECM environment contribute to 
neuroblast  migration.  The  matrix  metalloproteinase  MMP-9  may  be  involved  in  the  neurogenic 
response (Fowlkes et al., 2004; Karagiannis and Popel, 2006; Lee et al., 2006; Son et al., 2006). It is 
increased in the SVZ at 7-14 days post-ischaemia, where it co-localises with DCX (Zhao et al., 2006). 
Inhibition of MMPs reduces DCX migration from the SVZ following ischaemia (Lee et al., 2006; 
Wang et al., 2006; Zhao et al., 2006), and upregulation of MMP-9 has also been shown to promote 
migration MMPs are involved in ECM remodelling and may create an ECM environment that is 
permissive to neuroblast migration. MMPs may also promote neurogenesis by cleaving pro-growth  
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factor proteins and releasing proliferation or migration cues from the ECM. MMP-9 has been shown 
to cleave ECM matrix-bound signalling molecules such as VEGF (Zhao et al., 2007)and IGF-1 
(Zhao et al., 2007), growth factors which promote neurogenesis. 
The chemokine stromal cell-derived factor-1α (SDF-1α) may mediate neuroblast migration after 
ischaemia (Ohab et al., 2006). It is also regulated by the transcription factor HIF-1 (Chang et al., 
2007), is expressed during development and is important in neuronal migration (Lazarini et al., 2003; 
McGrath et al., 1999). Its normal function in the adult is as a chemoattractant, to recruit bone 
marrow  cells  expressing  the  CXCR-4  receptor  into  the  circulation  (Dar  et  al.,  2006).  SDF1α  is 
expressed  in  endothelial  cells  in  the  brain  (Stumm  et  al.,  2002),  and  reactive  astrocytes  in  the 
ipsilateral striatum up to four weeks post-ischaemia (Imitola et al., 2004). receptor for SDF-1α – 
CXCR4 – is expressed in SVZ progenitor cells (Ni et al., 2004; Thored et al., 2006), and SDF1α-
CXCR4 signalling is implicated in neural progenitor cell proliferation and migration (Imitola et al., 
2004). SVZ-derived neurospheres migrate towards a gradient of SDF-1α in vitro. Pharmacological 
inhibition of SDF-1α prevents migration in vitro and in vivo in response to cerebral ischaemia (Kokaia 
et al., 2006; Robin et al., 2006). SDF1α administration promotes neuroprotection and angiogenesis 
after ischaemia (Shyu et al., 2008). Overexpression of CXCR4 receptor in neural progenitors in the 
SVZ causes a decrease in neurogenesis in the absence of SDF1α, and increased neurogenesis after 
application of exogenous SDF1α (Liu et al., 2008). 
 
2.9.4.  Differentiation of  neuroblasts in response to cerebral ischaemia 
Newborn,  BrdU+  neurons  in  the  striatum  differentiate  into  regionally  appropriate  neurons, 
expressing markers for early – Meis2 and Pbx – and mature – DARPP-32 – striatal medium spiny 
neurons (Arvidsson et al., 2002), or calbindin-positive interneurons (Jin et al., 2003), and several 
studies have confirmed neuronal differentiation of newly generated cells in the striatum after an 
ischaemic even (Yamashita et al., 2006; Parent et al., 2002). 4 weeks after ischaemia, newborn cells 
develop  polarity,  form  dendrites  and  receive  excitatory  and  inhibitory  synaptic  input,  and  are 
themselves  electrophyisiologically  active  and  capable  of  generating  action  potentials  (Hou  et  al., 
2008).  These  cells  express  mature  neuronal  markers  such  as  NeuN,  MAP-2,  synapsin  1,  the 
GABAergic  neuronal  marker  glutamic  acid  decarboxylase,  and  the  cholinergic  neuronal  marker 
choline acetyltransferase (Hou et al., 2008).  
While newborn neurons are capable of differentiation into the correct phenotype, the majority die 
within  2  to  5  weeks  post-ischaemia.  Aarvidsson  et  al  estimate  that  neuronal  replacement  after 
ischaemia by neurogenesis is 0.2% of total cell loss (Arvidsson et al., 2002). This may be due to an 
increasingly inhibitory environment as the ischaemic lesion progresses, scar tissue forms, and the 
inflammatory profile changes. Neurogenesis and cell survival can be increased after ischaemia by 
treatment with FGF-2 (Ay et al., 2001; Dayer et al., 2007).   
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2.10.  Inflammation, microglia and neurogenesis 
Microglia and the peripheral immune system can also be mediators of neurogenesis. In the normal 
brain, microglia depletion decreases neurogenesis (Ziv et al., 2006), and SVZ extracts co-cultured 
with microglia increase neurogenesis (Aarum et al., 2003; Walton et al., 2006). In the hippocampus, 
environmental  enrichment  increases  neurogenesis  and  recruits  microglia  to  the  dentate  gyrus. 
Decreased neurogenesis is observed in immunodefficient SCID (severe combined immunodefficient) 
mice, and no increase in neurogenesis is observed following environmental enrichment. This effect 
can  be  rescued  with  bone  marrow  replenishment  (Ziv  et  al.,  2006).  These  results  suggest  that 
microglia may be required for neurogenesis. Furthermore, in Boyden chamber migration assays, there 
is an increase in directional migration of adult NSC towards microglia (Aarum et al., 2003), which 
suggests a soluble factor released from microglia may be involved in the regulation of neurogenesis 
(Nakanishi et al., 2007; Morgan et al., 2004).  
However, overactivated microglia may have a negative effect on neurogenesis. Chronic inflammation 
can inhibit neurogenesis (Ekdahl et al., 2003; Monje et al., 2003). Inhibition of activated microglia by 
minocycline increases neurogenesis in vivo (Liu et al., 2007b). In vitro, exposure to the cytokine IL-4 
causes microglial activation, whereas exposure to bacterial endotoxin causes microglial overactivation. 
Exposure of microglia to the former increases neurogenesis in co-culture, while exposure to the latter 
decreases  neurogenesis  (Butovsky  et  al.,  2006).  Together,  this  data  suggests  that  a  moderate 
inflammatory  environment  is  optimal  for  neurogenesis  and  NPC  migration  after  ischaemia. 
Conditioned media from bacterial endotoxin-treated microglia can also decrease neural stem cell 
survival in vitro, suggesting a soluble factor secreted by microglia mediates this response (Cacci et al., 
2008).  
IL-6 is one candidate factor – IL-6 decreases neurogenesis in vitro, and overexpression of IL-6 in 
astrocytes in vivo also decreases neurogenesis (Vallieres et al., 2002). The pro-inflammatory cytokine 
TNFα may also be a negative mediator of neurogenesis. It is normally upregulated after ischaemia 
(Ekdahl et al., 2009), and is expressed in microglia (Gregersen et al., 2000). Low levels of TNFα 
increase proliferation and neuronal differentiation of NPC in vitro via the TNFα receptor 1, whereas 
high levels of TNFα initiate apoptosis in NPC (Bernardino et al., 2008). Pharmacological inhibition 
of  TNFα  decreases  neurogenesis  after  ischaemia  (Heldmann  et  al.,  2005).  Iosif  et  al  also 
demonstrated that the TNFα receptor 1 is expressed in SVZ nestin-expressing progenitor cells, and 
in transgenic mice with TNFα receptor 1 knock out, neurogenesis was increased after ischaemia 
compared to mice that did not lack the receptor (Iosif et al., 2008).  
Microglial  expression  of  chemokines  or  growth  factors  may  also  a  mechanism  of  neurogenesis 
regulation. Microglia express BDNF and GDNF, which have been shown to be neuroprotective and 
promote neurogenesis. The chemokine monocyte chemotactic protein-1 (MCP-1) is expressed in  
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microglia following ischaemia, and has been shown to modulate neuroblast migration in vitro (Widera 
et  al.,  2004).  Neuroblasts  express  chemokine  receptors  such  as  CCR2,  and  may  therefore  be 
responsive to chemokine levels in vivo (Tran et al., 2004). Increased levels of iNOS and eNOS, 
expressed in microglia, have also been shown to increase neurogenesis and angiogenesis (Chen et al., 
2005; Zhu et al., 2003).  
 
2.11.  Non-SVZ neurogenesis 
While the contribution of SVZ stem cells to neurogenesis following stroke has been extensively 
studied, it has been suggested that other cell types may also contribute to neurogenesis. A local 
progenitor  cell  may  exist  in  the  cortex,  and  proliferate  to  generate  neuroblast  that  go  onto 
differentiate into mature neurons, much like the SVZ neuroblast. There is some conflicting evidence 
for the existence of such a cell type.  
Several studies have reported cortical neurogenesis following cerebral ischaemia (Gu et al., 2000; 
Jiang et al., 2001; Palmer et al., 1995; Palmer et al., 1999b; Magavi et al., 2000; Rakic, 2002), while 
others have reported that newborn neurons originate exclusively from the SVZ and migrate to their 
final destination for differentiation (Bhardwaj et al., 2006; Yamashita et al., 2006). NPC marker nestin 
is upregulated after ischaemia and is widely expressed in the ischaemic lesion (Duggal et al., 1997; Li 
and Chopp, 1999; Nakamura et al., 2003). In an inducible transgenic model where cells express GFP 
under the nestin promotor, the majority of GFP+ cells differentiate into neurons (Lagace et al., 
2007), suggesting that nestin is a marker for NPC. However, it is uncertain whether nestin expression 
is exclusive to neural stem and progenitor cells (Ernst and Christie, 2005), or whether it can be 
expressed in other cell types after ischaemia. Astrocytes have been shown to reexpress developmental 
markers such as nestin and vimentin after injury (Hartfuss et al., 2001; Malatesta et al., 2003). Nestin 
expression may not be an indicator of neurogenesis after ischaemia.  
As discussed above, in cell tracing studies involving intraventricular DiI infusions, Hua et al did not 
observe DiI in DCX+ cells at the lesion site, and Burns et al also observed DiI-negative DCX+ cells 
after ischaemia (Hua et al., 2008; Burns et al., 2007). The capacity of SVZ-derived neuroblasts to 
migrate into the cortex is also in dispute, and different animal models of ischaemia frequently give 
different contradicting results. In models that result in striatal and cortical injury, such as the MCAO 
model, few DCX+ cells are typically observe in the cortex (Arvidsson et al., 2002; Kokaia et al., 2006; 
Thored  et  al.,  2006;  Thored  et  al.,  2007).  In  exclusively  cortical  models  of  ischaemia,  such  as 
photothrombolysis, DCX+ cells have been observed in the cortex (Jin et al., 2003). However, it is 
unclear  whether  these  neuroblasts  originate  in  the  SVZ  or  from  a  local  progenitor  source. 
Longitudinal cell tracking would help to resolve these issues, and a method of labelling SVZ NPC is 
described in Chapter 6.  
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2.12.  Other sources of  cell proliferation and DNA synthesis 
Development of cell tracking techniques is essential to resolve these issues of cell migration and 
neurogenesis.  Labelling  methods  that  can  track  a  population  of  cells  and  its  progeny,  such  as 
retroviral labelling and the CRE-lox system, will be able to address the question of the origin of 
neurogenic cells following ischaemia. Additionally, while BrdU incorporates into newly synthesised 
DNA in S-phase during cell division, aberrant DNA synthesis during apoptosis and in damaged 
neurons has been reported in ischaemia (Burns et al., 2007; Gage, 2000), however DNA repair at this 
level may not be detectable by BrdU immunohistochemistry (Taupin, 2007). It is important to be able 
to  distinguish  between  these  forms  of  DNA  synthesis  in  CNS  damage,  and  understand  the 
limitations of using BrdU and mitotoic markers as indicators of cell proliferation.  
OLPs have been shown to proliferate and accumulate in the corpus callosum and border of the 
ischaemic lesion within 7 days, co-localising with reactive astrocytes and microglia at the infarct 
border (Gottlieb et al., 2000; Mabuchi et al., 2000; Mandai et al., 1997; Ohta et al., 2003). Young et al 
have also demonstrated that OLPs are capable of neurogenesis in the normal adult brain (Young et 
al., 2007a). In Chaper 7, we investigate the contribution of OLPs to post-ischaemic neurogenesis 
further. Furthermore, reactive astrocyte and microglia proliferation have been reported following 
ischaemia and represents a major contribution to total cell proliferation, particularly outside of the 
SVZ. In inducible nestin-Cre transgenic mice – where GFP is expressed under the nestin promoter 
and induced by tamoxifen administration, and permanently expressed in the cell and its progeny 
thereafter – the majority of BrdU+ cells were not GFP+, indicating that they were not derived from 
the nestin+ SVZ progenitor or stem cell populations (Burns et al., 2007).  
 
2.13.  Stem cell therapy in cerebral ischaemia 
Cellular therapy is a promising treatment for cerebral ischaemia and other neurodegenerative 
diseases such as multiple sclerosis, Parkinson’s and Huntington’s disease, which are characterised 
by extensive neuronal cell death. The main goal of cellular therapy is to replace cells lost during 
the injury event with stem cells that will respond to the injury environment and differentiate 
appropriately.  For  example,  following  cerebral  ischaemia  it  is  estimated  that  endogenous 
neurogenesis replaces only 0.2% of lost cells, and the aim of cellular therapy is to increase this cell 
replacement via the introduction of exogenous cells.  
The process of cellular therapy involves the culture and expansion stem cells in vitro, and grafting 
of stem cells into a tissue, where they contribute to repair. Several study parameters can influence 
the treatment outcome, such as the stem cell type used (for example, embryonic, fetal, adult, 
haematopoietic, umbilical cord blood, iPS, or cell lines); the number of grafted cells; the delivery 
route  (intravenous;  intracarotid;  grafting  into  the  ipsilateral  or  contralateral  cortex,  striatum, 
corpus callosum; or intraventricular injections); the time point of delivery (acute or delayed). The  
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mechanism of action of stem cells has yet to be fully elucidated, but may involve not only cell 
replacement of injured tissue, but also neuroprotection. 
Cellular therapy has been successful in several neurodegenerative disease models. In a rodent 
model  of  Parkinson’s  disease,  a  range  of  cell  types  have  been  used  to  replace  degenerating 
neurons in the substantia nigra, including dopaminergic neurons (Lindvall and Kokaia, 2004), fetal 
mesencephalic cells (Wenning et al., 1997), neural-differentiated ES cells (Barberi et al., 2003; 
Bjorklund et al., 2002), and neural stem cells (Ourednik et al., 2002). These studies have been only 
partially successful, with results showing some functional improvement and only some neuronal 
differentiation of grafted cells.  
In rodent models of Huntington’s disease, grafting of fetal NPC into the striatum has resulted in 
behavioural recovery, graft survival and some GABAergic cell replacement (Clelland et al., 2008; 
McBride et al., 2004). These studies have led to clinical trials using fetal NPC, whose results 
indicate that the cellular therapy slows disease progression and improves motor and cognitive 
functions in patients (Bachoud-Levi et al., 2000; Hauser et al., 2002; Reuter et al., 2008). Patient 
autopsies confirm graft survival and neuronal differentiation (Keene et al., 2007).  
Neurodegeneration in multiple sclerosis is chronic and dispersed, which present challenges for cell 
delivery to sites of degeneration. Several cell types have been studies in the EAE rodent model of 
MS,  including  oligodendrocyte  precursors,  embryonic  stem  cells  and  adult  neural  stem  cells 
(Einstein et al., 2006; Groves et al., 1993; Pluchino and Martino, 2005; Windrem et al., 2004; 
Wolswijk, 2002). Pluchino et al demonstrated that adult neural stem cells injected intravenously 
home  to  sites  of  injury,  accumulate  in  perivascular  areas,  and  improve  functional  outcome 
(Pluchino and Martino, 2005; Pluchino et al., 2003). Many cells remain undifferentiated, with only 
some going onto oligodendrocyte differentiation and remyelination. A small clinical trial using 
haematopoietic  stem  cells  has  reported  a  delay  in  disease  progression  as  well  as  functional 
improvement in 80% of patients treated (Burt et al., 2009). Other clinical trials have also observed 
at least a delay in disease progression (Saccardi et al., 2006).  
Several cell replacement studies in cerebral ischaemia in rodents have demonstrated an improved 
functional outcome with a range of cell types, summarized in Table 2.13.1.4.1. Cellular therapy 
can contribute to neurogenesis and angiogenesis in the post-ischaemic brain (Kelly et al., 2004), as 
well as neuroprotection. Clinical trials involving cellular therapy have also been partially successful 
in improving motor and cognitive function after cerebral ischaemia (Kondziolka et al., 2002; 
Kondziolka  et  al.,  2000;  Kondziolka  et  al.,  2005;  Bang  et  al.,  2005;  Savitz  et  al.,  2005).  et  al 
observed mild improvement in neurological score after intravenous infusion of mesenchymal 
stem cells in stroke patients. Similarly, Kondziolka and Savitz both observed some functional 
improvement after neural stem cell grafts in stroke patients and demonstrated the clinical safety of 
cellular therapy. However in all studies improvements were minor. 
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2.13.1.  Cell type 
One  important  consideration  for  cellular  therapy  in  all  disease  models  including  cerebral 
ischaemia is the cell type used, which can range from ES cells, foetal NPC, and immortalised 
neural stem cell lines to haematopoietic, mesenchymal and umbilical cord stem cells. Linked to 
the cell type choice is the hypothesis as to the mechanism of recovery. The primary hypothesis of 
neural stem cell grafts is the contribution to cell replacement and functional integration of graft 
cells  into  host  tissue;  while  haematopoietic  cells  are  thought  to  promote  endogenous 
neurogenesis, angiogenesis and cell survival in the lesion, through the release of growth factors 
and cytokines locally, and interaction with the host immune system. Furthermore, for appropriate 
cell integration and differentiation, the developmental stage of the cell appears to be important. 
While adult stem cells can be restricted in their differentiation capacity, embryonic stem cells can 
be tumorigenic when grafted into disease models. Fetal cells, taken from the stage of development 
that  commitment  to  the  desired  cell  type  occurs,  are  lineage-restricted  but  retain  some 
developmental plasticity, and can differentiate appropriately when grafted.  
 
2.13.1.1.  Embryonic stem cells 
Embryonic stem (ES) cells derived from the inner cell mass of the embryo are pluripotent and 
can generate cells of the endoderm, mesoderm and ectoderm. In vitro, ES cells can be prompted to 
differentiate into the neural lineage at low density culture or when exposed to signalling factors 
(Barberi et al., 2003; Liour and Yu, 2003; Schmandt et al., 2005; Smukler et al., 2006; Tropepe et 
al., 2001; Wichterle et al., 2002; Ying et al., 2003).  
ES cells can be expanded in vitro, but can form teratomas in vivo when transplanted into adult 
tissue in rodents (Bjorklund et al., 2002). Transplantation of ES cells into the ischaemic rodent 
brain has been shown to improve motor function, and some ES cells differentiate into neurons at 
the infarct border (Buhnemann et al., 2006; Hayashi et al., 2006), some studies have also observed 
no change in lesion size following cell therapy with ES cells (Hicks et al., 2008).  
 
2.13.1.2.  Bone marrow stem cells 
Stem cells of haematopoietic and mesenchymal lineage have also been used in cell therapy studies 
in rodents, and have been summarised in the table below (Table 2.13.1.4.1) (Athiraman et al., 
2009; Chen et al., 2001; Chopp and Li, 2002; Li and Chopp, 2009; Li et al., 2005; Li et al., 2002; Li 
et al., 2001b; Li et al., 2001a; Li et al., 2000; Shen et al., 2007; Shen et al., 2006); (Rempe and Kent, 
2002; Kurozumi et al., 2004; Kurozumi et al., 2005). For cellular therapy following ischaemia, 
haematopoeitic and mesenchymal cells are typically injeceted systemically – intravenously or via 
the carotid artery – and home to the ischaemic lesion. Because of their pathotropism, they can be  
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exploited  as  a  vehicle  for  drug  delivery,  modified  to  overexpress  growth  factors  or  other 
neuroprotective factors.  
Haematopoietic  and  mesenchymal  stem  cells  may  also  be  able  to  differentiate  into  neurons 
(Dezawa  et  al.,  2005).  However,  it  is  also  likely  that  these  cells  have  a  predominantly 
neuroprotective  effect  after  cerebral  ischaemia.  Chopp  and  colleagues  have  shown  in  several 
studies that bone marrow-derived mesenchymal stem cells improve functional outcome, reduce 
infarct size and apoptosis, increase VEGF, FGF-2, BDNF and IGF-1 expression in the lesion 
(Hardy et al., 2008; Chen et al., 2003), and increase neurogenesis and angiogenesis following 
cerebral  ischaemia.  Neovascularisation  of  the  ischaemic  infarct  is  associated  with  improved 
functional outcome, and haematopoietic cells have been shown to directly integrate into new 
vessel formation, and increase endogenous angiogenesis through expression of angiogenic factors 
such as VEGF and BDNF (Chen et al., 2003; Li et al., 2002; Zhang et al., 2005a).  
 
2.13.1.3.  Umbilical cord blood cells 
Umbilical  cord  blood  (UCB)  cells  are  another  stem  cell  source  that  has  demonstrated 
neuroprotection, cell replacement and differentiation into neural, glial and endothelial cell types 
after  grafting  in  cerebral  ischaemia  rodent  models  (Borlongan  et  al.,  2004;  Lu  et  al.,  2002; 
Vendrame  et  al.,  2004).  UCB  are  easily  available  and  enriched  for  haematopoietic  stem  cells 
(Sanberg  et  al.,  2005).  A  number  of  studies  have  suggested  that  UCB  can  differentiate  into 
neurons and glia (Bicknese et al., 2002; Sanchez-Ramos et al., 2001; Zigova et al., 2002). Improved 
behavioural outcome has been observed following cellular therapy with UCB, sometimes with 
little or no cell engraftment, which suggests a neuroprotection mechanism (Taguchi et al., 2004).  
 
2.13.1.4.  Neural stem cells 
Immortalised neural stem cell lines such as C17.2 cerebellar external granule cell layer progenitors 
(Snyder et al., 1997), MHP36 hippocampal progenitors (Modo et al., 2002a) have been used for 
cell  transplantation  after  cerebral  ischaemia  in  rodents.  These  studies  demonstrate  moderate 
functional improvement and some neuronal differentiation of transplanted cells. Veizovic et al 
found  that  grafting  of  MHP36  cell  line  decreased  lesion  volume  and  improved  functional 
outcome (Veizovic et al., 2001), and Modo et al demonstrated that this cell type is capable of 
neuronal differentiation at the lesion (Modo et al., 2002a; Modo et al., 2004). Chu et al have 
observed similar results with an immortalised human neural stem cell line, and also observed 
neuronal  differentiation  in the  ischaemic  brain  (Chu  et  al.,  2004;  Chu  et  al.,  2008).  In some 
studies, the cell lines are also modified to express growth factors such as VEGF (Maurer et al., 
2008). advantages of the immortalised cell lines are that they can be rapidly expanded in vitro, and 
are a clonally derived homogeneous population. However, the cells are immortalised with an  
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oncogene  and  may  therefore  be  tumorigenic  under  certain  conditions.  Temperature-sensitive 
immortalised stem cells, which are capable of proliferation at 33oC, but inhibited at 37-39oC, 
could prevent tumorigenicity of grafted cells. The ST14A neural stem cell line, derived from 
embryonic striatal tissue and immortalised by retroviral transduction of the temperature-sensitive 
SV40 Large T Antigen oncogene (Cattaneo and Conti, 1998), is one candidate cell type, and is 
described further in Chapters 4 and 5.  
For  cell  replacement,  the  lineage  commitment  of  stem  cells  plays  an  important  role  in  their 
differentiation potential after engraftment into injured tissue. Radial glia-like cells give rise to the 
cortical neuron layers in the normal developing embryo, and may have the appropriate migratory 
capacity and neurogenic potential to give rise to neurons after engraftment into host injury tissue, 
compared to adult neural stem cells or embryonic stem cells. It is this cell type that is of particular 
interest to our research, and the focus of cell engraftment and cell MRI contrast agent labelling 
studies in Chapter 4. Several of the immortalised stem cell lines are originally derived from fetal 
neural stem cells. Recent research has demonstrated that fetal telencephalic neural progenitor cells 
are able to migrate towards the ischaemic infarct, differentiate into neurons in the peri-infarct 
area, and can improve behavioural recovery (Darsalia et al., 2007; Kelly et al., 2004; Lee et al., 
2008; Ishibashi et al., 2004; Zhang et al., 2009; Takahashi et al., 2008). In addition, Jiang et al 
found that neural progenitor cells derived from adult tissue did not differentiate into neurons after 
grafting into the ischaemic brain, though the authors observed that cell treatment decreased lesion 
volume and improved functional outcome (Jiang et al., 2005).  
Kelly et al found that grafting of human fetal neural progenitor cells into the ischaemic brain 
resulted in NPC migration toward the lesion site and differentiation into neurons (Kelly et al., 
2004), and Darsalia et al oberseved a similar result (Darsalia et al., 2007). Zhu et al also found that 
fetal  NPC  could  migrate  and  differentiate  at  the  lesion,  and  also  observed  behavioural 
improvement (Zhu et al., 2005). The disadvantage of using this cell type is that primary NSC, 
derived  from  foetal  and  adult  CNS,  are  more  difficult  to  source  and  expand  in  vitro  than 
immortalised cell lines, and are a heterogeneous population of cells. 
Bible et al have also used a bio-scaffold to support neural stem cell integration into host tissue. 
MHP36 cells were co-injected with a synthetic scaffold material directly into the lesion necrotic 
core (Bible et al., 2009), which was shown to aid cell distribution throughout the lesion cavity. 
Grafted cells were in close association with the bio-scaffold. Cell proliferation of grafted cells was 
not assessed, but by seven days post-ischaemia some grafted cells expressed neuronal and glial 
markers. In future studies, co-injection of stem cells with bio-scaffolds coated with growth factors 
may further enhance cell survival and neurogenesis.  
 
Reference  Cell 
Type 
Origin  Delivery  Timepoint  Cell 
Survival 
Cell 
Migration 
Neuronal 
Differentiation 
Decrease 
Lesion Size 
Functional  
Improvement 
 
Buhnemann 2006  ES  Mouse  IC             
Erdo 2003  ES  Mouse  IC  14 D           
Hoehn 2002  ES  Mouse  IC  14 D           
Takagi 2005  ES  Mouse  IC  2 D           
Hayashi 2006  ES  Primate  IC  1 D           
Lappalainen 2008  ES-NSC  Rat  IV  Immediate           
Theus 2008  ES-NSC    IC  2 D           
Daadi 2008  ES-NSC  Human  IC             
Hicks 2008  ES-NSC  Human               
Jiang 2005  NPC (A)  Rat  Cisternal  2 D           
Kameda 2007  NPC (A)  Rat  IC  Prior           
Zhang 2004  NPC (A)  Rat  Cisternal  2 D           
Zhang 2009  NPC (F)  Human  IC  1 D           
Darsalia 2007  NPC (F)  Human  IC             
Fukunaga 1999  NPC (F)  Rat  IC  Immediate           
Ishibashi 2004  NPC (F)  Human  IC  4 D           
Jeong 2003  NPC (F)  Human  IV  1 D           
Kelly 2004  NPC (F)  Human  IC  1 D           
Lee 2008  NPC (F)  Human  IV             
Jin 2005  NPC (F)  Mouse  IC  1 D           
Takahashi 2008  NPC (F)  Rat  IC  Immediate           
Zhang 2008  NPC (F)  Rat  IC  7 D           
Zhu 2005  NPC (F)  Rat  IC  3 D           
Pastori 2008  NPC (P)  Mouse  ICa  Immediate           
Bliss 2006  NSC CL  Human  IC  7 D           
Borlongan 1998  NSC CL  Human  IC  28 D           
Chu 2005  NSC CL  Human  IC  1 D           
Chu 2004  NSC CL  Human  IC  1 D           
Chu 2008  NSC CL  Human  IC  Prior           
Lee 2007  NSC CL  Human  IC  7 D           
Pollock 2006  NSC CL  Human  IC             
Sapporta 1999  NSC CL  Human  IC  28 D            
 
Stroemer 2008  NSC CL  Human  IC             
Guzman 2008  NSC CL  Mouse  IC             
Guzman 2008  NSC CL  Mouse  IV  2 D           
Kim 2004  NSC CL  Mouse  IC  Immediate           
Mochizuki 2008  NSC CL  Mouse  IC   Immediate           
Modo 2002  NSC CL  Mouse  IC  14 D           
Modo 2008  NSC CL  Mouse  IC  14 D           
Modo 2002  NSC CL  Mouse  IC  14 D           
Modo 2002  NSC CL  Mouse  IC  14D           
Veizovic 2001  NSC CL  Mouse  IC  14 D           
Shyu 2008  OEC  Human               
Borlongan 2005  Haem  Human  IV  Immediate           
Shyu 2006  Haem  Human  IC  7D           
Willing Sanberg 2003  Haem  Human  IV  1 D           
Schwarting 2008  Haem  Rat  IV  1 D           
Chen 2008  Haem    IC             
Yoo 2008  MSC  Human  IC  3 D           
Chen 2003  MSC  Human  IV  1 D           
Kurozumi 2004  MSC  Human  IC  1 D           
Li 2002  MSC  Human  IV  1 D           
Zhao 2002  MSC  Human  IC  7D           
Chen 2001  UCB  Human  IV  1 D           
Ding 2007  UCB  Human  IC             
Kozlowska 2007  UCB  Human  IC  2 D           
Taguchi 2004  UCB  Human  IV  2 D           
Vendrame 2004  UCB  Human  IV  1 D           
Willing 2003  UCB  Human  IC  1 D           
Xiao 2005  UCB  Human  IV  2 D           
 
Table 2.13.1.4.1 Table of cellular therapy studies for cerebral ischaemia. Green, improved outcome relative to control. Yellow, no difference in outcome relative to control. Red, 
poor outcome relative to control. Grey, not assessed. ES, embryonic stem cell. ES NSC, embryonic stem cell-derived neural stem cell. NPC (F), fetal neural progenitor cell. NPC (P), 
postnatal neural progenitor cells. NPC (A), adult neural progenitor cells. NSC CL, neural stem cell immortalised cell line. OEC, olfactory ensheathing cells. Haem, haematopoietic stem 
cells. MSC, mesenchymal stem cells. UCB, umbilical cord blood cells. IV, intravenous. IC, intracerebral. ICa, intracarotid.   
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2.13.2.  Mechanism of  action in cellular therapy 
While many cell types have demonstrated functional improvement in cell therapy studies, the 
mechanism  of  action  is  not  well  understood.  Several  actions  have  been  observed:  neuronal 
differentiation and cell replacement; trophic support of endogenous cells; neuroprotection; and 
immunomodulation. Understanding the mechanisms of action is important, and this knowledge 
will determine study parameters such as the optimal cell type, delivery route and timepoint. A 
primarily immunomodulatory role for stem cells suggests that systemic cell delivery would be 
appropriate, whereas a neuronal differentiation role would require cell grafting at or near the 
injury site for maximum cell replacement.  
A number of studies have demonstrated some neuronal differentiation of graft stem cells after 
cerebral ischaemia (Table 2.13.1.4.1). The graft cells differentiate appropriately and can integrate 
into local circuitry. However, this cell replacement occurs at relatively low levels, and it is unlikely 
that the low level of neuronal differentiation accounts for the functional improvement reported 
following NSC cell therapy. Neuroprotection, immunomodulation and trophic support are likely 
important roles of graft cells that contribute to the improved outcome.  
The concept of the ectopic neurovascular niche has been proposed for NSC and bone marrow 
stem cell therapy, where transplanted cells support endogenous neurogenesis by recreating the 
components of the SVZ neurovascular niche at the lesion site, by increasing neovascularisation; 
increasing  the  recruitment  of  endogenous  NSC  to  the  lesion;  and  inducing  plasticity  in  the 
ischaemic hemisphere (Martino and Pluchino, 2006; Bliss et al., 2007). Transplanted NSC are able 
to home to lesion areas, termed ‘pathotropism’, migrating towards gradients of proinflammatory 
cytokines and chemokines (Aboody et al., 2000; Ben-Hur et al., 2003), are closely associated with 
endothelial cells and astrocytes at the lesion (Chang et al., 2007).  
Grafted cells may also act by neuroprotection and prevention of cell death. NSC and BMSC grafts 
are  associated  with  reduced  apoptosis  and  latent  cell  loss  at  the  lesion,  reduced  glial  scar 
formation,  and  increased  survival  of  neurons  and  endogenous  neuroblasts  at  the  penumbra 
(Camarero et al., 2003; Otaegi et al., 2006). Grafted cells may also modulate the immune response 
to injury locally and peripherally. In the EAE model, grafted NPC reduce brain inflammation via 
reduced immune cell infiltration and reduction of proinflammatory cytokines (Einstein et al., 
2007). This effect has also been observed in cerebral ischaemia. Lee et al demonstrated that acute 
intravascular  administration  of  neural  stem  cells  reduced  neuroinflammation  after  cerebral 
ischaemia, but this effect was reversed if rats received splenectomy prior to ischaemia, indicating a 
peripheral immunomodulatory effect of NSC rather than local CNS effect (Lee et al., 2008).  
These neuroprotective and trophic effects of stem cell grafts promote the expression of growth 
factors at the ischaemic lesion, and stem cells themselves secrete growth factors. The protective  
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and neurogenic actions of growth factors were previously described, and stem cell grafts may act 
by promoting these pathways after stroke. SDF1α is normally expressed in bone marrow stromal 
cells (Stumm et al., 2002). The receptor CXCR4 is expressed in SVZ NPC (Ni et al., 2004; Thored 
et al., 2006), and this may be one pathway by which bone marrow grafts enhance neurogenesis 
after  stroke.  Capone  et  al  demonstrated  that following  neural  progenitor  cell  transplantation, 
several growth factors were upregulated at the ischaemic lesion - IGF-1, VEGF, TGFb1, BDNF, 
SDF1α (Capone et al., 2007). 
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3.  Magnetic resonance imaging in cerebral ischaemia 
Magnetic  resonance  imaging  (MRI)  is  a  powerful  non-invasive  imaging  modality  for  cerebral 
ischaemia  that  can  provide  anatomical  and  physiological  information  for  the  normal  and 
pathological CNS. Relative to other in vivo imaging modalities, it has high spatial resolution, but 
weak sensitivity and signal to noise.  
MRI is a technique based on the detection of protons (1H) of water molecules. Water protons in 
different  tissues  will  have  different  relaxation  times  based  on  their  unique  physiochemical 
environment,  and  this  difference  can  be  exploited  to  maximise  contrast  between  tissues  and 
generate an anatomical image. Furthermore, through the development of MRI contrast agents 
that can label cells or bind to specific cellular markers, a new field cellular and molecular imaging 
is emerging.   
Some atomic nuclei, such as 1H, 13C and 31P, possess spin. The classical approach is to visualise 
the nucleus of a proton spining around its own axis, generating a magnetic moment. The sum of 
all spins in a sample is the net magnetisation vector (Mz). Under normal conditions its polarity is 
random and net magnetisation is 0.  The magnetic moment is dependent on the gyromagnetic 
ratio, which varies depending on the structure of a given nucleus. 1H has a unique gyromagnetic 
ratio compared to 13C or 31P. The spin quantum number I for 1H protons is ½.   
 
3.1.  Relaxation 
When an external magnetic field (B0) is applied along the z-axis, net magnetisation (Mz) becomes 
aligned parallel to B0 (figure 3.1.1). Spins precess around B0 at the Larmor frequency (ω0), which 
is proportional to the strength of the applied magnetic field and the gyromagnetic ratio of the 
nucleus. This is given by the equation:  
ω0  = B0  x λ 
where  ω0  is  the  Larmor  frequency  at  which  nuclei  precess; B0  is  the  external  magnetic  field 
strength, and λ is the gyromagnetic ratio.  
The Larmor frequency is specific to protons at a given field strength. Nuclei will adopt an energy 
state, m, parallel or anti-parallel to the applied magnetic field B0, where a greater proportion will 
adopt the lower energy parallel state (Fig 3.1.1). Transition between energy states can occur, and 
this change is used to detect an NMR signal. Because of the small energy difference between spin 
states, NMR sensitivity is inherently low. The energy difference between parallel and antiparallel 
nuclei is proportional to the applied field strength B0. At greater field strength there is a greater 
energy difference and greater net signal, generating better signal to noise.   
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Figure  3.1.1  Net  magnetization  of  nuclear  magnetic  moments  parallel  to  applied 
magnetic field B0 (from Westbrook et al.)  
 
When a 90o radiofrequency (RF) pulse is applied in the xy plane at the Larmor frequency ω0, this 
tilts magnetization into the transverse xy plane Mxy, which returns to equilibrium, parallel to the z 
plane,  over  time.  This  relaxation  can  be  described  according  to  two  time  constants,  the 
longitudinal relaxation time T1, and the transverse relaxation time T2. The longitudinal relaxation 
time T1 is the time constant for the recovery of Mz magnetization parallel to B0. The transverse 
relaxation time T2 is the time constant for the decay of transverse magnetisation. The T1 and T2 
values for different samples and tissues will vary according to the molecular environment of the 
1H protons, and in this way image contrast between tissues can be generated.   
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Figure 3.1.2 Longitudinal Relaxation, recovery of Mz magnetization (from Westbrook et 
al.). Top, T1 time constant. Middle and bottom, example of recovery of Mz magnetization in 
water  (bottom),  and  contrast  agent  solution  (middle),  which  accelerates  the  longitudinal 
relaxation rate. Contrast agents are discussed further in Section 3.7.  
 
 
 
 
Figure 3.1.3 Transverse Relaxation, decay of transverse magnetization (from Westbrook 
et al.). Top, T2 time constant. Bottom, schematic of loss of Mxy phase coherence.   
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3.2.  Signal detection 
Using a transmitter coil near the sample, an RF pulse of defined frequency and duration is sent 
through the transmitter coil by the transmitter, generating an oscillating magnetic field B1 in the 
sample. Nuclei absorb energy at the Larmor frequency, and signal at the resonant frequency is 
detected  by  a  receiver  coil.  This  signal  is  termed  the  free  induction  decay  (FID),  and  is  a 
waveform  expressed  as  a  function  of  time,  with  many  frequency  components.  By  Fourier 
transformation, spatial and contrast information can be resolved from the FID signal, and an 
image can be constructed. Signal to noise is affected by the magnetic field strength B0, the voxel 
size, the T1 and T2 of the sample, and pulse sequence parameters.  
 
3.3.  Spin echo sequence and measurement of  T2 
When a 90o RF pulse is applied, the phase coherence of Mxy also decays over time (Figure 3.1.3). 
Protons in different molecular environments precess at slightly different frequencies, causing a 
spread in magnetization and loss of signal. Loss of Mxy phase coherence can be accelerated by 
local magnetic field inhomogeneities of tissues, which dephase spins in the xy plane. The time 
constant T2* reflects the combined T2 and local field inhomogeneity effects. A 180o refocusing 
pulse is used to reduce the effects of the T2* component, reversing the decay to produce a spin 
echo.  At  time  TE/2,  the  magnetisation  phase  is  inverted  and  the  direction  of  precession  is 
reversed,  eventually  returning  to  phase  coherence  at  the  echo  time  TE.  The  180o  pulse 
counteracts  the  dephasing  effects  of  local  field  inhomogeneities,  and  the  dephasing  from  T2 
relaxation effects is predominantly detected. T2-weighting is proportional to TE, where greater T2 
weighting occurs at longer echo times. The T2 relaxation time of a sample can be measured by 
taking a series of T2 measurements at varying echo times, which generates a relaxation curve from 
which the T2 constant can be measured.  
 
Figure 3.3.1 The spin echo sequence (modified from Westbrook et al.). RF, radiofrequency  
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pulse. FID, free induction decay. TR, repetition time. TE, echo time.  
 
3.4.  Gradient echo sequence and measurement of  T2* 
Rather than using a 180o RF refocusing pulse, for the gradient echo sequence, the frequency 
encoding gradient is used to rephase the FID. The first gradient dephases the magnetisation, and 
on reversal of the gradient, magnetisation rephases, where the maximum rephasing occurs at full 
reversal, producing a gradient echo signal. The gradient echo does not refocus the dephasing 
effects of the local field inhomogeneities, generating a T2*-weighted image. The gradient echo 
sequence  is  sensitive  to  local  field  inhomogeneities  generated  from  the  presence  of 
superparamagnetic conrast agents in a sample. The gradient echo sequence is used to detect iron 
oxide-based MRI contrast agents in vivo in Chapters X and X.  
 
Figure 3.4.1 The gradient echo sequence (from Westbrook et al.) 
 
3.5.  Inversion recovery sequence and measurement of  T1 
The T1 constant of a sample can be measured using the inversion recovery pulse sequence. A 180o 
pulse is applied and magnetisation is inverted, antiparallel to the z axis. The spins relax towards 
M0 equilibrium at a rate dependent on the T1 time constant. After a give inversion time TI , 
another 90o pulse is then applied to rotate Mz into the xy plane. The FID signal amplitude is 
dependent on Mz at the time of the 90o pulse, which is determined by the T1 relaxation constant. 
If a series of measurements are taken at varying inversion times TI, then an inversion recovery 
curve can be generated and the T1 constant measured. The inversion recovery pulse sequence is 
used to measure the T1 or gadolinium-based MRI contrast agents in Chapter 5.    
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Figure 3.5.1 The inversion recovery sequence (from Westbrook et al.). 
 
3.6.  MRI and ischaemia 
Magnetic resonance imaging is an important non-invasive imaging modality in cerebral ischaemia. 
In  experimental  animal  models,  it  can  provide  longitudinal  data  for  individual  subjects,  both 
anatomical and physiological. Relative to other non-invasive imaging modalities, MRI provides a 
high spatial resolution and sensitivity.   
In the normal CNS, the cerebrospinal fluid (CSF) has a long T1 and T2, whereas grey and white 
matter have shorter T1 and T2. Under pathological conditions such as cerebral ischaemia, the 
water distribution in affected tissues changes, changing the T1 and T2 values of the tissue, and in 
this way pathological anatomy can be imaged.  During and subsequent to cerebral ischaemia, 
changes  in  water  compartment  occur  due  to  cytotoxic  and  vasogenic  oedema,  and  BBB 
breakdown. Cerebral blood flow changes occur during ischaemia and reperfusion (Calamante et 
al., 1999b; Thomas et al., 2000; Lythgoe et al., 2003),(Calamante et al., 1999a; Lythgoe et al., 2003; 
Thomas  et  al.,  2000),  as  well  as  inflammation  and  infiltration  of  peripheral  leukocytes  and 
macrophages. These water movements and pathological events can be imaged using MRI. T2-
weighted  imaging  can  detect  the  acute  ischaemic  response  (Calamante  et  al.,  1999a),  and 
demarcate  the  mature  and  evolving  lesion  (Wegener  et  al.,  2006).  This  closely  correlates  to 
histological data.  Diffusion-weighted imaging (DWI) is sensitive to cytotoxic oedema in the acute 
phase of ischaemia, as cell swelling causes a change in water diffusivity within ischaemic cells 
relative to normal cells. These diffusion changes correspond to regions of periinfarct acidosis and 
infarct core. Cerebral perfusion can be measured non-invasively using arterial spin labelling (ASL), 
and the infarct core and surrounding region of reduced perfusion can be detected (Weber et al., 
2006; Dijkhuizen and Nicolay, 2003). The penumbra can be identified where DWI and ASL 
images do not overlap and only perfusion changes are observed, outside of the ischaemic core, 
but  where tissue has experienced reduced perfusion but not cytotoxic oedema and cell death  
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(Neumann-Haefelin et al., 2000; Lythgoe et al., 2003; Thomas et al., 2000).  
Breakdown  of  the  BBB  can  be  imaged  using  MRI  contrast  agents.  Systemically  injected 
gadolinium leaks into the brain parenchyma from the CNS vasculature at areas of BBB disruption 
and  endothelial  damage.  This  generates  an  area  of  hyperintensity  in  T1-weighted  images 
(Dijkhuizen and Nicolay, 2003). Furthermore, the peripheral immune response to ischaemia can 
be imaged.  Ferumoxide agents taken up by peripheral macrophages can be visualised in the 
ischaemic brain upon macrophage infiltration (Jander et al., 2007; Rausch et al., 2001; Rausch et 
al.,  2002;  Weber  et  al.,  2005).  MRI  contrast  agents will  be  discussed  in further  detail  in  the 
following section. 
Other imaging modalities can be used for imaging cerebral ischaemia. Ischaemic lesions can be 
detected by PET imaging by observing the uncoupling of regional cerebral blood flow (rCBF) and 
the cerebral metabolic rate of oxygen consumption (CMRO2) (Marchal et al., 1996).  
 
3.7.  MRI contrast agents 
A novel application of magnetic resonance imaging is the use of contrast agents for cellular 
imaging. Cellular imaging has been defined as the “non-invasive and repetitive imaging of targeted 
cells and cellular processes in living organisms” (Bulte and Kraitchman, 2004a). Traditionally, 
contrast on MR images is achieved by exploiting differences in relaxation rates of different tissues 
in the body, or between normal and pathological tissue, on T1- or T2-weighted images, but in 
many  cases  tissue  contrast  is  insufficient.  Contrast  agents  (CA)  are  designed  to  accelerate 
relaxation rates of surrounding water protons, decreasing local T1 and T2 and generate contrast 
against non-contrast agent enhanced tissue. They can be categorised based on their predominant 
effect on T1 or T2 relaxation: a dominant T1 reduction effect will increase signal intensity and 
generate positive contrast on a T1-weighted image; whereas a predominantly T2-shortening effect 
will reduce signal intensity and generate negative contrast on T2-weighted images (Modo et al., 
2005). Relaxivity – the ability of a contrast agent to reduce the T1 or T2 relaxation rate – is the unit 
of measurement of contrast enhancement. Increased relaxivity will lead to increased contrast on 
an  MR  image,  or  the  same  contrast  can  be  achieved  with  a  smaller  dose  of  contrast  agent. 
Relaxivity (r1 or r2) is calculated using the equation:  
[ ] Gd r
T T
1 0
1
obs
1
1 1 ￿ ￿     
or    
   
respectively, and measured as mM-1 sec-1.    
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3.7.1.  Paramagnetic contrast agents 
Paramagnetic agents are typically organic compounds that form a complex with lanthanide or 
transition metal ions. The majority of paramagnetic agents are complexes synthesised with the 
Gd3+ ion (Hermann et al., 2008). The first gadolinium-based contrast agents were developed in 
the 1980s (Kabalka et al., 1987). Gadolinium-DTPA [Gd(DTPA)(H2O)2] (Magnevist ®) was the 
first to be licensed for clinical MRI by the Food and Drug Administration (FDA), and now over 
30% of clinical MRI scans use gadolinium for contrast enhancement (Caravan et al., 1999). 
Typical applications of gadolinium-based contrast MRI imaging include renal, tumour, blood 
brain barrier imaging, and angiography, or to decrease the total acquisition time in anatomical 
imaging. Relaxivity and cytotoxicity of novel gadolinium-based contrast agents, designed and 
synthesized for cellular imaging, are assessed in Chapter 5.  
The Gd3+ ion has 7 unpaired electrons and a high magnetic moment. The greater access and 
proximity  of  water  to  the  Gd3+  ion,  the  better  it  can  affect  proton  spin  and  increase  the 
relaxation of water protons. There are two main mechanisms by which gadolinium affects water 
protons, via inner sphere and outer sphere effects. Inner sphere effects refer to water directly 
coordinated  to  the  Gd3+  ion.  Gadolinium-bound  water  protons  relax,  and  water  molecules 
undergo rapid chemical exchange with each other. The net effect is that gadolinium enhances the 
relaxation rate of surrounding water. The outer sphere effect refers to the remote relaxation 
effect gadolinium has on nearby diffusing water that is not bound to the Gd3+ ion.  
 
3.7.1.1.  Paramagnetic contrast agent design 
Several factors affect relaxivity of gadolinium contrast agents: the number of free sites available 
for inner sphere water proton coordinated to the Gd3+ ion, q; the water exchange rate, τM; the 
rotational correlation time, or molecular tumbling time, of the contrast agent, τR; and outer 
sphere indirect water interaction with gadolinium (Hermann et al., 2008) All of these parameters 
can be altered through ligand design.  
Gadolinium  must  be  coordinated  in  a  ligand  that  has  high  thermodynamic  stability  and  is 
kinetically inert. Because of the toxicity of the free Gd3+ ion, it must remain encapsulated in the 
ligand. Gadolinium contrast agents are typically 9-coordinate structures: an 8-coordinate organic 
ligand  and  a  single  water  molecule  coordinated  to  a  Gd3+  ion.  Structures  that  allow  two 
coordinated water molecules have less thermodynamic stability, and may lead to dissociation of 
the toxic Gd3+ ion into a biological environment. In vivo, endogenous Zn2+ and Ca2+ ions are the 
main  competitors  to  Gd3+  (Hermann  et  al.,  2008),  so  the  contrast  agent  must  also  resist 
transchelation and loss of the Gd3+ ion. Other chelating agents found in vivo include phosphate, 
citrate and bicarbonate.   
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Gadolinium contrast agents achieve the optimum relaxivity when the rotational diffusion τR of 
the molecule approaches the Larmor frequency ω0, which is typically slower than the rotational 
diffusion  of  the  contrast  agent.  Slower  τR  allows  for  more  water  exchange  to  occur,  and 
therefore increased relaxation of surrounding water by gadolinium via inner sphere effects. In 
vivo, slower rotational diffusion can be achieved by increasing the effective molecular weight of 
the complex, through non-covalent binding of the complex to larger proteins, or by covalent 
binding  to  become  part  of  a  larger  polymer  (Caravan  et  al.,  1999).  A  number  of  clinical 
gadolinium-based contrast agents have been designed to non-covalently bind to human serum 
albumin (HSA) in the blood to increase relaxivity, for example MS-325, Vasovist and Multihance 
(Hermann et al., 2008). An additional advantage of this strategy is that contrast agent relaxivity is 
enhanced only in areas of high physiological concentration of HSA, eg in the blood pool.  
 
3.7.1.2.  Cellular imaging with paramagnetic contrast agents 
Cellular imaging using gadolinium-based contrast agents is less common than with iron oxide-
based agents. Gadolinium T1 relaxivity is an order of magnitude weaker than iron oxide T2 
relaxivity and this is a disadvantage for cellular imaging that depends on high sensitivity and 
spatial resolution for cellular detection. However, T1 relaxivity is desirable as it can produce 
increased  and  hyperintense  signal  on  T1-weighted  images,  and  can  be  distinguished  from 
magnetic susceptibility effects, unlike superparamagnetic contrast agents.  
A number of gadolinium-based approaches to cellular labelling have been successful. Rudelius et 
al used the transfection agent lipofectin to label embryonic stem cells with gadolinium DTPA 
(Rudelius  et  al.,  2003).  Gd-DTPA  was  localised  in  the  cytoplasm,  as  assessed  by  electron 
microscopy, and labelled cells generated positive contrast on MRI images. However the study 
also found that the labelling efficiency was low (less than 50%) and caused reduced cell viability. 
Other studies have similarly found that cells can be labelled with gadolinium contrast agents and 
generate positive contrast in vitro, for example mononuclear cell labelling with gadophorin-2 
using  lipofectin  transfection  agent;  monocyte  labelling  with  gadofluorine-M  (Henning  et  al., 
2007);  and  mesenchymal  cell  labelling  with  gadolinium  fullerene  (Anderson  et  al.,  2006). 
However several of these studies report, where viability has been assessed, that the contrast 
agent labelling is associated with reduced cell viability.  
Brekke  et  al  found,  using  the  rhodamine-conjugated  gadolinium  contrast  agent  GRID,  that 
labelling neural stem cells resulted in localisation of the contrast agent in the cytoplasm (Brekke 
et  al.,  2007).  The  GRID  contrast  agent,  however,  acts  primarily  as  a  T2  agent,  generating 
hypointensity in vitro and in vivo (Brekke et al., 2007; Modo et al., 2002a; Modo et al., 2004). 
Labelling with GRID also induced cellular stress, decreased viability and proliferation, although  
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labelling did not affect cell differentiation or migration (Modo et al., 2008).   
Another  gadolinium  cellular  imaging  approach  has  been  used  to  image  tumor  cells  in  vivo. 
Exploiting the fact that proliferating tumor cells have upregulated glutamine transporter systems 
on the cell memebrane, Lattuada et al covalenetly bound glutamine to gadolinium DOTA and 
found that the gadolinium-glutamine agent preferentially localised to tumor cells, generating T1 
hyperintensity (Lattuada et al., 2006). This enhancement of T1 contrast in tumor cells was also 
demonstrated in an in vivo tumor in mouse (Geninatti et al., 2006).  
Macromolecular  gadolinium  contrast  agents  have  also  been  developed  for  cellular  imaging 
tumour targeting. Fu et al describe a polymer with a polyethylene glycol/polylysine backbone and 
Gd-DTPA compenents at the ends, developed for tumour angiogenesis detection (Fu et al., 
2007). Wiener et al describe a folate-conjugated DTPA- polyamidoamine dendrimer structure 
(Wiener  et  al.,  1997).  The  highly  branched  dendrimer  contrast  agents  were  observed  to 
accumulate in tumour cells expressing the folate receptor, and decreased the T1 relaxation time 
of  cells  relative  to  unlabelled  tumour  cells.  In  Chapter  5,  we  investigate  the  relaxivity  and 
cytotoxicity of gadolinium polymer contrast agents designed and synthesised for cellular imaging.  
 
3.7.2.  Superparamagnetic contrast agents 
Superparamagnetic  contrast  agents  are  typically  iron  oxide-based  agents  composed  of  a 
magnetite  crystal  core  embedded  in  a biocompatible coating  (Modo  et  al.,  2005).  Magnetite 
crystals possess a large magnetic moment in the presence of an external magnetic field, and 
create a local magnetic field inhomogeneity. This causes remote dephasing of water protons, 
which decreases the T1 and T2 locally (Bulte and Kraitchman, 2004b; Modo et al., 2005).  
r2*  relaxivity,  or  the  susceptibility  effect,  describes  the  increase  in  T2*  relaxation  due  to 
magnetisation differences between neighbouring regions or adjacent voxels. Non-homogeneous 
distribution of iron oxide particles in a tissue will give rise to local field inhomogeneities around 
the iron oxide particles. T2*-weighted sequences are sensitised to the proton dephasing caused 
by local magnetic field inhomogeneities, and are typically used to detect susceptibility effects 
from superparamagnetic iron oxide contrast agents (Bulte and Kraitchman, 2004a). For cellular 
imaging, the magnetic field distortion can extend beyond the volume of a single cell containing 
iron oxide (Magnitsky et al., 2005), and this has been termed a ‘blooming effect’ (Bulte et al., 
2001). No water has access to or is bound directly to the magnetite crystals, therefore there are 
no inner sphere effects associated with superparamagnetic contrast agents (Modo et al., 2005). 
Superparamagnetic  iron  oxide  (SPIO)  particles,  or  ferumoxide  particles,  are  composed  of 
multiple  magnetite  crystals  forming  the  core,  with  an  average  particle  diameter  of  200  nm. 
Ultrasmall SPIO (USPIO), or ferumoxtran particles, consist of a single crystal core and have an  
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average particle diameter of 50 nm (Modo et al., 2005). For SPIO and USPIO, the magnetite 
core size is in the range of 4-10 nm. Relaxivity increases with increasing crystal density, and so 
SPIO – with several magnetite crystals per core and a large magnetic moment – can generate 
more contrast per mol of iron than USPIO (Bulte and Kraitchman, 2004a). The extent of in vivo 
r2* relaxivity of an SPIO contrast agent is dependent on several other factors including the 
compartmentalisation or aggregation of the agent in tissue, cells or the bloodstream, and the 
imaging sequence and parameters used.  
The compounds are typically coated in a biocompatible material, most commonly dextran or 
other polysaccharides. These surface modifications are required for stabilisation – to prevent 
crystal  aggregation  –  as  well  as  for  solubility  and  biocompatibility.  The  composition  of  the 
coating provides possible conjugates for ligand binding such as antibodies, proteins or peptides 
etc, for targeted labelling. Other surface modification strategies designed to increase specificity, 
biocompatibility, or cell labelling include magnetite encapsulation in an apoferritin protein shell 
(Bulte et al., 1994); magnetodendrimers (Bulte et al., 2001); biotin-streptavidin system – binding 
biotinylated  antibodies  to  streptavidin-SPIO  (Artemov  et  al.,  2004),  and  covalent  linking  of 
dextran to antibodies by (Bulte and Kraitchman, 2004a). The latter method pre-dates molecular 
imaging and was originally designed for isolation of specific cell types by antibody recognition 
and separation through a magnetic column (Dutton et al., 1979).  
The most commonly used category of superparamagnetic contrast agents is the SPIO. This 
category includes Endorem/Ferridex, an FDA-approved iron oxide-based contrast agent. This is 
a dextran-coated particle with an average diameter of 150-200 nm, and has been licensed for use 
in MRI of the liver.  Other contrast agents that will be discussed in further sections include the 
USPIO Sinerem and Bangs particles. These are larger micron-sized iron oxide nanoparticles, 
with a divinyl benzene coating and conjugated to a fluorophore, which allows for fluorescent 
microscopy of the Bangs particles in histological sections.   
SPIO  cellular  uptake  commonly  occurs  by  endocytosis,  and  SPIO  localise  intracellularly  in 
endosomes. Cellular internalisation and particle clustering increases particle susceptibility effects 
(Kraitchman and Bulte, 2008). Cell iron content after SPIO uptake is in the range of 10-20 pg 
iron per cell, whereas non-labelled cells contain 0.01-0.1 pg iron per cell (Arbab et al., 2003). 
SPIO degrade in acidic environments such as the lysosome, and SPIO-containing endosomes 
have been observed to fuse with lysosomes after 5 days. Once in the lysosome, iron in SPIO 
particles  may  enter  endogenous  iron  homeostasis  pathways  and  be  stored  as  ferritin  or 
hemosiderin. Iron homeostasis pathways in the CNS are discussed in section 3.9.  
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3.7.2.1.  Cell labelling strategies using SPIO 
Cellular internalisation of SPIO can occur via several mechanisms of endocytosis. Phagocytosis 
is the internalisation of cellular debris, bacteria, virus, etc., by macrophages or microglia. It is 
known that peripheral macrophages preferentially uptake SPIO and USPIO via this mechanism, 
and  phagocytosis  has  been  exploited  to  label  macrophages  endogenously  with 
superparamagnetic  contrast  agent  for  cellular  imaging  of  inflammation  processes.  This  is 
described in further detail in section 3.7.2.3 (Bulte and Kraitchman, 2004a). Pinocytosis describes 
the  internalisation  of  molecules  via  non-specific  binding  to  the  cell  membrane  into  an 
intracellular pinosome. This is an active process and can occur in all cell types and is the likely 
method of SPIO uptake for most cell types including stem cells (Modo et al., 2005). Clathrin- or 
caveolin-mediated endocytosis rely on specific receptor-ligand or protein transport interactions 
on the cell membrane, and can be exploited in SPIO design to increase cellular uptake. For 
example, transferrin-transferrin receptor interactions lead to clathrin-mediated invagination of 
the cell membrane and internalisation of transferrin into intracellular endosomes (Kresse et al., 
1998; Moore et al., 1998).  
Cell labelling with SPIO can occur through incubation of SPIO in the culture media alone, and 
has  been  achieved  in  a  variety  of  non-phagocytic  cells:  human,  rat  and  mouse  stem  and 
progenitor cells, glioma cells, dendritic cells, lymphocytes, fibroblasts, cancer cells and several 
cell lines. Cellular uptake is proportional to the SPIO concentration in the culture media (Modo 
et al., 2005). Labelling by incubation can be modified to improve cellular uptake efficiency or to 
reduce labelling time, for example by transfection, electroporation, magnetoliposomes, and the 
CLIO-Tat system.   
Transfection agents (TA) used are typically polycations that form complexes with the SPIO 
through electrostatic interactions and facilitate SPIO binding to the cell membrane, initiating 
endocytosis of the TA-SPIO complex (Politi 2007). A number of commercially available TA 
have been successfully used to increase SPIO uptake (FuGene, lipofectamine, Polyfect, etc), as 
well as poly-L-lysine and protamine sulphate (Arbab 2004).  
Protamine sulphate is an attractive TA for cell labelling and cellular imaging because it has a 
higher  transfection  efficiency  than  poly-L-lysine (Cornetta  and  Anderson,  1989;  Sorgi  et  al., 
1997), and has FDA approval for administration to humans. It is commonly used to reverse 
heparin anticoagulation, but has also been used as a contrast agent in clinical gene therapy trials  
(Porter et al., 1998; Cornetta and Anderson, 1989). In conjunction with the SPIO Endorem 
which  is  also  licensed  by  the  FDA,  cellular  labelling  with  the  Endorem-protamine  sulphate 
complex (termed FePro) has a high possibility of translating to the clinic for application in 
cellular therapy clinical trials. The FePro complex has been tested for cell viability in several cell 
types and demonstrated to be well-tolerated (Arbab et al., 2003; Arbab et al., 2004; Arbab et al.,  
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2005b). We investigate the cytotoxicity and effects on NPC behaviour of FePro in Chapter 4. 
Cell labelling through electroporation is less favoured as this method is not well tolerated by 
many  cell  types,  and  can  decrease  cell  viability  (Suzuki  et  al.,  2007).  This  method  involves 
generating transient pores in the cell membrane by applying an electrical current to the cells. 
Material such as DNA or MRI contrast agents can then enter the cell via these pores. Walczak et 
al describe successful magnetoelectroporation in the C17.2 neural stem cell line, with minimal 
effects on cell viability (Walczak et al., 2006). Magnetoliposomes are SPIO within liposomes. 
The  liposome  exterior  facilitates  cell  internalisation  (Bulte  and  Kraitchman,  2004a;  De  and 
Joniau, 1988), and has been used in several cell types.  
The  CLIO-Tat  system  links  iron  oxide  particles  to  peptides  with  membrane  translocation 
properties,  to  improve  particle  internalisaion.  The  human  immunodeficiency  virus-1 
transactivator  transcription  (HIV-1  Tat)  protein  has  been  conjugated  with  cross-linked  iron 
oxide particles (CLIO) to form the CLIO-Tat complex (Josephson et al., 1999; Lewin et al., 
2000).  Cell  labelling  with  the  CLIO-Tat  system  has  been  shown  to  be  increased  100-fold 
compared to using iron oxide particles alone. The FITC fluorophore has also been conjugated to 
the CLIO-Tat complex to form a bimodal contrast agent (Pittet et al., 2006).  
 
3.7.2.2.  Cellular imaging with superparamagnetic contrast agents 
The large T2* relaxivity of the superparamagnetic contrast agents increases the sensitivity greatly 
over paramagnetic agents, and cellular detection has been achieved at the single cell level in in 
vitro systems (Shapiro et al., 2006b). Sensitivity is dependent on the concentration of the label 
within the cell, as well as the field strength of the system and the imaging sequence used. It has 
been estimated that approximately 1.4-3.0 pg iron per cell is required for detection. By contrast, 
unlabelled cells contain 0.1pg of endogenous iron (Arbab and Frank, 2008).  
Several studies have successfully labelled stem cells and monitored them after transplantation in 
vivo over a period of time (Bulte and Kraitchman, 2004a). Cellular imaging in the brain was first 
described by Norman and Hawrylak, who transplanted fetal neural progenitor cells labelled with 
ferrite particles into the normal adult brain, and detected transplanted cells with MRI (Hawrylak 
et al., 1993). Hoehn et al (Hoehn et al., 2002) demonstrated that cells could be labelled with 
USPIO,  transplanted  into  the  ischaemic  brain,  and  their  response  to  ischaemia  imaged. 
Immortalised neural stem cells were transplanted in the contralateral hemisphere and observed 
to migrate into the ischaemic hemisphere via the corpus callosum over a period of weeks using 
MRI. Zhang and Guzman report monitoring C17.2 neural stem cell migration (Guzman et al., 
2008) or primary neural progenitor cells (Zhang et al., 2003) after cerebal ischaemia by SPIO 
labelling.   
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In  vivo  cellular  imaging  with  MRI  has  been  achieved  in  other  models  of  neurodegenerative 
disorders, for example EAE (Ben Hur et al., 2004; Ben Hur et al., 2007; Pluchino et al., 2003); 
Parkinson’s disease (Savitt et al., 2006) and brain tumours (Hakumaki et al., 2002; Zhang et al., 
2004d). Recently, MRI contrast agents have been used to label the endogenous population of 
stem cells in the SVZ of the adult rat, and to track their normal migration through the RMS to 
the olfactory bulb (Shapiro et al., 2006a; Sumner et al., 2009).  
There are many limitations to stem cell imaging using MRI contrast agents. As with other cellular 
markers, issues surrounding contrast agent toxicity and labelling efficacy are important to ensure 
that cells, once labelled, do not alter their molecular identity and normal behaviour. The negative 
contrast  can  be  difficult  to  discriminate  from  other  image  artefacts.  In  vivo  quantitation  is 
difficult, as signal is dependent on sequence parameters, and not directly proportional to iron 
oxide concentration. Cellular resolution and adequate signal must be achieved in vivo for cellular 
tracking studies. To date, single-cell resolution has only been achieved in vitro (Shapiro et al., 
2006b). Cell tracking in injury models is also complicated by the presence of macrophages. If a 
labelled cell dies in this situation, leaked contrast agent from the cell may be phagocytosed by 
surrounding  macrophages,  and  these  events  would  be  indistinguishable  on  MRI  images. 
However, Guzman et al were able to distinguish between living and non-living contrast agent-
labelled neural stem cells, where cell death resulted in increased T2* signal over time, indicating a 
reduction in contrast agent at the implantation site (Guzman et al., 2007).  
 
3.7.2.3.  Macrophage imaging 
SPIO particles with particle size of 200 nm can be rapidly internalised in vivo by phagocytic cells, 
including circulating macrophages, which take up the nanoparticles and store them in cytoplasmic 
vesicles (Raynal et al., 2004). Smaller USPIO have a longer plasma half-life. Macrophages have 
been  shown  to  upregulate  the  transferring  receptor  TfR-1  and  ferritin  following  uptake 
(Pawelczyk et al., 2008).  
SPIO  and  USPIO  uptake  by  macrophages  has  been  exploited  to  investigate  the  peripheral 
immune  response  in  a  number  of  models  of  neurodegenerative  diseases  including  cerebral 
ischaemia and EAE. In cerebral ischaemia, macrophage infiltration into the lesion and boundary 
zone was observed from 24 hours, where negative T2 contrast was observed against positive T2 
oedema (Kleinschnitz et al., 2003; Rausch et al., 2001; Rausch et al., 2002; Schroeter et al., 2004). 
Peak infiltration was estimated at 5-8 days post-ischaemia (Kleinschnitz et al., 2003). USPIO 
accumulation  occurred  outside  of  the  stroke  lesion,  which  may  predict  the  area  of  delayed 
neuronal death (Rausch et al., 2002). Saleh et al also described USPIO-macrophage accumulation 
in human stroke patients (Saleh et al., 2004). Macrophage accumulation has been observed in 
EAE at sites of inflammation and blood brain barrier breakdown (Berger et al., 2006; Dousset et  
68 
al., 1999; Floris et al., 2004). 
 
3.8.  Other Imaging Modalities for Cellular Imaging 
As discussed, MRI has high spatial resolution, but relatively low sensitivity and signal to noise. 
MRI  can  also  simultaneously  integrate  cellular  imaging  with  anatomical  and  physiological 
imaging. Other imaging modalities have been used for cellular imaging with superior sensitivity, 
at the expense of spatial resolution.  
Optical or bioluminescence imaging has been used to image neural stem cell CNS transplants 
(Bradbury et al., 2007; Shah, 2009; Ogawa et al., 2009), including in a model of cerebral ischaemia 
(Kim et al., 2004) and endogenous neural stem cells (Reumers et al., 2008). These studies typically 
involve lentiviral transduction of cells to express the firefly luciferase gene under the promoter of 
a gene of interest. Firefly luciferase spontaneously generates light as a byproduct of an enzymatic 
reaction, and this can be detected by an ultra-sensitive CCD camera. Very little light is generated 
by the luciferase reaction, and the CCD camera, while highly sensitive to light, has low spatial 
resolution. An additional limitation is the maximum tissue depth through which signal can be 
detected. These can be an impediment to small animal imaging studies.  
Single photon emission computed tomography (SPECT), x-ray computed tomography (CT) and 
positron emission tomography (PET) all require the use of high energy radiation (gamma or x-
rays), which can be toxic at accumulated or high doses. SPECT uses the contrast agents Indium-
III-oxine or Iodine I-123 or I-131, which can be taken up by cells but have short half-lives. 
SPECT/CT  has  been  used  to  image  the  accumulation  of  Indium-III-oxine-labelled  human 
embryonic and rat hippocampal stem cells in the brain following cerebral ischaemia (Lappalainen 
et al., 2008). The authors injected labelled cells intravenously or intra-arterially via the common 
carotid artery, and observed accumulation of cells in the ischaemic hemisphere after intra-arterial 
injection. Intravenously injected cells predominantly accumulated in the liver, spleen and kidneys, 
from immediately after injection. The SPECT/CT had relatively high sensitivity and could detect 
approximately 1000 labelled cells. Spatial resolution in the brain was low, however, and anatomical 
localisation was limited. 
 
3.9.  Iron homeostasis in the brain 
Iron is present in high concentrations in the brain relative to other tissues, in particular in the 
subsantia nigra and globus pallidus (Gaasch et al., 2007) and has independent metabolic pathways 
from non-CNS tissues. Disruption of these pathways can lead to degenerative disease in the brain 
(Sipe 2002). Iron is an enzyme co-factor, and is involved in the synthesis of neurotransmitters  
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dopamine  and  serotonin,  the  formation  of  myelin  by  oligodendrocytes,  the  synthesis  of 
cholesterol  and  other  CNS  lipids,  as  well  as  as  in  the  mitochondria  (Sipe  et  al.,  2002). 
Physiologically, iron can exist in two states, as ferrous (Fe2+) or ferric (Fe3+) iron, and systemic 
and CNS iron paythways are tightly, but independently, regulated.  
Iron uptake from the blood stream occurs in endothelial cells of the blood brain barrier (BBB). 
Transferrin-bound ferrous iron binds to transferrin receptor 1 (TfR1) on endothelial cells and 
endocytosis occurs (Moos, 2002). Plasma transferrin is recycled back into the plasma, and iron is 
transported out of the endothelial cells into the interstitial fluid by the transmembrane protein 
ferrotportin (Rouault and Cooperman, 2006). Brain transferrin – synthesised by oligodendrocytes 
and the choroid plexus – binds to the interstitial iron. This active transport of iron into the brain 
via endothelial cells means that brain iron levels are decoupled from plasma iron levels, and 
plasma iron levels do not alter brain iron levels (Moos, 2002). Free iron is in excess relative to 
transferrin in the brain by a ratio of 2 to 1, meaning that iron-bound transferrin is saturated in the 
brain (Gaasch et al.,  2007). Ferrous iron can be oxidised into ferric iron by the membrane protein 
cerulosplasmin in astrocytic end feet processes in contact with endothelial cells (Sipe et al., 2002). 
Transferrin and a parallel non-transferrin mechanism of iron regulation exist in the brain. TfR1 is 
expressed in neurons, with regional variability in expression levels across the brain (Gaasch et al.,  
2007). Transferrin has been observed in the cytoplasm and lysosomes of neurons, which suggests 
that neurons participate in the transferrin pathway (Moos, 2002). The transferrin-iron bond is 
weaker in acidic environments such as the endosome, and ferrous iron is released here.  
Extracellular transferrin-bound iron is excreted back into the blood via the choroid plexus, and 
high levels of transferrin, sythesised by the choroid plexus, are present in the ventricular CSF 
(Moos, 2002). This is regulated by epithelial cell control of solute movement between the CSF 
and systemic circulation, as the choroids plexus vasculature is different from the rest of the CNS 
in that it has fenestrated blood vessels instead of a tightly regulated blood brain barrier (Carbonell 
and Rama, 2007).  
Ferritin is an iron sequestration protein, which is the main source of iron within cells. The ferritin 
protein  is  a  hollow  spherical  shell  with  24  subunits.  Heavy  ferritin  is  the  catalytically  active 
ferroxidase  subunit  that  oxidises  ferrous  Fe2+  into  ferric  Fe3+  iron  for  storage  as  a  solid 
crystalline  nanoparticle  in  the  ferritin  core.  Ferritin  can  encapsulate  2000-4500  iron  atoms 
(Carbonell and Rama, 2007). The light ferritin subunit is involved in mineralization of iron in the 
ferritin  core.  Ferritin  protein  synthesis  has  been  observed  in  neuronal  and  glial  cell  bodies. 
However, no TfR1 or transferrin has been identified in glial cells. Ferric iron is reduced to ferrous 
iron on release from the ferritin core.  
Excess free iron present in the interstitial space can bind to other proteins or low molecular 
weight molecules such as citrate or phosphate. Oligodendrocytes and neurons express divalent  
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metal transporter-1 (DMT1) on the cell membrane, which transports free iron into intracellular 
endosomes (Carbonell and Rama, 2007; Gaasch et al., 2007; Sipe et al., 2002). Within the neuron, 
free  and  ferritin-bound  iron  can  be  transported  along  axons,  and  the  iron  transport  protein 
ferroportin is expressed at the synapse, suggesting iron transport out of neurons occurs at the 
synapse (Rouault and Cooperman, 2006). Brain iron pathways are discussed further in Chapter 4, 
in relation to ischaemic environments and interactions with iron oxide from an MRI contrast 
agent source.  
Constitutive expression of ferritin, transferrin, or both of these genes in cells results in increased 
uptake of endogenous iron from the blood pool or extracellular space (Deans et al., 2006; Genove 
et al., 2005). This represents an interesting crossover between MRI and genetic studies and may 
become  a  valuable  tool  in  transgenic  imaging,  and  with  high  levels  of  extracellular  free  and 
transferrin-bound iron, the brain is an ideal organ for these studies. There are several advantages 
to  this  genetic  strategy  over  conventional  MRI  contrast  agents,  particularly  the  possibility  of 
integration into the cellular genome in cell transplant studies, or as an in vivo marker of gene 
expression in lineage tracing transgenic studies. Overexpression of ferritin or transferrin has been 
achieved by adenoviral and lentiviral transduction (Cohen et al., 2005; Deans et al., 2006; Genove 
et al., 2005).   
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4.  Investigation of  cell labelling with ferumoxides and the evolution of  MR contrast and in a 
model of  cell transplantation in cerebral ischaemia 
4.1.  Introduction 
Stroke  remains  a  common  cause  of  mortality  and  disability  worldwide,  with  few  effective 
treatments available. Cerebral ischaemia, caused by the reduction of blood flow in a cerebral 
artery, is the most common type of stroke, accounting for 80% of strokes. Cellular therapy is an 
emerging and promising avenue for treatment of cerebral ischaemia. Several experimental studies 
have demonstrated that treatment with stem cells after an ischaemic event improves neurological 
score and behavioural recovery, and can reduce infarct volume (Arvidsson et al., 2002; Kokaia 
and Lindvall, 2003; Lindvall and Kokaia, 2006). These findings have led to a small number of 
clinical trials of cellular therapy in stroke patients, with only modest effects on neurological 
outcome and motor skill recovery observed (Aarum et al., 2003; Bang et al., 2005; Kondziolka et 
al., 2003; Kondziolka et al., 2000; Savitz et al., 2005). It is clear that further optimisation of cell 
type and delivery, and a greater understanding of the behaviour of engrafted cells is required for 
improved therapeutic outcome.  
For cell replacement, the lineage commitment of stem cells plays an important role in their 
differentiation potential after engraftment into injured tissue. Recent research has demonstrated 
that fetal telencephalic neural progenitor cells (NPC) are able to migrate towards the ischaemic 
infarct, differentiate into neurons in the peri-infarct area, and can improve behavioural recovery 
(Abrous et al., 2005; Darsalia et al., 2007; Ishibashi et al., 2004; Kelly et al., 2004; Lee et al., 2007; 
Takahashi et al., 2008; Zhang et al., 2009; Zhu et al., 2005). Developmentally, these radial glia-like 
cells give rise to the cortical neuron layers in the normal developing embryo, and may have the 
appropriate migratory capacity and neurogenic potential to give rise to neurons after engraftment 
into host injury tissue.  
Cellular  imaging  with  MRI  contrast  agents  can  be  used  to  monitor  the  distribution  of 
transplanted cells in models of cerebral ischaemia. Cells are labelled in vitro with iron oxide- or 
gadolinium-based compounds prior to engraftment, and generate contrast on MRI images in vivo. 
Hoehn et al.. demonstrated that C17.2 immortalised cerebellar stem cells could be labelled with 
the iron oxide-based agent Sinerem (Hoehn et al., 2002), and subsequently migrate into the 
infarcted area from the contralateral hemisphere. Modo et al.. demonstrated similar results with 
MHP36 immortalised hippocampal stem cells and a gadolinium-based contrast agent (Modo et 
al., 2002a; Modo et al., 2004). 
As yet, no MRI contrast agents have been approved for use in clinical trials of cellular therapy in 
stroke or other disease. Characterisation of the effect of MRI contrast agent labelling on stem  
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and progenitor cells is essential prior to use in a clinical setting. Previous studies have described a 
contrast  agent  complex  comprising  the  ferumoxide  Endorem  and  the  transfection  agent 
protamine sulphate, both of which have FDA approval for use in humans (Arbab et al., 2004; 
Arbab et al., 2005b; Panizzo et al., 2009). Endorem is a dextran-coated superparamagnetic iron 
oxide agent, and can form a complex with the polycationic protamine sulphate – the FePro 
complex. In previous studies it has been shown to have little effect on cell viability (Arbab et al., 
2005b).  
The aim of this study was to assess whether neural progenitor cell labeling and in vivo imaging 
could be optimized by using the FePro complex to label cells. We assessed the effect of FePro 
labelling  on  fetal  neural  progenitor  cell  (NPC)  metabolism,  proliferation  and  differentiation 
capacity. FePro-labelled NPC were engrafted into the ipsilateral parenchyma at 48 hours post-
ischaemia and monitored over 4 weeks using MRI. Assessment of NPC viability demonstrated 
no  difference  in  the  behaviour  of  FePro-labelled  NPC  compared  to  unlabelled  NPC. 
Furthermore,  cells  could  proliferate  and  differentiate  into  neurons,  oligodendrocytes  and 
astrocytes.  In  vivo,  we  observed  the  evolution  of  hypointense  T2  contrast  in  the  ischaemic 
striatum over several weeks in both control and FePro-NPC engrafted animals. We noted that 
from day 14 following ischaemia the observed hypointensities could be attributed to areas of 
labelled cells or tissue damage. We did not observe migration of FePro-NPC into the ischaemic 
striatum.  This  study  highlights  the  need  to  characterise  the  long-term  profile  of  cerebral 
ischaemia, and points to confounding image contrast at later timepoints that must be overcome 
in order for iron oxide based cellular imaging to be a viable method of cell tracking.  
 
4.2.  Methods 
4.2.1.  Neurosphere dissection and cell culture   
Forebrain tissue was dissected from E13.5 CD1 mouse embryos and digested in 1X trypsin with 
DNase for 7 minutes at 37oC.  Cells were washed in trypsin inhibitor and EBSS, and plated in 6 
well culture dishes. Proliferation medium contained DMEM:F12 with glutamax (Invitrogen), N2 
supplement (GIBCO), 10 ng/ml EGF (Peprotech), 20 ng/ml FGF-2 (Peprotech), 0.05% heparin 
and 1% Penicillin-Streptomycin.  Cells were incubated at 37oC with 5% CO2, and medium was 
replaced 24 hours after dissection.  Cells were passaged 7 days after dissection once neurosphere 
formation had occurred, and replated into 6 well culture dishes. NPC were passaged every 7 days. 
For each assay, NPC from the same litter and passage number (passage 2 or 3) were used.  
4.2.2.  ST14A cell culture 
Cells were cultured as described. The ST14A cell line was established by immortalisation of fetal  
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striatal cells through retroviral transduction of the SV40 Large T Antigen oncogene (Cattaneo 
1998). The cells proliferate at 33oC, and proliferation is inactivated at 39oC.  Cells were cultured 
on  adherent  flasks  in  DMEM  (Invitrogen)  with  10%  foetal  calf  serum  and  1%  Penicillin-
Streptomycin.  Cells  were  incubated  at  33oC  with  5%  CO2  and  100%  humidity.  Cells  were 
passaged every 48 hours, using 1X Trypsin-EDTA to detach cells from adherent flasks, collected 
and centrifuged in 10ml culture medium, replated 1:3 in fresh culture medium, and returned to 
the incubator.  
4.2.3.  Cell labelling with contrast agent 
Endorem: Cells were incubated with 500 µg/ml Endorem for 24 hours in cell culture medium to 
allow contrast agent internalisation.  
FePro complex: Endorem was incubated with protamine sulphate in a ratio of 9:5 for 10 minutes 
to form the FePro complex, to make a final concentration of 100 µg/ml Endorem and 10 µg/ml 
protamine sulphate in culture medium. The FePro complex was added to proliferation medium 
without heparin, and cells were incubated in FePro-proliferation medium for 24 hours.  Cells 
were  washed  in  EBSS  with  heparin  to  wash  excess  FePro  and  dissociate  the  extracellular 
complex.  
For adherent ST14A cells, cells were washed after labelling by replacing culture medium with 
Earl’s balanced salt solution without Ca2+ or Mg2+ (EBSS) to remove and dilute the contrast 
agent. This was repeated three times, then cells were trypsinised and passaged as described.   
For NPC labelling, neurospheres at 6 days after passage were dissociated as described above, and 
replated into medium containing Endorem or FePro contrast agent for cell labelling. NPC were 
incubated with contrast agent for 24 hours, then culture medium was diluted in 1:5 in EBSS and 
centrifuged to retain the pellet of labelled cells and discard the excess contrast agent and medium. 
The  dilution  and  centrifugation  process  was  repeated  three  times  to  wash  cells.  NPC  were 
dissociated as described above for replating or use in intracerebral microinjections. 
4.2.4.  Cellular viability assays 
Cells were incubated with Endorem, FePro, or no contrast agent (control) for 24 hours. Cells 
were washed three times, trypsinised, and replated into 96 well plates at a density of 104 cells per 
well for cell metabolic activity assays as a measure of cell viability.  
MTT  assay:  MTT  (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl  tetrazolium  bromide;  Sigma)  is  an 
indicator dye that measures the metabolic activity and proliferation of cells. Soluble MTT is mild-
yellow in colour in the absence of viable cells. Purple MTT formazan crystals are formed when 
the tetrazolium component of the MTT molecule is cleaved by mitochondrial dehydrogenase 
enzymes during normal metabolic activity. The crystals are insoluble and retained within viable  
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cells.  They  can  be  dissolved  and  quantified  as  a  measure  of  cell  metabolism  using  a 
spectrophotometer.  
Cells were replated into 96 well culture plates at a density of 104 cells per well, and 8 wells per 
treatment, in 100 ul growth medium with 10% MTT. Cells were incubated for 4 hours, then 
culture medium was removed and replaced with 100 ul per well MTT solvent 0.04M HCl in 
isopropanol. Plates were left on a gyratory shaker for 30 minutes to allow the formazan crystals 
to dissolve. Absorbance was measured at 570nm using an ELISA microplate spectrophotometer. 
Three readings were taken for each assay, and the assay was repeated twice.  
Alamar Blue assay: Alamar Blue is a non-toxic oxidation-reduction (redox) indicator dye used to 
quantify cell metabolism and growth. Reduction of NADH occurs during cell metabolism and 
growth, and the Alamar Blue dye changes colour in a reduced environment. This change is 
exploited to measure the metabolism of cells under various conditions.  
Labelled cells were replated into 96-well plates at a density of 104 cells per well, and 8 wells per 
treatment, in 100 µl growth medium with 10% Alamar Blue solution. Cells were incubated for 4 
hours, then absorbance was measured at 570nm using an ELISA microplate spectrophotometer. 
Three readings were taken for each assay, and the assay was repeated twice.   
Trypan blue assay: The Trypan Blue exclusion dye is internalised by non-viable cells that have lost 
cell membrane integrity, and all non-viable cells in a sample appear blue. Viable cells exclude the 
dye and appear normal and colourless under a light microscope.  
Cells were resuspended 10:1 in 0.5% Trypan Blue, and transferred to a haemocytometer for 
counting.  Under  a  light  microscope,  non-viable  blue-stained  cells  and  total  viable  cells  were 
counted. For each assay, two samples were counted for each treatment group, and the assay was 
repeated three times.  
4.2.5.  Cellular proliferation assays 
To assess the neurosphere-forming capacity of NPC following treatment with MRI contrast 
agents, cells were plated at a density of 104 cells per ml in neurosphere proliferation medium. 
Cells were plated into 96 well plates, where each well contained 100 µl of proliferation medium 
and 1000 cells. After 5 days in culture, the number of neurospheres generated per 103 cells was 
counted, and neurosphere diameter was measured. For each assay, a minimum of 8 wells per 
treatment group was counted, and each assay was repeated twice.  
4.2.6.  Prussian blue stain for iron in neurospheres 
In some  assays,  neurospheres  were  also stained  with the  Prussian Blue stain for  iron.  NPC 
cultured at a density of 104 cells per ml for 7 days were transferred to polyornithine-coated 
coverslips in 24 well plates for one hour to allow neurosphere adherence to coverslips. NPC were  
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then  fixed  in  4%  PFA  in  PBS  for  10  minutes,  incubated  in  6%  hydrochloric  acid  and  4% 
potassium ferrocyanide for 20 minutes, then washed in PBS washed and mounted. 
4.2.7.  Cellular differentiation assays 
Neurospheres at 6 days after passage were transferred onto polyornithine-coated coverslips in 24 
well plates, and cultured in differentiation medium containing DMEM:F12 with B27 medium 
(Invitrogen) and 10% foetal calf serum for 6 days to allow differentiation to occur. Differentiated 
neurospheres  were  fixed  in  4%  PFA  at  4oC  for  immunohistochemical  analysis  of  cellular 
differentiation. 
For immunocytochemistry, coverslips were incubated in blocking solution (10% goat serum with 
0.1% Triton-X) for 30 minutes, then incubated in primary antibody in blocking solution for one 
hour at 37oC: mouse anti-β3-tubulin (1:1000, Promega); rabbit anti-GFAP (1:1000, Chemicon); 
monoclonal O4 IgM (1:2, generous gift Prof Rhona Mirsky). Coverslips were washed three times 
in PBS, then incubated with secondary antibody for 30 min at 37oC cy3-conjugated goat anti-
mouse (1:100); Alexa 488-conjugated goat anti-rabbit 1gG (1:1000, Invitrogen); and Alexa 680-
conjugated  goat  anti-mouse  IgM  (1:1000,  Invitrogen).  Coverslips  were  washed  in  PBS  and 
mounted onto slides with Citifluor mountant medium for fluorescence microscopy. Sections 
were photographed using a Zeiss Axiophot microscope, OpenLab imaging software and Jenoptik 
digital camera. 
4.2.8.  Measurement of  iron using super quantum interference device (SQUID)   
Contrast agent-labelled cells were fixed in 4% PFA, and washed in PBS with heparin to remove 
excess contrast agent.  Cells were transferred to gelatin pill caps containing cotton wool, at a 
density of 1.25 X 106 per gel cap.  Iron content was measured using SQUID and amount of iron 
per cell was calculated.   
Sample magnetization was measured over a range of magnetic field strengths at 300K (Kelvin; 
room temperature) and 10K, and hysteresis loops were plotted. To calculate the amount of iron 
in  each  sample,  remanent  magnetization  and  saturation  magnetization  of  the  samples  were 
compared to the magnetization of a sample with Endorem alone, that has a known iron content 
against which cell magnetisation can be calibrated. Remanent magnetization is the magnetization 
at 0 field strength, and saturation magnetisation is the maximum magnetization of the sample. To 
calculate the iron content based on saturation magnetisation, the diamagnetic component of the 
sample hysteresis curves was subtracted.  The diamagnetic signal is produced by organic material 
in the cells, and is not a component of the Endorem-only hysteresis curve.  At remanence 
magnetization, diamagnetism is 0, therefore no subtraction is required.    
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4.2.9.  Middle cerebral artery (MCA) occlusion 
All procedures were in accordance with the UK Animals (Scientific) Procedures Act of 1986. 
Eleven  250g  male  Sprague-Dawley  rats  (Charles  Rivers  UK)  were  used.    Animals  were 
anaesthetised  with  2%  isofluorane  and  100%  O2.  Temperature  was  monitored  with  a  rectal 
probe. The right common carotid artery was exposed.  A sterile 4-0 suture with an epoxy resin tip 
(Araldite®, Huntsman Advanced Materials) was inserted into the carotid artery and advanced 
17mm into the brain to occlude the MCA for 30 minutes. Following occlusion, the MCA was 
reperfused, the suture removed and animals recovered.   
4.2.10.  Intracerebral microinjections of  FePro-labelled cells 
Animals  were  anaesthetised  with  2%  isofluorane  and 100%  O2,  and  their  head secured  and 
aligned in a stereotactic frame.  Animals were injected with 1.25 X 105 in a maximum of 3µl 
FePro-labelled cells at 0.2l min-1 into the right corpus callosum, 48 hours after MCA occlusion 
surgery. The coordinates used were AP +1.0, ML -0.30; DV -0.2 to Bregma.  The injection 
needle was left in place for 10 minutes following injection, slowly removed and the animals 
recovered.   
4.2.11.  MRI 
For in vitro MRI, contrast agent-labelled cells were washed and fixed in 4% PFA.  Cells were 
transferred to 250µl Eppendorf tubes and centrifuged to produce a cell pellet.  Eppendorfs were 
placed in a custom-made rack inside a 50 ml falcon tube filled with 2.5 mg/ml copper sulphate 
solution.  Cell pellets were imaged using a 2.35T system. A 2D spin echo sequence was used with 
the following parameters: TR = 1500 ms; TE = 80 ms; FOV 25 mm; slice thickness 1mm.   
For in vivo MRI, animals were anaesthetised with 2% isofluorane and 100% O2, and secured on a 
stereotactic  probe.  Animals  were  imaged  using  a  2.35T  system.  A  2D  gradient  echo  (T2*-
weighted) sequence was used with the following parameters: TR = 500ms; TE = 30ms; FOV 
30mm; 128 X 128 voxels; 1mm slice thickness; and 16 averages. A 2D spin echo (T2-weighted) 
sequence was also used: TR = 1500ms; TE = 120ms; FOV 30mm; 128 X 128 voxels; slice 
thickness 1mm; 16 averages.  Animals were imaged at 3, 7, 14, 21, and 28 days post MCA 
occlusion surgery.  
4.2.12.  Perfusion Fixation 
Following MRI, animals were transcardially perfused with 0.9% saline at 4oC then perfused fixed 
with 4% PFA. Brains were removed from the skull and transferred to 30% sucrose in PBS for 48 
hours until no longer buoyant, then frozen and stored at -80oC for tissue processing.    
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4.2.13.  Histology and immunohistochemistry 
Coronal brain sections of 30 µm thickness were taken on a cryostat. For Prussian blue staining, 
sections were incubated in 6% hydrochloric acid and 4% potassium ferrocyanide for 20 minutes, 
then washed in PBS.  For fluorescence immunohistochemistry, sections were incubated in 10% 
foetal calf serum with 0.1% Triton-X (Sigma) for 30 minutes, followed by anti-doublecortin 
(1:50), anti-nestin (1:100), or anti-GFP (1:1000, Chemicon) in 10% foetal calf serum with 0.1% 
Triton-X, overnight at 4oC.  Sections were washed in PBS, and incubated in cy3-conjugated 
secondary antibodies with 1:1000 Hoechst (anti-goat; anti-mouse; anti-rabbit respectively) for 
one hour at 37oC. Sections washed in PBS and mounted with Citifluor.   
4.2.14.  Generation  of   cerebral  ischaemia  homogenate  for  ischaemia-conditioned 
medium 
The MCA occlusion surgery was performed as described.  MRI was performed at 24 hours post-
ischaemia using a 2D spin echo sequence to determine the lesion volume, as described.  Animals 
were sacrificed by Schedule 1 method at 24 or 48 hours post-ischaemia.  Brains were extracted 
and stored in L-15 medium on ice.  Under sterile conditions, the area of infarct as determined by 
MRI was dissected from the brain. The contralateral hemisphere was used as non-ischaemic 
control tissue.  Tissue was homogenized using a glass homogenizer, then resuspended in L-15 
medium. The homogenate was filtered through a 0.4 m sterile filter to remove large debris and to 
sterilize. Protein content of the homogenate was calculated against an albumin standard using the 
Pierce BCA Protein Assay Kit.   
4.2.15.  Neurosphere migration assay 
Neurospheres  after  two  passages  were  used  for  the  migration  study.  96  well  plates  were 
incubated with 12.5% polyornithine for one hour at 37oC. Polyornithine is a substrate on which 
neurospheres adhere.  Single neurospheres were transferred into individual wells of the 96 well 
plates, and 100 µl of control medium was added to each neurosphere-containing well.  Individual 
neurospheres were photographed on a Zeiss AxioVert inverted microscope with a Hamamatsu 
digital camera and using OpenLab imaging software, then tissue homogenate or growth factors 
were added to the control medium.  Treatment groups were as follows: 1400, 700, 300 g/ml 
MCAO homogenate from 24 hours time point; 1400, 700, 300 g/ml MCAO homogenate from 
48 hours time point; 10 ng/ml EGF in N2 medium; 10 ng/ml FGF in N2 medium; 25 ng/ml 
VEGF  in  N2  medium.    Control  groups  were  as  follows:  DMEM:F12  with  N2  medium; 
DMEM:F12 with control tissue homogenate. Neurospheres were photographed at 24 hours, 48 
hours and 72 hours following treatment. Assays were repeated three times, 8 wells per assay.   
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4.2.16.  Data Analysis 
Data are expressed as mean +/- standard deviation. Data analysis was performed using ImageJ 
for MRI image analysis and neurosphere area measurements; Adobe Photoshop for microscopy 
image analysis, and SPSS software for statistical analysis and graphical dislplay.  
For  in  vitro  assays,  neurosphere  area  was  measured  using  ImageJ,  and  MCAO  homogenate 
treatment  conditions  were  compared  to  control  homogenate  using  analysis  of  variance 
(ANOVA) contrast tests. Homogeneity of variance was assessed with the Levine test. The Tukey 
test was used for post-hoc analysis. Significance level p=0.05. 
For in vivo lesion volume analysis, lesion volumes were expressed as total volume, volume at the 
central MCA territory slice, and as a percentage of the total ipsilateral hemisphere volume. The 
ratio of lesion volume at day 28 to day 7 was also calculated, and two-tailed independent samples 
t-tests were performed to test for a difference in lesion volume change between control and 
treatment group animals.  
 
4.3.  Results 
4.3.1.  FePro cell labelling and viability 
The effects of iron oxide-based MRI contrast agents on cell viability were first assessed in a fetal 
neural stem cell line. ST14A cells were incubated with Endorem or FePro for 24 hours, and cell 
viability was assessed using metabolic activity assays. Figure 4.3.1.1 shows the results of the MTT 
and Alamar Blue assays, where data are expressed as a percentage of control unlabelled cells. No 
significant difference in viability was observed between Endorem, FePro and control non-treated 
cells for the MTT assay (ANOVA, p>0.05; Figure 4.3.1.1a). The Alamar Blue assay showed a 
significant difference between the treatment groups (ANOVA, p=0.005; Figure 3.1.1b), where 
decreased metabolic activity was observed in cells treated with Endorem, relative to control 
untreated cells, but no difference was observed in the FePro cells. Therefore, treatment with the 
FePro complex did not significantly affect cell viability of ST14A cells, whereas treatment with 
Endorem may have a small negative effect on cell viability. Figure 4.3.1.1c-e show Prussian Blue 
labeling in control, Endorem- and FePro-labelled cells, demonstrating that unlabelled cells do not 
contain iron oxide (Figure 4.3.1.1c), and that cells can be labeled with Endorem (Figure 4.3.1.1d) 
and FePro (Figure 4.3.1.1e).   
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Figure 4.3.1.1 ST14A cell viability after FePro-labelling. A, MTT assay.  No significant difference 
observed between control, Endorem-, and FePro-labelled cells after 24 h treatment with MRI contrast 
agent (ANOVA, p>0.05). B, Alamar Blue assay.  No significant difference between FePro-labelled and 
control  unlabelled  cells.    Decrease  in  metabolic  activity  of  Endorem-labelled  cells  relative  to  control 
unlabelled cells (ANOVA, p<0.01). C-E, Prussian blue stain of ST14A cell monolayer.  C, control.  D, 
Endorem.  E, FePro.  
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4.3.2.  Superconducting  quantum  interference  device  SQUID  analysis  of   iron 
uptake 
Iron uptake was compared for cells incubated with Endorem or the FePro complex, using a 
superconducting quantum interferece device (SQUID) to quantify the amount of iron oxide 
present in each sample. With remanent magnetization as the reference point, cell uptake was 3.75 
pg Fe/cell for Endorem-labelled cells, and 13 pg Fe/cell for FePro-labelled cells.  With saturation 
magnetisation as a reference point, cell uptake was 4.1 pg Fe/cell for Endorem-labelled cells and 
16 pg Fe/cell for FePro-labelled cells (Figure 4.3.2.1). Together, these results suggest that FePro 
labelling increases cell uptake of iron by 3.4-3.9 fold.   
 
Figure  4.3.2.1Analysis  of  iron  uptake  by  cells  using  superconducting  quantum  interference  
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device (SQUID). Hysteresis curves of Endorem- and FePro-labelled cells at 300K (Kelvin) (top left), and 
10K  (top  right).  Hysteresis  curves  of  Endorem  CA  at  300K  (middle  left)  and  10K  (middle  right). 
Hysteresis curve of FePro-labelled cells as raw data, and with diamagnetic component subtracted, at 300K 
(bottom left) and 10K (bottom right). FePro-labelling results in greater iron oxide uptake than Endorem 
labeling.  
In summary, iron oxide content was greater in FePro-labelled cells than Endorem-labelled cells, 
suggesting the protamine sulphate increases efficiency of contrast agent uptake.   
 
4.3.3.  NPC viability, proliferation and differentiation capacity 
Next, the effect of cell labelling with the FePro complex and Endorem on cell viability and 
proliferative capacity was assessed in primary fetal neural stem and progenitor cells (NPC). Figure 
4.3.3.1a and 4.3.3.1b show the effects of Endorem and FePro on NPC viability in the Trypan 
Blue  exclusion  assay  and  Alamar  blue  assay.  No  significant  difference  between  control, 
Endorem- or FePro-treated NPC was observed in the Trypan Blue exclusion assay (ANOVA, 
p=0.91) or the Alamar Blue assay (ANOVA, p=0.49), indicating that both Endorem and the 
FePro complex have little effect on cell viability or metabolism. 
The neurosphere forming assays measured the number of neurospheres generated per 1000 cells 
and the average neurosphere diameter per sample, which are indicators of the number of stem 
and progenitor cells in the sample and their rate of proliferation, respectively. Figure 4.3.1.1c and 
4.3.3.1d show the effect of Endorem and FePro on NPC proliferative capacity. No significant 
difference in neurospheres per 1000 cells plated was observed between control, Endorem- and 
FePro-labelled NPC (Figure 4.3.3.1d; ANOVA, p=0.833). For Endorem-labelled NPC, the mean 
neurosphere diameter was larger than control neurospheres (Figure 4.3.3.1c; ANOVA p=0.001). 
Figure  4.3.3.1e  and  4.3.3.1f  show  Prussian  Blue-stained  neurospheres  from  Endorem-  and 
FePro-labelled  NPC  after  7  days  in  culture,  respectively.  The  iron  is  distributed  within  the 
neurosphere, indicating that the contrast agent is retained within cells across cell divisions.   
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Figure 4.3.3.1 NPC viability, proliferation and differentiation  capacity  in control, FePro- and 
Endorem-labelled  NPC.  A,  Trypan  Blue  assay.  No  significant  difference  in  cell  survival  (ANOVA, 
p=0.91).    B,  Alamar  Blue  assay.  No  significant  difference  in  cell  metabolism  (ANOVA,  p=0.45).  C, 
Neurosphere diameter.  Neurosphere diameter of Endorem-labelled neurospheres significantly different 
from  control  unlabelled  neurospheres  (ANOVA,  p<0.05).  D,  Neurosphere  generation.  No  significant 
difference in neurosphere generation per 1000 cells (ANOVA, p=0.83). E, F. Prussian Blue stain for iron 
in Endorem (E) and FePro (F) labelled neurospheres. 
 
4.3.4.  NPC differentiation 
To further characterise the effects of Endorem and FePro, the differentiation capacity of contrast 
agent-labelled  NPC  was  assessed.  The  differentiation  assay  is  a  measure  of  the  capacity  of 
neurospheres  to  generate  the  cell  types  of  neural  lineage  -  neurons,  oligodendrocytes  and 
astrocytes. Figures 4.3.4.1a-f show that FePro and Endorem-labelled NPC can differentiate into  
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neurons, oligodendrocytes, and astrocytes. Figures 4.3.4.1g-h demonstrates that cells retain the 
contrast agent label following differentiation, as shown by the Prussian blue stain for iron. A 
pellet of FePro-labelled cells were imaged in a Eppendorf tube using a 2.35T MRI system, and 
produce hypointensity relative to control, unlabelled cells (Figure 4.3.4.1i). 
 
Figure 4.3.4.1 Differentiation capacity of FePro-labelled NPC. A-F. Immunocytochemistry of FePro 
(A-C) and  Endorem (D-F) labelled neurospheres.  A,D, anti-b3-tubulin (neuron, red). B,E, anti-GFAP 
(astrocyte,  green).  C,F,  anti-O4  (oligodendrocyte,  red).  Blue,  Hoescht  nuclear  stain.  FePro-labelled 
neurospheres  can  differentiate  into  neurons  (A,D),  astrocytes  (B,E),  and  oligodendrocytes  (C,F).  G, 
immunocytochemistry of FePro-labelled astrocyte (GFAP, green).  H, corresponding light micrograph 
showing Prussian blue stain.  I,J  MRI T2-weighted image of FePro-labelled neurosphere pellet (I) and 
control unlabelled neurospheres (J). FePro-labelled cell pellets produce hypointensity on MRI images. Scale 
bars, 20um.  
 
4.3.5.  Serial MRI of  cerebral ischaemia following FePro-NPC injection 
Next, in vivo MRI imaging of FePro-labelled NPC was assessed in a model of cerebral ischaemia. 
FePro-labelled NPC (FePro-NPC) were injected into the ipsilateral corpus callosum 48 hours 
following cerebral ischaemia and animals were imaged at 3, 7, 14, 21, and 28 days post-ischaemia, 
to determine whether NPC could be identified and monitored over time with MRI, relative to a  
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control  uninjected  group.  Figure  3.5.1a  shows  the  temporal  profile  of  a  FePro-NPC-treated 
animal and control on spin echo images across the 28 day time period. The T2-weighted images 
revealed heterogeneous ischaemic lesions in both groups, with hypointense regions developing in 
the striatum and medium cortical layers, from day 7 and persisting until day 28. This lesion 
heterogeneity was present in all control animals as well as the FePro-NPC group. Signal intensity 
in  hypointense  ischaemic  striatum  regions  was  significantly  different  from  corresponding 
contralateral  region  (Figure  4.3.5.2E;  p<0.001).  However,  on  T2*-weighted  images,  contrast 
between ischaemic and normal tissue was less apparent (Figure 4.3.5.2A-D). 
To  determine  whether  cell  injections  have  an  effect  on  the  outcome  of  cerebral  ischaemia, 
change  in  lesion  volume  over  time  was  compared  between  control  stroke  and  FePro-NPC 
groups. For both total lesion and MCAO territory, no significant difference in lesion volume 
change over time was observed (Figure 4.3.5.1b-d; ANOVA, p=0.321 and p=0.136, respectively). 
The ratio of ipsilateral to contralateral hemisphere volume at the SVZ level was assessed. We 
observed that the ipsilateral total hemisphere volume was decreased by 28 days post-ischaemia 
relative to the contralateral hemisphere in both groups (ANOVA p<0.001; Figure 4.3.5.1e), but 
did  not  observe  a  difference  between  FePro-NPC  and  control  groups.  This  reduction  in 
ipsilateral hemisphere volume over time may represent secondary, delayed neuronal death in the 
ischaemic hemisphere, lesion compaction, brain reorganisation or a combination of these factors.  
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Figure 4.3.5.1 In vivo MRI. A, serial T2-weighted imaging up to 28 days post-ischaemia in FePro-NPC 
and control. Regions of T2 hypointensity develop in the lesion at later timepoints, and the injection site of 
FePro-labelled cells can be identified in the FePro-NPC group. B-E, analysis of lesion volume change at 7 
days and 28 days in FePro-NPC and control. B, total lesion volume.  No significant difference between 
control  and  FePro-NPC  lesion  volumes  (ANOVA,  p=0.921).  C,  lesion  volume  at  MCA  region.    No 
significant  difference  between  control  and  FePro-NPC  lesion  volumes  at  the  MCA  slice  (ANOVA, 
p=0.577). D, lesion volume: ipsilateral hemisphere volume.  No significant difference between control and 
FePro-NPC in lesion size as a proportion of ipsilateral hemisphere volume (ANOVA, p=0.922). For all 
graphs,  variability  within  groups  is  high.  E,  ipsi:contralateral  hemisphere  volume.  Change  in 
ipsi:contralateral hemisphere volume ratio over time (ANOVA, p<0.0001), but no significant difference 
between control and FePro-NPC ipsi:contralateral hemisphere volume ratios.  
86 
 
Figure 4.3.5.2Hypointensity at 28 days post-ischaemia. A-D, T2- (B,D) and T2*-weighted (A,C) 
images of MCA region in one control (A,B) and one FePro-NPC (C,D) animal. Hypointense regions 
within the ischaemic lesion (arrows) were observed in both T2- and T2*-weighted images, in particular on 
T2-weighted images.  E, Signal intensity in regions of T2 hypointense ipsilateral striatum at 28 days post-
ischaemia, and in corresponding contralateral regions in control (green) and FePro-NPC (blue) groups. 
Signal intensity in the ischaemic striatum was lower than in the ontralateral striatum. Signal intensity was 
significantly  different  between  contralateral  and  ipsilateral  hemispheres  (p<0.001).    F,  Diagram  of  T2 
hypointensity in control (green) and cell treatment (blue) groups.  Composite of all imaged animals at 28 
days. 
 
4.3.6.  Histological analysis 
No GFP was detected outside of the injection tract in the FePro-NPC group, suggesting that no 
migration toward the ischaemic lesion occurred. We investigated the origin of the hypointense  
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signal on T2-weighted MRI images on histological sections. Iron oxide can be a source of T2 
hypointensity, and we assessed its distribution in the brain in both groups with the Prussian blue 
stain for iron. No iron was detected in the contralateral cortex or striatum in either the control or 
FePro-NSC group (Figure 4.3.6.1K-L). However, in both groups, iron oxide was detected in the 
ipsilateral (ischaemic) striatum at the ischaemic border, and in the cortex in some animals (Fig 
4.3.6.1A-D),  which  may  indicate  that  factors  other  than  Endorem  are  contributing  to  the 
hypointensity. Iron accumulation was detected in the mid-striatum at the lesion border, which 
approximates the area of hypointensity on MRI images. Additionally in the FePro-NSC group, 
iron oxide was detected at the injection site.  
We  investigated  whether  the  MRI  image  hypointensity  was  linked  to  the  distribution  of 
macrophage/microglia in the brain. We observed macrophage/microglia in the infarcted cortex 
and  striatum  in  both  FePro-NSC  and  control  groups  (Figure  4.3.6.1g-j).  The  majority  of 
macrophage/microglia  were  negative  for  Prussian  blue.  Prussian  blue-positive  cells  were  a 
mixture of OX-42-positive and OX-42-negative. No macrophage/microglia were observed in the 
contralateral hemisphere. In some animals, we observed red blood cells in the ischaemic striatum, 
which were not positive for Prussian blue (Fig 4.3.6.1M). This may represent the development of 
microhemorrhages within the lesion over time..  
In  summary,  on  histological  sections  we  observed  a  number  of  possible  sources  of  the 
hypointensity in the spin echo and gradient echo MRI images. We observed the accumulation of 
iron oxide at the lesion boundary, associated with blood vessels, and red blood cells in the 
ischaemic striatum. The contribution these sources may make to hypointensity on MRI images is 
addressed in detail in the Discussion section.   
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Figure 4.3.6.1Histological analysis at 28 days at the ipsilateral striatum.  A,b, Prussian blue stain 
for iron and hematoxylin-eosin staining at the ipsilateral striatum. Iron oxide detected in the ischaemic 
lesion. C,D,  Prussian blue stain with nuclear fast red counterstain in the ipsilateral striatum. G-J, OX-42 
immunohistochemistry stain for macrophages, and Prussian blue stain for iron. Prussian blue-positive and 
–negative  macrophages  are  present  at  the  ischaemic  lesion.  K,L  OX-42  immunohistochemistry  and 
Prussian blue stain for macrophages in the contralateral hemisphere. No macrophages or iron oxide were 
observed in the striatum or cortex of the contralateral hemisphere. M, Prussian blue stain for iron at blood 
vessel (arrow). N, Prussian blue-negative red blood cells (arrow). Scale bars, 30um.   
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4.3.7.  E14 neurosphere response to cerebral ischaemia  
We  did  not  observe  NPC  migration  into  the  ischaemic  lesion  in  vivo  on  MRI  images  or 
histological sections. Although fetal NPC migration has been previously reported, one possibility 
is that the NPC were not responsive to the ischaemic environment. We therefore assessed the 
migration  capacity  of  NPC  in  vitro,  and  developed  an  assay  to  assess  the  response  of  NPC 
neurospheres to cerebral ischaemia. The migratory capacity of the NPC was assessed at two 
different  timepoints  –  24  and  48  hours  –  representing  different  inflammatory  environments 
following ischaemia. Tissue homogenates were generated from the brain at 24 and 48 hours post-
ischaemia.  
Figure 4.3.7.1 demonstrates the migratory response of NPC to 24 hr and 48 hr ischaemic tissue. 
Migration in both 24 hr and 48 hr post-ischaemia groups was significantly different to control 
migration  (ANOVA,  p<0.001).  Post  hoc  analysis  showed  that  at  24  hr,  the  1400  µg/ml 
concentration, and at 48 hr the 300 and 700 µg/ml concentrations, were significantly different 
from control non-ischaemic homogenate. Figure 4.3.7.1b shows the percentage of neurospheres 
per assay that respond to homogenate or growth factors by migration. The majority of MCAO 
homogenate treated neurospheres migrate after 72 hours of treatment, whereas few neurospheres 
treated with contralateral hemisphere homogenate or N2 medium respond by migration after 72 
hours. That not 100 per cent  of neurospheres respond by migration in different treatment 
groups also accounts for the large standar deviations in the treatment groups. In summary, NPC 
demonstrate  a  migratory  response  to  both  24  and  48  hr  ischaemic  homogenate,  and  the 
migratory cue is likely a soluble extracellular factor. These results indicate that fetal NPC are 
responsive to cerebral ischaemia factors in vitro.   
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Figure 4.3.7.1 E14 Neurosphere response to cerebral ischaemia. A, migration of E14 neurospheres 
at 72 hours post-treatment. B, percentage of neurospheres that responded by migration to homogenate or 
growth  factors.,  showing  a  high  response  rate  to  MCAO  homogenate,  but  not  contralateral  control 
homogenate.  C,  D,  migration  of  individual  neurosphere  in  response  to  1400  ug/ml  24  hr  MCAO 
homogenate, at t=0 hr (C) and t=72 hr (D). E, F, migration of  individual neurosphere in response  to 
contralateral  hemisphere  MCAO  homogenate  at  t=0  hr  (E)  and  t=72  hr  (F).  Scale  bar,  400  um.  
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4.4.  Discussion  
This study raises important issues surrounding the use of MRI and MRI contrast agents for 
longitudinal cell tracking studies in models of injury, where the evolution of endogenous contrast 
over time within lesioned tissue can be a source of uncertainty in image interpretation.  We found 
that labeling with the FePro complex did not affect NPC viability, proliferation or differentiation 
capacity in vitro. However, in the in vivo studies we identified a source of T2 image contrast in the 
ischaemic lesion that develops over time, creating a challenge for longitudinal cellular imaging 
studies. These results are discussed in the following sections.  
 
4.4.1.  In vitro characterisation of  FePro labelling 
In summary, we observed NPC can be labelled with the FePro complex with no significant effect 
on  cell  viability  or  proliferation  relative  to  control,  unlabelled  cells,  and  labelled  NPC  can 
differentiate  into  neurons,  oligodendrocytes  and  astrocytes.  The  FePro  label  is  retained 
throughout multiple cell divisions during the formation of new neurospheres, and FePro-labelled 
neurospheres produced hypointensity on MRI images. Endorem labelling may have a small effect 
on proliferation rate, but no effect on NPC number, viability or differentiation. In addition, data 
from the ST14A cell line also confirm that FePro does not affect cell viability, and has greater 
labelling efficiency than Endorem. By these observations, FePro is a superior MRI contrast agent 
for NPC cell labelling than Endorem.  
The effects of the FePro complex on fetal NPC were characterized in vitro.  The FePro complex 
did not alter the metabolic activity of the NPC, suggesting that there were no cytotoxic effects 
associated  with  FePro  labelling.  FePro-labelled  NPC  were  able  to  proliferate  to  generate 
neurospheres, and retain the label through several cell divisions. FePro-NPC could differentiate 
appropriately into neurons, oligodendrocytes and astrocytes, and retain the FePro contrast agent 
through  differentiation.  Imaging  NPC  in  vitro  demonstrated  that  FePro  uptake  under  the 
described labeling conditions was sufficient to generate MRI contrast. SQUID measurement of 
iron oxide uptake also confirmed and quantified cellular uptake of FePro. Other studies have 
similarly shown that cytotoxicity of FePro is low in other cell types, and that FePro uptake is 
sufficient to generate contrast on T2*-weighted images (Arbab et al., 2003; Arbab et al., 2004; 
Arbab et al., 2005b; Arbab et al., 2006).  
Similarly, labeling with Endorem alone was assessed, and Endorem was generally found to be 
non-toxic and have little effect on NPC behaviour. However, the mean diameter of neurospheres 
generated  from  Endorem-labelled  NPC  was  greater  than  non-labelled  NPC,  suggesting  that 
Endorem  may  interfere  with  cell  proliferation  pathways.  Furthermore,  cell  metabolism  was  
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reduced in Endorem-labelled ST14A cells, an effect which was not observed in FePro-labelled 
cells. Other studies have similarly found that labeling with Endorem, or Endorem + transfection 
agent, to have little effect on cell metabolic processes (Arbab et al., 2005b).  
SQUID measurements indicated that iron oxide uptake by NPC was less when cells were labelled 
with Endorem than with FePro. The concentration of iron oxide in culture medium was five 
times greater with Endorem labeling than FePro complex labeling, yet Endorem labeling resulted 
in less iron oxide uptake by cells. This result demonstrates the superior labeling efficiency of the 
FePro complex. Even if we conclude that both contrast agent labeling methods have little effect 
on NPC viability and behaviour, labeling with the FePro complex results in increased iron oxide 
uptake.   
Protamine sulphate may facilitate SPIO internalization via increased complex contact with the 
cell  membrane.  Transfection  agent-membrane  interaction  has  been  shown  to  initiate 
internalization  of  SPIO  via  endocytosis  (Politi  et  al.,  2007),  whereas  free  Endorem  is  likely 
internalized via non-specific membrane binding and pinocytosis of Endorem particles (Modo et 
al., 2005). This possible difference in cellular uptake between Endorem and the FePro complex 
may explain both the difference in total particle uptake, as well as the observed differences in cell 
viability and metabolism between Endorem and FePro, where cellular uptake by pinocytosis may 
be less efficient and more toxic to cells.  
 
4.4.2.  Evolution  of   MRI  T2  contrast  and  heterogeneity  following  cerebral 
ischaemia 
In this study, cellular imaging was in part hampered by the evolution of T2 heterogeneity in the 
ischaemic  lesion  in  all  animals,  obscuring  cell  detection  on  MRI.  The  evolution  of  T2 
hypointensity might be related to the accumulation of macrophages and granulocytes to the 
lesion over time, leading to localized hypercellularity. Sibson et al have previously shown in a 
model  of  multiple  sclerosis  that  accumulation  of  MHC  Class  II-expressing  cells  (such  as 
macrophages, dendritic and B cells) are spatially coincident with regions of T2 hypointensity and 
reduced ADC. In this study, hypercellularity increases from one week, peaks at 3 weeks and 
persists  in  later  timepoints,  and  regions  of  T2  hypointensity  develop  by  3  weeks,  which  is 
consistent with our results (Broom et al, 2005). Further studies found similar results (Newman et 
al, 2001; Sibson et al, 2002).  
The T2 heterogeneity may also arise as a consequence of the accumulation of iron in the lesion, 
the development of microhemorrhages, the degradation of blood products, macrophage activity, 
paramagnetic  properties  of  inflammatory  cells,  or  neuronal  degeneration.  In  the  FePro-NSC 
group, an additional factor is clearly the presence of iron oxide particles in the FePro contrast  
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agent.  
Palweczyk et al. have shown that iron exchange can occur between labeled cells and macrophages 
in vitro, although the transfer of iron to macrophages is low (Pawelczyk et al., 2008). In our study, 
macrophages  were  observed  at  the  injection site,  and  it  is  likely  that  FePro-NPC  cell  death 
occurred  over  weeks  following  injection,  releasing  iron  to  the  surrounding  parenchyma.  In 
another study, Lepore et al. observed some macrophage uptake of Endorem from labeled NPC in 
a model of spinal cord injury (Lepore et al., 2006). However, Stuckey et al. did not observe 
macrophage uptake of iron following transplantaion of bone marrow stromal cells in a model of 
myocardial infarction (Stuckey et al., 2006).(Stuckey 2006). Endorem from labeled cells may enter 
endogenous  iron degradation  pathways:  Arbab  et  al. have  shown  that  cell  labeling  results  in 
sequestration  of  Endorem  in  endosomes,  which  fuse  with  lysosomes  and  degrade  into 
hemosiderin over time (Arbab et al., 2005a). 
Weber et al. observed the evolution of hypointensity in ischaemic striatum on T2*-weighted MRI 
images at 2 and 10 weeks post-ischaemia, but not changes in T2, in a 60 minute MCA occlusion 
model  (Weber  et  al.,  2005).  These  T2*  hypointense  regions  colocalised  with  iron-containing 
macrophages, and were distinct from T2* patterns observed in hemorrhagic transformation. The 
authors attributed the iron in macrophages to the phagocytosis of red blod cells from damaged 
blood vessels, distinct from hemorrhage.  
Macrophages are involved in the normal recycling of senescent erythrocytes: heme oxygenase-1 
(HO-1) is a component of this pathway, and is expressed in macrophages (Sipe et al., 2002). The 
development  of  microhemorrhages  following  delayed  vascular  degradation  and  erythrocyte 
degradation may be sources of iron in the ischaemic lesion (Hoehn et al., 2007). Koistinaho et al.. 
also observed HO-1-positive microglia in the ischaemic striatum (Koistinaho et al., 1996), and 
HO-1  has  also  been  detected  in  neurons  and  oligodendrocytes  following  ischaemia  in  the 
ipsilateral  cortex  and  thalamus  (Bidmon  et  al.,  2001).  Danielisova  et  al..  have  observed  iron 
deposition in the striatum and pyramidal cells of cortical layers III and V following 20 minute 
MCA occlusion (Danielisova et al., 2002).  
Delayed neuronal death after shorter occlusion times may be another mechanism that contributes 
to  the  evolution  of  T2  hypointensity  in  the  lesion.  Garcia  et  al..  observed  delayed 
neurodegeneration following short periods of ischaemia (Garcia et al., 1997). The authors report 
selective neuronal necrosis in the striatum and cortex, predominantly in layer III, after 10 or 20 
minutes MCA occlusion. Sbarbati et al also describe the delayed development of T2 hypointensity 
in the medium cortical layers, where they observe neuronal death and macrophage accumulation 
around blood vessels (Sbarbati et al., 2002). Van Lookeren Campagne et al.. also describe delayed 
neuronal death, increased cerebral blood volume and a reduction in lesion volume from 14 days 
post-ischaemia following shorter 30 minute MCA occlusion times (van Lookeren et al., 1999).  
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Justicia et al.. have linked  iron accumulation and T2 hypointensity to delayed neuronal death in 
the thalamus between 3 and 7 weeks following cerebral ischaemia (Justicia et al., 2008). The 
authors suggested that iron accumulation was mediated by heme oxygenase-1-positive (HO-1) 
microglial activity and neuronal degradation, although they did not describe iron accumulation in 
the infarcted striatum or cortex. Other studies observe retrograde neurodegeneration over weeks 
following  ischaemia,  where  reactive  astrocytes  and  microglia  accumulate  in  the  thalamus, 
neuronal degerneration occurs and thalamic volume decreases (Fujie et al., 1990; Iizuka et al., 
1990). These studies suggest that iron accumulation may be linked to neurodegeneration, lesion 
contraction and microglial activity. Iron accumulation is associated with other neurodegenerative 
diseases such as Alzheimer’s, Parkinson’s and Huntington’s disease (Berg and Youdim, 2006; 
Gaasch et al., 2007; Palmer et al., 1999a; Simmons et al., 2007; Thompson et al., 2001).  
Following cerebral ischaemia, dysregulation of iron homeostasis also occurs, and leads to non-
heme  iron  accumulation  surrounding  the  necrotic  core  (Carbonell  and  Rama,  2007).  The 
dysregulation may result from blood brain barrier breakdown and inflammatory events following 
ischaemia (Selim and Ratan, 2004), where plasma transferrin and iron in endothelial cells may 
enter  the  parenchyma,  as  well  as  hemoglobin-containing  erythrocytes  (Carbonell  and  Rama, 
2007).  Iron  can  become  unbound  from  brain  storage  proteins  under  hypoxic-ischaemic 
conditions. Release of ferric iron by ferritin or tranferrin is facilitated by low pH, superoxide and 
nitric  oxide,  which  are  present  during  ischaemia.  Ferritin  upregulation  has  been  reported  in 
microglia  and  oligodendrocytes  following  ischaemia,  and  is  correlated  to  neurodegeneration 
(Bishop and Robinson, 2001; Danielisova et al., 2002; Kondo et al., 1997). Iron deprivation in the 
diet  decreases  necrosis,  and  excess  dietary  iron  increases  necrosis  after  cerebral  ischaemia. 
Treatment  with  iron  chelating  compounds  after  ischaemia  decreases  neuronal  damage  and 
recovery. In the clinical setting, increased plasma iron stores and CSF ferritin levels correlate with 
stroke progression and poor clinical outcome (Armengou and Davalos, 2002).  
Together with our results, these studies support the hypothesis that microglial activity, heme-
oxygenase-1 expression, microhemmorrhage iron accumulation and delayed neuronal death may 
account for change in T2 and T2* at later time points following ischaemia. In summary, BBB 
breakdown,  microhemorrhage  and  iron  dysregulation  after  ischaemia,  leading  to  iron 
accumulation in the lesion, are possible causes of delayed neuronal death and the evolution of T2 
hypointensity.  Brain  iron  accumulation  after  the  ischaemic  event  may  contribute  to  the 
development of a neurotoxic environment that leads to delayed neuronal death. The sources of 
iron are likely from both the blood and brain iron stores. Together, the studies described above 
confirm  our  observation  that  the  evolution  of  the  ischaemic  lesion  is  a  dynamic  process 
occurring  over  several  weeks  following  cerebral  ischaemia,  and  delayed  neuronal  death  may 
reshape the lesion at later time points.   
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4.4.3.  Cell treatment and cerebral ischaemia 
In this study, E14 forebrain-derived neural stem and progenitor cells were injected into the 
ipsilateral corpus callosum 48 hours following cerebral ischaemia. Our hypothesis was that the 
cells would migrate towards the ischaemic boundary, but we did not observe cell migration from 
the injection site. In vitro, these cells demonstrated a migratory response to cerebral ischaemia. 
The  developmental  stage  of  progenitor  cells  may  determine  their  capacity  to  differentiate 
appropriately and contribute to repair. Foetal forebrain tissue is a source of neural stem cells, and 
the cells can be expanded in vitro. NPC are cultured from the embryonic stage E14, which is 
within the period of cortical neurogenesis: at this stage NPC proliferate at the ventricular zone 
and progeny migrate radially to establish the neuronal layers of the cortex. Fetal NPC might 
therefore  be  highly  migratory  and  capable  of  neurogenesis.  Furthermore,  in  transplantation 
studies in the normal brain, fetal NPC are capable of migrating through the adult brain and 
differentiating into neurons, whereas adult neural stem cells predominantly generate astrocytes 
when transplanted into non-neurogenic tissue (Brustle, 1999; Brustle et al., 1997; Doetsch et al., 
1999b; Gage, 2000). Ourednik et al. have also suggested that NPC have an inherent cell rescue 
response,  and  spontaneous  express  neuroprotective  agents  such  as  GDNF  following  cell 
injection  (Ourednik  et  al.,  2002;  Ourednik  et  al.,  2000).  The  time  point  of  48  hours  post-
ischaemia was chosen as the acute inflammatory response has subsided and cytokines and growth 
factors are being upregulated at this time point (Durukan and Tatlisumak, 2007; Darsalia et al., 
2005; Fisher, 2004; Huang et al., 2006).  White matter tracts may provide a scaffold for migration 
of neurons (Ben-Hur et al., 2003), and so the ipsilateral corpus callosum was chosen as the 
injection site.   
In the in vitro migration assay, the filtered ischaemic homogenate did not contain cells, only 
soluble  extracellular  cues  that  may  be  produced  by  a  combination  of  inflammatory  cells, 
astrocytes,  endothelial  cells  and  ischaemic  neurons.  Under  these  conditions,  the  ischaemic 
environment was non-toxic to NPC and promoted cell migration. It is possible that macrophages 
phagocytosed FePro-NPC in vivo, as macrophages were identified at the injection site. Other 
studies have shown significant cell death of injected cells (Bliss et al., 2007). The contralateral 
hemisphere was used as control, non-ischaemic tissue. While this tissue was not affected from 
the MCAO ischaemic event, the tissue may have experienced acute ischaemia during the tissue 
processing stage prior to filtration and freezing. Any factors produced by the tissue as a result of 
this acute ischaemic event did not lead to neuroblast migration.  
In this study immunosuppression was not used following cell injection. Other cellular therapy 
studies have demonstrated an improved functional outcome and neurogenesis with (Kelly et al., 
2004; Pollock et al., 2006) and without (Daadi et al., 2008; Darsalia et al., 2007) the use of  
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cyclosporine A. Modo et al. also concluded that cyclosporine A had no effect on cell survival in 
their model of cerebral ischaemia (Modo et al., 2002b). Cyclosporine A has been shown to be 
neuroprotective  following  brain  injury,  including  cerebral  ischaemia  (Korde  et  al.,  2007; 
Ravikumar et al., 2007; Shin et al., 2007; Yamaguchi et al., 2006).  
 
4.4.4.  Future work 
Following the results of this study, there is scope for further work. There is significant scope for 
refining  the  cell  delivery  strategy  by  optimisation  of  the  injection  site,  the  timepoint  of  cell 
delivery following ischaemia and the option of immunosuppression.  
For cellular imaging using MRI to be successful, a method of distinguishing between labelled 
cells  and  the  evolving  ischaemic  lesion  must  be  established.  Several  approaches  may  be 
considered. Firstly, optimisation of T2 and T2*-weighted imaging may improve discrimination 
between concentrated iron in FePro-labelled cells and iron accumulating in the ischaemic lesion. 
In this study we observed that the hypointensity within the lesion was less on T2*-weighted 
images  than  T2-weighted  images,  and  this  finding  can  be  further  optimised  and  explored. 
However, if the likely source of the observed T2 hypointensity is iron deposition in the ischaemic 
lesion, the problem of distinguishing endogenous iron from FePro-derived iron will always exist, 
and may not be possible to overcome.  
A  second  option  is  to  explore  other  MRI  contrast  agents.  Gadolinium  agents  that  generate 
positive  contrast  on  T1  images  are  an  attractive  option,  and  could  be  distinguished  from 
endogenous iron accumulation. However, the relaxivity of gadolinium agents can be an order of 
magnitude less than for superparamagnetic iron oxide agents, which may present a challenge for 
cell detection. Additionally, few gadolinium contrast agents for cellular imaging currently exist, 
and  free  gadolinium  (Gd3+)  is  toxic  to  cells.  A  gadolinium  agent  of  low  toxicity  and  high 
relaxivity is therefore required.     
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5.  Assessment of  relaxivity, cell labelling and cytotoxicity in novel monomeric and polymeric 
gadolinium contrast agents 
5.1.  Introduction 
Iron oxide-based contrast agents are more commonly used for cellular imaging because of their 
strong  r2  relaxivity,  however  gadolinium-based  agents  have  different  advantages.  Although 
gadolinium r1 relaxivity is an order of magnitude weaker than iron oxide r2 relaxivity, r1 relaxivity 
is a desirable property for cellular detection because it produces an increased and hyperintense 
signal on T1-weighted images, and can be distinguished from susceptibility effects due to magnetic 
field inhomogeneities, unlike superparamagnetic contrast agents. The ideal gadolinium contrast 
agent would have high r1 relaxivity, generate positive contrast on T1-weighted images, and be non-
toxic when internalised by cells. There are relatively few gadolinium-based contrast agents that 
exist to date that fulfil both the low toxicity criteria as well as having high relaxivity values. As 
discussed in section 3.7.1.2, many gadolinium contrast agents with high r1 relaxivity have been 
shown to be toxic when internalised by cells.   
Relaxivity of gadolinium complexes can be altered through ligand design. As discussed in section 
3.7.1.1, several factors affect r1 relaxivity of gadolinium contrast agents: the number of inner 
sphere water molecules coordinated to the Gd3+ ion, q; the water exchange rate, τM; the rotational 
correlation rate, or molecular tumbling rate, of the contrast agent, τR; and outer sphere water 
interactions (Hermann et al., 2008). All of these parameters can be altered through ligand design.  
Gadolinium contrast agents achieve the optimum relaxivity when the rotational diffusion of the 
contrast agent τR is slow, allowing more water exchange to occur and affect the relaxation of 
surrounding  water.  This  can  be  achieved  by  non-covalent  binding  of  the  complex  to  larger 
proteins, or by covalent binding to become part of a larger molecule, thereby increasing the 
effective molecular weight of the complex  (Caravan et al., 1999); (Modo et al., 2005) If the 
conjugation of gadolinium chelates is restricted to the surface or periphery of a macromolecule, as 
in  HSA-conjugated  DOTA,  the  freedom  of  rotation  around  their  linker  and  the  molecular 
tumbling rate of a single chelate can still be high relative to the tumbling rate of the whole 
macromolecule, diminishing the effect of greater molecular weight on molecular tumbling time 
and relaxivity.  
The aim of this study is to develop a gadolinium-based contrast agent suitable for cell labeling, to  
overcome some of the limitations experienced using an iron oxide-based contrast agent approach: 
the optimal gadolinium-based contrast agent would have low toxicity, high labeling efficiency and 
high T1 relaxivity. We investigate whether hyperbranched polymers synthesised from gadolinium 
chelates increase r1 relaxivity of a contrast agent. Polymerisation of several gadolinium chelate 
monomers  into  a  rigid  hyperbranched  polymer  structure  is  one  strategy  to  achieve  slower  
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molecular tumbling and increased r1 relaxivity per mol of gadolinium, which may overcome the 
limitations  of  peripheral  conjugation  discussed  above.  Incorporating  gadolinium  chelates 
internally in the macromolecular structure would further reduce the freedom of rotation of the 
chelates  and  increase  their  individual  molecular  tumbling  time,  with  a  predicted  increase  in 
relaxivity (Aime 2005). And in terms of the molar r1 relaxivity for the polymer contrast agent, this 
should also be increased due to more Gd3+ ions per polymer unit.  
An additional advantage to this approach is the possibility of controlling the polymer branching 
and gadolinium loading during synthesis. This can be achieved by altering the ratio of chelate to 
linker  and  other  reaction  parameters  to  influence  the  final  polymer  size  and  structure.  For 
example,  a  very  large  polymer  size  may  reduce  access  of  the  internal  gadolinium  to  water 
molecules, which should have a negative effect on r1 relaxivity. Polymer synthesis with ‘empty’ 
chelate and subsequent gadolinium loading allows control of the amount of gadolinium loading 
per macromolecule. Partial loading may confer non-toxicity to the polymer, because any Gd3+ ion 
that becomes free within the polymer could coordinate with an ‘empty’ neighbour, thus trapping 
Gd3+ and preventing its release into a biological compartment, in which it would be toxic. This 
strategy of Gd3+ partial loading may therefore protect against in vivo gadolinium toxicity if the 
compounds remain in living systems for long term cell tracking. 
In this study, novel monomeric and polymeric gadolinium chelates were synthesised, and their 
relaxivity  and  effects  on  cell  viability  were  assessed.  Monomeric  chelates  were  composed  of 
DOTA-tetraamides  with  different  branching  arms–  allyl,  styryl  or  propargyl  (Figure  5.2.3.1). 
Polymeric chelates were composed of DOTA-tetraamides and diazide linkers, either synthesised 
as empty polymer with subsequent partial gadolinium loading, or synthesised with gadolinium-
coordinated Gd-DOTA-tetraamides, resulting in 100% loading. DOTA was used due to its high 
stability in biological environments (Aime et al., 2002; Tweedle, 1992), and the possibility for 
structural modification. Diazides were used as linkers because they have reactions sites at both 
ends of the linker and are water soluble. Up to four linkers can bind to each gadolinium chelate, 
and this is expected to reduce rotational freedom of the chelate. 
We observed a lower r1 relaxivity in all monomeric chelates than gadoterate meglumine (Gd-
DOTA, Dotarem®) or gadopentate dimeglumine (Gd-DTPA, Magnevist®) at 2.35T and 9.4T. 
Monomeric chelates had minimal cytotoxicity effects on neural stem cells, which could be labelled 
and imaged. Several polymeric chelates had higher relaxivity per mol Gd3+ than their monomeric 
units, however cytotoxicity also varied considerably among polymers, with many polymers toxic at 
even low concentrations. This study characterises the relaxivity and toxicity of novel monomeric 
and  polymeric  gadolinium  chelates,  and  demonstrates  that  relaxivity  can  be  increased  by  a 
hyperbranched polymer structure.  
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5.2.  Methods 
5.2.1.  MRI   
MRI was performed using a 2.35T horizontal magnet with a 120 mm bore (Oxford Instruments 
Eynsham,UK), interfaced to a Surrey Medical Imaging Systems (SMIS, UK) console. A volume 
coil (60 mm length) was used to transmit radiofrequency excitation pulses. Signal was detected 
using  a  passively  decoupled,  single  loop,  surface  coil  of  2  cm  diameter  positioned  over  the 
samples. Concentrations of monomer (0.1-2.5mM) or polymer (0.5-2.0mM) were imaged in 250µl 
Eppendorf tubes placed in a rack within a water-filled 50ml Falcon tube. T1 relaxation times were 
measured for each concentration by acquiring a series of spin echo sequences with a fixed TE (30 
ms) and an array of TR (100; 120; 130; 150; 180; 200; 250; 300; 400; 500; 600; 700; 800; 900; 1000; 
1200;  1500;  1800;  2500;  4000;  8000  ms).  T2  relaxation  times  were  measured  for  each 
concentration by acquiring a series of spin echo sequences with a fixed TR (1000 ms) and an array 
of TE (30; 40; 60; 80; 100; 120; 140; 160; 200 ms). For all sequences, FOV = 30 x 30 mm, 
resolution 128 x 64 voxels, slice thickness 1mm and 1 average. A 0.2mM Magnevist sample was 
included  in  each  scan  as  a  standard.  Data  analysis  was  performed  using  an  in-house  Matlab 
programme (Jack Wells, unpublished), which calculates T1 and T2 values of self-selected ROI 
across the TR array or TE array for T1 and T2 measurement, respectively.  
MRI  was  also  performed  using  a  9.4T  horizontal  20  cm  bore  Varian  VNMRS  system.  T1 
relaxation  times  were  measured  for  each  concentration  by  acquiring  an  inversion  recovery 
sequence, where TR = 17500 ms, TE = 13.34 ms, IR array = 15; 30; 60; 100; 150; 200; 300; 450; 
600; 900; 1500; 3000; 6000; 17000 ms. T2 relaxation times were measured by acquiring a spin 
echo sequence, where TR = 2000; TE array = 20; 30; 40; 50; 60; 90; 120; 180; 250 ms. For all 
sequences, FOV = 100 x 40 mm; slice thickness 2 mm, resolution 64 x 64 voxels. Data analysis 
was performed using an in-house C++ programme (Andrew Lowe, unpublished) to create T1 or 
T2  maps.  ROI  were  drawn  using  ImageJ  software,  and  mean  T1  or  T2  times  at  each 
concentration were calculated.  
5.2.2.  Cell culture 
ST14A cells were cultured as described in Chapter 4. Cells were cultured on adherent flasks (TPP) 
in DMEM (Invitrogen) with 10% foetal calf serum (Gibco) and 1% Penicillin-Streptomycin. Cells 
were incubated at 33oC with 5% CO2 and 100% humidity. Cells were passaged every 48 hours, 
using 1X Trypsin-EDTA to detach cells from adherent flasks, collected and centrifuged in 10ml 
culture medium, replated 1:3 in fresh culture medium, and returned to the incubator. 
For viability experiments, 104 cells in 100 µl culture medium were plated per well in 96-well plates. 
Monomeric (0.01 – 3mM) or polymeric (0.01 – 1.0mM) chelates were incubated with cells for 24  
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hours, with 8 wells per concentration. At 24 hours, prior to cell viability testing, contrast agents 
were removed, and cells washed in EBSS 3 times.  
MTT assay:  Cells were incubated in growth medium with 10% MTT for 4 hours, then culture 
medium was removed and replaced with 100 µl per well MTT solvent 0.04M HCl in isopropanol. 
Plates were left on a gyratory shaker for 30 minutes to allow the formazan crystals to dissolve. 
Absorbance  was  measured  at  570nm  using  an  ELISA  microplate  spectrophotometer.  Three 
readings were taken for each assay, and the assay was repeated twice.  
Alamar Blue assay: Cells were incubated in 100ul growth medium with 10% Alamar Blue solution 
for  4  hours,  then  absorbance  was  measured  at  570nm  using  an  ELISA  microplate 
spectrophotometer. Three readings were taken for each assay, and the assay was repeated twice. 
Data  analysis:  To  assess  whether  absorbance  readings  for  each  monomeric  and  polymeric 
gadolinim  chelate  were  different  to  control  unlabelled  cells,  analysis  of  variance  test  was 
performed, with significance level p<0.05 and Tukey post-hoc test. Mean absorbance readings for 
each concentration and gadolinium chelate were expressed as a percentage of control cells for 
graphical display.  
5.2.3.  Gadolinium Complexes 
All  chelates  were  synthesised,  purified  and  characterised  at  Imperial  College  Chemistry 
Department by Jonathan Martinelli or Claire Grignolo. For monomeric chelates, allyl-, styryl- and 
propargyl-derivatives of DOTA-tetraamide were sythesised. Gadolinium was complexed to the 
DOTA amides by reacting with GdCl3 salt and purification by filtration or extraction (Figure 
2.3.1; Table 2.3.1). Methylthymol blue (MTB) or xylenol orange were used as an indicator of free 
Gd3+ ion in solution. The gadolinium chelates were characterised by mass spectrometry and x-ray 
chrystallography to confirm the structure and the coordination sites of four nitrogen atoms, four 
carboxylate groups and one water molecule.   
 
Figure 5.2.3.1 Sythesis of gadolinium monomers. DOTA-tetraamides (left) react with GdCl3 salt to 
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form the Gd-DOTA complex (right). R denotes the allyl, propargyl or stryrl branching arm of the DOTA-
tetraamide.  
Figure  5.2.3.2  Monomer  variants  and  their  chemical  names.  MW  denotes  molecular  weight  in 
kiloDaltons. 
 
Polymers were synthesised with the propargyl-derivative of DOTA-tetraamide (monomer 72) as 
ligand, with diazide linkers (Figure 5.2.3.3), by thermal cycloaddition or click chemistry. A number 
of  compounds  with  different  ligand:linker  ratios  were  synthesised,  summarised  below  (Table 
5.2.3.2). Polymers were either synthesised using gadolinium-loaded (g-polymers) or unloaded (e-
polymers)  ligands.  Where  unloaded  ligands  were  used,  partial  gadolinium  loading  occurred 
subsequent to polymer synthesis by reacting with a known amount of gadolinium salt.  The 
concentration of gadolinium in polymeric chelates was determined by Inducively coupled plasma 
mass spectrometry (ICP) analysis at the Natural History Museum using Varian Vista Axial Pro 
ICP-AES. Polymer molecular weight (MW) was determined by GPC chromatography. Based on 
the known molecular weight of the component ligand and linker and their expected ratio, it was 
estimated that most polymers were composed of 3-5 monomer units. The expected polymer size 
was significantly larger than this observed size, and it is not clear why the polymer reaction limits 
polymer size to only 3-5 monomers. Polymers e(1.65:1) and e(1.33:1) were mostly insoluble in 
water, and only the soluble fraction was used for MRI and cell viability assays.  
 
Figure 5.2.3.3 Components of the gadolinium complex. Gadolinium unloaded propargyl-derivatives 
of DOTA-tetraamide ligand (left), the diazide linker (middle) and gadolinium-loaded DOTA-tetraamide 
ligand(right).  
Name  Chemical name  MW (kDa)
56  Gd-1,4,7,10-tetrakis(2-styrylcarbamoylmethyl)-1,4,7,10-tetraazacyclododecane 906.55 
60  Gd-1,4,7,10-tetrakis(allylcarbamoylmethyl)-1,4,7,10-tetraazacyclododecane  842.38 
72  Gd-1,4,7,10-tetrakis(2-propynylcarbamoylmethyl)-1,4,7,10-tetraazacyclododecane834.29  
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Figure 5.2.3.4 Polymerisation of Gd-loaded DOTA-tetraamide to form g-polymer. 
 
Polymer  Ligand:Linker  Gadolinium-loading 
e(2:1)50  1:0.5  50% 
e(2:1)80  1:0.5  80% 
e(1.5:1)50  1:0.67  50% 
e(1.5:1)80  1:0.67  80% 
e(1.33:1)50  1:0.75  50% 
e(1.33:1)80  1:0.75  80% 
e(1.165:1)50  1:0.86  50% 
g(1.5:1)  1:0.67  100% 
g(1:2)  1:2  100% 
g(1:4)  1:4  100% 
g(1:6)  1:6  100% 
Figure 5.2.3.5. Table of synthesised polymers, ligand:linker ratio and Gd-loading percentage. ‘g’ 
denotes polymerisation from Gd-loaded DOTA-tetraamide ligand units, ‘e’ denotes polymerisation from 
‘empty’ DOTA-tetraamide ligands.  
 
5.3.  Results:  
5.3.1.  Longitudinal relaxivity of  monomers at 2.35T.  
Longitudinal relaxivity (r1)  values were calculated using the equation:  
[ ] Gd r
T T
1 0
1
obs
1
1 1 + =  
[ ] Gd r
T T
1 0
1
obs
1
1 1 ￿ ￿  
where T1obs is the observed T1 of a given solution or tissue containing the contrast agent; T10 is the 
T1 of the solution or tissue without contrast agent (water), [Gd] is the concentration of Gd3+, and  
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r1  is  the  longitudinal  relaxivity.  The  slope  of  1/  T1obs  vs  [Gd]  will  give  the  relaxivity  of  the 
gadolinium  complex.  T1  values  at  2.35T  were  measured  for  a  range  of  gadolinium  complex 
concentrations (Table 5.3.1.1):  
 
  56     60     72    
mM  T1  1/T1  T1  1/T1  T1  1/T1 
0  2480.0  4.03E-04  2510.0  3.98E-04  2490.0  4.01E-04 
0.1  1330.0  7.51E-04  1560.0  6.42E-04  1730.0  5.79E-04 
0.2  932.6  1.07E-03  1110.0  8.97E-04  1290.0  7.77E-04 
0.4  480.3  2.08E-03  619.6  1.61E-03  736.4  1.36E-03 
0.7  321.4  3.11E-03  433.1  2.31E-03  511.2  1.96E-03 
0.8  279.6  3.58E-03  396.1  2.52E-03  422.1  2.37E-03 
1  241.2  4.15E-03  325.7  3.07E-03  371.8  2.69E-03 
1.3  194.5  5.14E-03  273.0  3.66E-03  298.5  3.35E-03 
1.7  142.2  7.03E-03  202.3  4.94E-03  202.3  4.94E-03 
2.5  81.7  1.22E-02  129.5  7.72E-03  129.5  7.72E-03 
 
Figure 5.3.1.1. T1 values for monomers 56, 60 and 72 across a range of concentrations, 
measured at 2.35T.   
 
T1 values for Gd-DOTA and Gd-DTPA were also measured (Table 3.1.2):   
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   Gd-DTPA    
mM  T1  1/T1 
0  2.40E+03  4.16E-04 
0.1  1.01E+03  9.86E-04 
0.2  681.0476  1.47E-03 
0.4  393.6303  2.54E-03 
0.5  309.0985  3.24E-03 
1  177.2756  5.64E-03 
 
   Gd-DOTA    
mM  T1  1/T1 
0  2925.499236  0.000341822 
0.5  460.3998573  0.002172025 
0.8  294.3751387  0.003397026 
1  214.6680073  0.004658356 
1.5  132.3600984  0.007555147 
2  93.1515016  0.0107352 
 
Figure 5.3.1.2. T1 values for Gd-DTPA and Gd-DOTA across a range of concentrations at 
2.35T. 
From  these  data,  1/T1  was  plotted  against  [Gd]  to  obtain  the  r1  relaxivity  value  for  each 
gadolinium complex (Figure 5.3.1.1).   
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Figure 5.3.1.3. Graph of gadolinium concentration [Gd] against 1/T1 for monomers 56, 60 and 
72, Gd-DOTA and Gd-DTPA.  
From this graph (Figure 5.3.1.1), the following relaxivity values were calculated (Table 5.3.1.4): 
compound  r1 (mM s-1) 
Gd-DTPA  5.2471 
Gd-DOTA  5.277 
56  4.4891 
60  2.8383 
72  2.8622 
Figure 5.3.1.4. Relaxivity values calculated from the slope of [Gd] vs 1/T1 for each monomer 
from Figure 5.3.1.1.  
 
5.3.2.  Transverse Relaxation of  monomers at 2.35T 
Transverse relaxivity values (r2) were calculated using the equation:  
 
where T2obs is the observed T2 of a given solution or tissue containing the contrast agent; T20 is 
the T2 of the solution or tissue without contrast agent, [Gd] is the concentration of the Gd3+, and 
r2  is  the  transverse  relaxivity.  The  slope  of  1/  T2obs  vs  [Gd]  will  give  the  relaxivity  of  the 
gadolinium complex.  T2 values at 2.35T were measured for a range of gadolinium complex 
concentrations (Table 5.3.2.1):   
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   56     60     72    
mM  T2  1/T2  T2  1/T2  T2  1/T2 
0  887.2741  0.001127047  828.8924  0.001206429  754.5281  0.001325332 
0.4  363.4771  0.002751205  404.2957  0.002473437  286.0481  0.003495916 
0.7  320.4794  0.003120325  380.323  0.002629344  393.9962  0.002538096 
1  260.2279  0.003842785  270.9828  0.003690271  269.7793  0.003706734 
1.3  225.023  0.00444399  190.847  0.005239799  264.4606  0.003781282 
2.5  119.9127  0.0083394  95.8814  0.010429552  124.6159  0.008024658 
Figure 5.3.2.1. T2 values for Gd monomers at 2.35T. 
 
For these data, 1/T2 was plotted against [Gd] to obtain the r2 relaxivity value for each gadolinium 
complex (Figure 5.3.2.1). 
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Figure 5.3.2.2.r2 relaxivity curves for gadolinium monomers at 2.35T.  
 
The r1 and r2 relaxivity for each gadolinium complex is summarised below (Table 5.3.2.2):  
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Figure 5.3.2.3.r1 and r2 relaxivity of gadolinium monomers at 2.35T.  
 
The 0.2mM Gd-DTPA was used as a standard for each acquisition, and the T1 and T2 of 0.0mM 
monomer (water) was also measured for each acquisition. The variability between acquisitions was 
calculated:  
   T1     r1    
   H2O  0.2mM Gd-DTPA  H2O  0.2mM Gd-DTPA 
mean  2734.257016  714.2277176  0.000366053  0.001406717 
stdev  155.6213862  44.80328052  2.07101E-05  8.49241E-05 
Figure 5.3.2.4.Variance in T1 and r1 for H2O and the Gd-DTPA reference.  
 
5.3.3.  Relaxivity of  monomers at 9.4T.   
Longitudinal (Table 5.3.2.1) and transverse (Table 5.3.2.2) relaxivity was calculated at 9.4T. 
   56     60     72    
mM  T1  1/T1  T1  1/T1  T1  1/T1 
0  28015.914  3.5694E-05  28213.125 
3.54445E-
05  28015.914  3.5694E-05 
0.4  5655.2  0.000176828  6412.565  0.000155944  7636.22  0.000130955 
0.7  3715.884  0.000269115  4614.833  0.000216693  4855.24  0.000205963 
1.3  2319.414  0.000431143  2933.708  0.000340866  3644.34  0.000274398 
1.7  1717.213  0.000582339  2333.13  0.000428609  2689.605  0.000371802 
2.5  1190.949  0.000839667  1583.045  0.000631694  1883.167  0.00053102 
Figure 5.3.3.1T1 values for gadolinium monomers at 0-3 mM concentration 
2.35T     
  r1 (mM s-1)  r2 (mM s-1) 
Gd-DTPA  5.2471  6.3287 
Gd-DOTA  5.277  4.528 
56  4.4891  2.7775 
60  2.8383  3.7391 
72  2.8622  2.4729 
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   56     60     72    
mM  T2  1/T2  T2  1/T2  T2  1/T2 
0  6936.823  0.000144158  5024.039  0.000199043      
0.4  2125.426  0.000470494  2988.472  0.000334619  2313.841  0.000432182 
0.7  1691.982  0.000591023  2532.088  0.000394931  3123.81  0.000320122 
1.3  1666.052  0.000600221  1712.774  0.000583848  2353.07  0.000424977 
1.7  928.275  0.001077267  1284.038  0.000778793  1471.818  0.000679432 
2.5  859.567  0.001163376  996.286  0.001003728  660.87  0.001513157 
Figure 5.3.3.2T2 values for gadolinium monomers at 0-3 mM concentration 
 
T1 and T2 was also calculated for Gd-DTPA at 9.4T (Table 5.3.3.3).  
   Gd-DTPA          
mM  T1  1/T1  T2  1/T2 
2.5  698.736  0.001431156  744.433  0.001343304 
1.8  1088.065  0.000919063  988.127  0.001012016 
1.25  1504  0.000664894  1270.25  0.000787247 
0.2  7177.163  0.000139331  4220.98  0.000236912 
Figure 5.3.3.3 T1 and T2 values for Gd-DTPA  
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For these data, 1/T1 and 1/T2 was plotted against [Gd] to obtain r1 and r2 relaxivity values for 
each gadolinium complex at 9.4T (Figure 5.3.3.1).  
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Figure 5.3.3.4r1 and r2 relaxivity curves for monomers at 9.4T. 
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The r1 and r2 relaxivity at 9.4T for each gadolinium complex is summarised below (Table 5.3.2.4): 
2.35T        9.4T    
   r1 (mM s-1)  r2 (mM s-1)  r1 (mM s-1)  r2 (mM s-1) 
Gd-DTPA  5.2471  6.3287  5.5067  4.8195 
Gd-DOTA  5.277  4.528       
56  4.4891  2.7775  3.1573  3.9592 
60  2.8383  3.7391  2.253  3.4087 
72  2.8622  2.4729  2.8577  4.7913 
 
Figure 5.3.3.5 r1 and r2 values for all monomers at 2.45T and 9.4T 
 
5.3.4.  Monomer cell viability.  
Next, monomers were assessed for their effect on cell viability in the neural stem cell line ST14A. 
Cells were incubated in a range of concentrations of gadolinium monomers - 0-3mM for the 
Alamar Blue assay, and 0-1mM for the MTT assay – to assess cell metabolism. Across the range 
of  concentrations,  gadolinium  monomers  56,  60  and  72  showed  similar  metabolic  activity  as 
control cells not exposed to gadolinium (Figure 5.3.4.1; ANOVA, p>0.05).  
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Figure 5.3.4.1Cell viability assays for gadolinium monomers in ST14A cell line. Top, Alamar Blue assay. 
Bottom, MTT assay.  
 
5.3.5.  MRI imaging of  monomer-labelled neural stem cells  
Neural stem cells were incubated with 0.01mM, 0.1mM and 1.0mM of each of the monomers for 
24 hours to assess cell labelling. Cells were then washed in EBSS and fixed in 4% PFA in PBS for 
cell imaging. Fixed cells were pelleted into 250ul eppendorfs and imaged at 2.35T to measure T1 
and  T2.  Cell  pellets  of  monomer-labelled  cells  were  imaged  at  2.35T.  T1  and  T2  relaxation 
decreased as the gadolinium incubation concentration increased, where T1 decreased by up to 
60%  compared  to  control unlabelled  cells,  in  cells  incubated  at  the  highest  concentration of  
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compound 56 and 72. This indicates that cells can be labelled and retain the gadolinium contrast 
agent following incubation, and that gadolinium labelling affects T1 and T2 of cells relative to 
control, unlabelled cells. For 60 1.0mM, it was not possible to measure T1 and T2 , and T2 in 72 
1.0mM, due to lack of signal.  
T1 cells 
0
100
200
300
400
500
600
700
800
900
1000
 0.01mM
56
0.1mM 1.0 mM  0.01mM
60
0.1mM 1.0 mM  0.01mM
72
0.1mM 1.0 mM control
ctrl
T
1
 
(
m
s
)
 0.01mM
56
0.1mM
1.0 mM
 0.01mM
60
0.1mM
 0.01mM
72
0.1mM
1.0 mM
control
ctrl
 
T2 cells 
0
10
20
30
40
50
60
70
80
 0.01mM
56
0.1mM 1.0 mM  0.01mM
60
0.1mM 1.0 mM  0.01mM
72
0.1mM 1.0 mM control
ctrl
T
2
 
(
m
s
)
 0.01mM
56
0.1mM
1.0 mM
 0.01mM
60
0.1mM
 0.01mM
72
0.1mM
control
ctrl
 
Figure 5.3.5.1T1 and T2 of gadolinium monomer-labelled cells at 2.35T.   
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   T1  T2 
control  945.5262  56.6679 
56 0.01mM  802.9539  72.7408 
56 0.1mM  623.8157  49.6278 
56 1.0 mM  399.4852  25.3204 
60 0.01mM  921.8495  50.4671 
60 0.1mM  714.5837  35.9959 
60 1.0 mM    
72 0.01mM  915.3766  55.0261 
72 0.1mM  699.4756  36.2085 
72 1.0mM  370.0727    
Figure 5.3.5.2 T1 and T2 of gadolinium monomer-labelled cells at 2.35T. 
 
5.3.6.  T1-weighted cell imaging at 2.35T and 9.4T 
T1-weighted (T1W) images were also acquired at 2.35T and 9.4T to assess the contrast generated 
relative  to  control,  unlabelled  cells  at  both field  strengths.  Positive  contrast  was  observed  in 
monomer 56 relative to control cells at 2.35T but not 9.4T. In monomers 60 and 72, a T2 effect 
was observed in the T1-weighted images, which resulted in negative contrast relative to the control 
cells.  This  effect  was  most  apparent  in  monomer  60,  which  had  the  greatest  r2  relaxivity  in 
solution (Figure 5.3.6.1).  
control  56 72 60
T1W
2.35T
T1W 
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Figure 5.3.6.1.MRI of cells labelled with 1.0mM 56, 60, 72 gadolinium monomer at 2.35T and 9.4T. Top, 
T1W MRI of labelled cells at 2.35T. Bottom, T1W MRI of labelled cells at 9.4T.  
 
5.3.7.  Relaxivity of  gadolinium polymers 
Polymers were synthesised from the monomer 72. Although this monomer did not have the 
highest r1 relaxivity of the monomers assessed, the carbon triple bonds of the propargyl groups 
on the four branching arms were required to react with the diazide linkers to synthesise the 
hyperbranched  polymer.  As  discussed  in  the  methods  section,  the  following  polymers  were 
synthesised, with different ligand:linker ratios and gadolinium loading (Table 5.3.7.1), with an 
average polymerisation of 3-5 monomer units.  
Polymer  Ligand:Linker  Gadolinium-loading 
e(2:1)50  1:0.5  50% 
e(2:1)80  1:0.5  80% 
e(1.5:1)50  1:0.67  50% 
e(1.5:1)80  1:0.67  80% 
e(1.33:1)50  1:0.75  50% 
e(1.33:1)80  1:0.75  80% 
e(1.165:1)50  1:0.86  50% 
g(1.5:1)  1:0.67  100% 
g(1:2)  1:2  100% 
g(1:4)  1:4  100% 
g(1:6)  1:6  100% 
Figure 5.3.7.1Gadolinium polymers synthesised from the monomer 72 and diazide linkers.  
 
r1 and r2 relaxivity was calculated for each polymer at 2.35T (Table 5.3.7.2). Polymer e(1.5:1)50 had 
the highest r1 relaxivity of all polymers. Polymers e(1.5:1)50, e(1.33:1)50, e(2:1)80, and e(2:1)50 had r1 
values  greater  than  monomer  72.  None  of  the  100%  loaded  polymers  (g-polymers)  had  r1 
relaxivity greater than monomer 72. No clear pattern in gadolinium loading effect on r1 relaxivity 
was observed among the e-polymers, and neither was a relationship between ligand:linker ratio 
and relaxivity observed.  
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2.35T       
   r1 (mM s-1)  r2 (mM s-1) 
Gd-DTPA  5.2471  6.3287 
Dotarem  5.277  4.528 
56  4.4891  2.7775 
60  2.8383  3.7391 
72  2.8622  2.4729 
e(1.165:1)50  1.9855  1.5302 
e(1.33:1)50  3.2401  1.4544 
e(1.33:1)80  0.8602  0.9612 
e(1.5:1)50  4.522  4.4952 
e(1.5:1)80  2.4464  3.8205 
e(2:1)50  2.9858  4.804 
e(2:1)80  3.3829  3.432 
g(1.5:1)  3.054  4.0973 
g(1:2)  2.4779  2.6983 
g(1:4)  2.2802  2.4435 
g(1:6)  2.5628  3.0891 
Figure 5.3.7.2 r1 and r2 relaxivity of gadolinium polymers at 2.35T. 
  
r1 and r2 relaxivity was calculated for e(1.5:1)50, g(1.5:1), g(1:4) at 9.4T, and r1 values were slightly lower 
at 9.4T than 2.35T (Table 5.3.7.3).  
9.4T       
   r1 (mM s-1)  r2 (mM s-1) 
Gd-
DTPA  5.5067  4.8195 
        
56  3.1573  3.9592 
60  2.253  3.4087 
72  2.8577  4.7913 
e(1.5:1)50  4.5139  0.6772 
g(1.5:1)  2.5063  8.09 
g(1:4)  2.0411  4.0237 
Figure 5.3.7.3 r1 and r2 relaxivity of gadolinium polymers at 9.4T 
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5.3.8.  Polymer cell viability 
Polymers were then assessed for their effect on cell viability in the neural stem cell line ST14A. 
Cells  were  incubated  in  a  range  of  concentrations  of  polymers,  0-1.0mM,  to  assess  cell 
metabolism using the Alamar Blue and MTT assays (Figure 3.8.1). Polymers e(2:1)50, e(1.33:1)50, 
g(1.5:1), g(1:2), and g(1:6) were not assessed because they formed a precipitate when mixed with the cell 
culture medium.  In some polymers cell viability at 1.0mM was not assessed due to a lack of 
sufficient synthesised polymer for the experiment. 
In the Alamar blue assay, a trend of increasing aberrance from control cell metabolic activity at 
higher concentrations was observed in all e-polymers, but not the g(1:4) g-polymer or Gd-DOTA 
(ANOVA, p<0.05 for e(1.5:1)50, e(1.5:1)80, e(1.65:1)80, e(1.65:1)50, g(1:4), e(2.1)80). All cell conditions were also 
photographed  after  the  absorbance  reading  (Figure  3.8.2).  Although  the  absorbance  readings 
suggest an increase in metabolic activity relative to control cells, the microscopy indicated that at 
higher absorbance readings, cell death and cell lysis had occurred. Although cells were washed 
between polymer incubation and Alamar blue assay, cell lysis products from the 4 h assay interval 
may have interfered with the absorbance reading, resulting in high rather than low absorbance 
readings to indicate cell death.  
In the MTT assay, a similar trend in metabolic activity was not observed. In all e-polymers, a 
decreased metabolic activity relative to control cells was observed, at least at low concentrations. 
The MTT requires an additional experimental step of cell fixation and washing, which may have 
partially,  but  not  fully,  removed  cell  lysis  products,  leading  to  mixed  results  at  higher 
concentrations.   
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Figure 5.3.8.1Cell viability assays for gadolinium polymers. Top, Alamar Blue assay. Bottom, MTT assay.  
Figure 5.3.8.2 Light micrographs of cells after incubation with gadolinium polymers. A, example of 
healthy confluent cells. B, example of intermediate mixed population of dead and living cells. C, cell death 
and cell debris.  Scale bar, 200um.  
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5.4.  Discussion:  
In summary, r1 and r2 relaxivity, cell viability and cell labelling was assessed for allyl-, styryl, and 
propargyl-derivatives of the Gd-DOTA-tetraamide monomer. Gadolinium polymers based on the 
propargyl-derivative were synthesised, with varying ligand:linker ratios and gadolinium loading, to 
determine optimum polymer design for high r1 relaxivity. Cell viability was also assessed for 
polymers.  
For monomers, r1 and r2 relaxivity were lower than Gd-DOTA or Gd-DTPA, at 2.35T and 9.4T. 
For all monomers, r1 and r2 relaxivity were lower at 9.4T than 2.35T. No trend was observed for 
r2 relaxivity across field strengths.  
 
2.35T        9.4T    
   r1 (mM s-1)  r2 (mM s-1)  r1 (mM s-1)  r2 (mM s-1) 
Gd-DTPA  5.2471  6.3287  5.5067  4.8195 
Gd-DOTA  5.277  4.528       
56  4.4891  2.7775  3.1573  3.9592 
60  2.8383  3.7391  2.253  3.4087 
72  2.8622  2.4729  2.8577  4.7913 
Figure 5.4.1 Summary of r1 and r2 relaxivity for gadolinium monomers at 2.35T and 9.4T 
 
Cell viability was good for all monomers.  Cells incubated with monomers could be labelled and 
imaged.  No  histological  stain  exists  for  gadolinium,  but  T1  and  T2  effects  were  observed  in 
pelleted  labelled  cells.  T1-weighted  positive  contrast  was  observed  in  monomer  56  but  not 
monomers 60 or 72, where negative contrast was observed. One possible explanation for this 
could be a strong T2 effect in the cells. Dependent on the route of cell internalisation, gadolinium 
monomers  may  be  sequestered  in  endosomes  or  lysosomes.  If  water  exchange  between  cell 
components (eg between endosome and cytoplasm) is slow relative to the optimal water exchange 
rate of the monomer, the r1 of the complex will be decreased due to less water gaining access to 
the  Gd3+  ion.  In  this  situation,  the  inner  sphere  effects  of  gadolinium  may  be  limited. 
Additionally, at high concentrations, paramagnetic contrast agents can affect T2 through outer 
sphere effects of gadolinium, decreasing signal intensity locally on T2-weighted images (Modo et 
al., 2005). If this is the case, cell labelling can be modified to promote cytoplasmic localisation, for 
example  by  electroporation  or  liposome  transfection.  Electron  microscopy  analysis  will  be 
necessary  to  determine  the  internal  localisation  of  the  contrast  agents.  The  chemistry  of  the 
monomer branching arms appears to have a significant effect on cell labelling, and T1 and T2.  
Polymer e(1.5:1)50 had the highest r1 relaxivity of all polymers, with e(1.33:1)50, e(2:1)80, and e(2:1)50  
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also recording r1 values greater than monomer 72. The mean polymer was composed of only 3-5 
monomer units, which was much less than expected. The effect of a larger macromolecule in 
increasing r1  relaxivity  will also  be  less than  expected,  but  an  increased r1  relaxivity  was still 
observed. Optimising the synthesis reaction to obtain higher molecular weight polymers with 
greater monomer units per polymer may lead to a further increase in r1 relaxivity.  
None of the 100% loaded polymers (g-polymers) had r1 relaxivity greater than monomer 72. 
These initial results suggest that partial loading of polymers with gadolinium yields higher r1 
relaxivity  values  than  100%  loading,  however  ligand:linker  ratios  were  also  different  for  g-
polymers compared to e-polymers, so few direct comparisons can be made. No clear pattern in 
gadolinium loading effect on r1 relaxivity was observed among the e-polymers, and neither was a 
relationship between ligand:linker ratio and relaxivity observed. 
Sample  ligand:linker 
        
Gd3+ 
loading  r1  r2 
e(1.165:1)50  1:0.86  50%  1.9855  1.5302 
e(1.33:1)50  1:0.75  50%  3.2401  1.4544 
e(1.33:1)80  1:0.75  80%  0.8602  0.9612 
e(1.5:1)50  1:0.67  50%  4.522  4.4952 
e(1.5:1)80  1:0.67  80%  2.4464  3.8205 
e(2:1)50  1:0.50  50%  2.9858  4.804 
e(2:1)80  1:0.50  80%  3.3829  3.432 
g(1.5:1)  1:0.67  100%  3.054  4.0973 
g(1:2)  1:2  100%  2.4779  2.6983 
g(1:4)  1:4  100%  2.2802  2.4435 
g(1:6)  1:6  100%  2.5628  3.0891 
Figure 5.4.2 Summary of r1 and r2 relaxivity for gadolinium polymers at 2.35T 
  
Cell viability was reduced for polymers, relative to control cells and gadolinium monomers, and 
viability  assays  were  confirmed  with  microscopy.  Monomer  72,  the  ligand  from  which  the 
polymer  was  synthesised,  did  not  affect  cell  viability  in  Alamar  Blue  or  MTT  assays,  so  the 
viability effects may be due to the polymer size or the presence of diazides. This must be further 
investigated  for  polymers  to  be  considered  candidate contrast  agents  for  cellular  imaging.  In 
future studies, incubated cells will be imaged as a cell pellet to determine polymer internalisation 
and effect on T1-weighted contrast.  
Most g-polymers reacted with the cell culture medium to form a precipitate, possibly reacting with 
the phenol red indicator dye, as the precipitate formed was red. Further viability tests with g- 
120 
polymers could be carried out in culture medium without phenol red. The polymer may also be 
reacting with fetal calf serum, in which case cell culture in serum-free medium may be optimised 
for cell labelling.  
Further optimization of the polymers would be required before they have the potential to be an 
improved MRI contrast agent to what is currently available.  The monomeric chelates had lower 
r1 relaxivity compared to Gd-DTPA or Gd-DOTA, and relaxivity was not significantly increased 
in the polymers. Optimisation of polymer size and gadolinium loading might lead to improved r1 
relaxivity. Labelling efficiency and cellular localisation could be optimized by the use of targeting 
vectors or transfection agents.  
In conclusion, the characterisation of novel gadolinium monomer and polymer contrast agents is 
described. R1 and r2 relaxivity was measured for a number of gadolinium-based monomer and 
polymer compounds at 2.35T and 9.4T. Relaxivity was comparable or less than Gd-DOTA or 
Gd-DTPA. For monomers, cytotoxicity was low, but most polymers had a toxic effect on the 
ST14A neural stem cell line.  For optimal contrast agent design, compound chemistry, relaxivity, 
and cytotoxicity must all be considered at early stages of design.   
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6.  In vivo magnetic resonance imaging of  endogenous neuroblasts labelled with a ferumoxide-
polycation complex 
6.1.  Introduction  
Neural stem and progenitor cells (NPC) persist in the adult brain (Reynolds et al., 1992; Morshead et 
al., 1994), and have been identified in the subventricular zone (SVZ) of the lateral ventricles (Merkle 
et al., 2006; varez-Buylla et al., 2004; varez-Buylla et al., 2002), a region which is capable of generating 
new neurons in the mature brain. NPC proliferate, generating neuroblasts that migrate along the 
rostral migratory stream (RMS) to the olfactory bulb (OB), where they differentiate into olfactory 
interneurons  (Lois  et  al.,  1993).  In  pathological  environments,  for  example  following  cerebral 
ischaemia, neural stem and progenitor cells and neuroblasts respond by proliferation and migration 
towards sites of injury (Arvidsson et al., 2002; Parent et al., 2002; Zhang et al., 2001; Kokaia et al., 
2006). This intrinsic sensitivity and responsiveness to disease states raises the prospect of developing 
therapeutic strategies to enhance the neurogenic response of the SVZ and contribution to brain 
repair (Tureyen et al., 2005; (Consiglio et al., 2004).   
Development of methods capable of monitoring and tracking of endogenous NSC in an in vivo 
imaging system would be of great benefit to the understanding of neuroblast migration away from 
the SVZ under normal and pathological conditions. Currently, only a few cell tracing methods allow 
for in vivo labelling of endogenous NPC. The most commonly used labelling methods for adult neural 
stem cells are bromodeoxyuridine (BrdU) (Taupin et al., 2007),; retroviral GFP transduction (Tanaka 
et al., 2004; Levison et al., 1997);  and Cre/loxP transgenic systems such as the targeted expression of 
CRE  recombinase,  where  expression  of  GFP  or  other  reporter  genes  are  activated  under  the 
promoter of a stem cell gene of interest (Garcia et al., 2004; Young et al., 2007). All of these labelling 
methods require histological preparation and the use of fluorescence microscopy for imaging.  
In vivo monitoring of endogenous NPC has been reported using magnetic resonance spectroscopy 
(1H-MRS) and MRI contrast agents. Manganas et al observed a prominent peak in the spectroscopic 
profile of NPC, which was identified as a metabolic biomarker exclusive to NPC, and this could be 
spatially resolved using 1H-MRS in the rodent and human brain (Manganas et al., 2007). Using this 
method, they were able to distinguish neural stem cells from non-neural stem cells and from mature 
neural cell types. The limitation of this method is that NPC, as they migrate away from the SVZ, 
adopt a mature phenotype at their end destination of the OB or infarct lesion, and would lose the 
unique biomarker expression.   
MRI contrast agents have been used to label neural stem cells in vitro (Hoehn et al., 2002; Modo et 
al., 2002) and transplanted labelled cells have been monitored in vivo under normal and pathological 
conditions.  Neural  stem  cells  labelled  with  iron  oxide-based  MRI  contrast  agents  have  been 
transplanted into the rodent brain following cerebral ischaemia, and monitored over several weeks  
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using MRI (Hoehn et al., 2002; Arbab et al., 2006). Endogenous cell labelling using MRI contrast 
agents  has  been  achieved  peripherally,  where  iron  oxide  MRI  contrast  agents  are  preferentially 
phagocytosed by circulating macrophages (Weber et al., 2005; (Wiart et al., 2007).Within the nervous 
system, Shapiro et al demonstrated that NSC could be labelled in vivo with iron oxide beads, Bangs 
particles, and their migration through the RMS to the OB was successfully imaged (Shapiro et al., 
2006). In a subsequent study, Sumner et al confirmed that NPC in the SEZ internalise the iron oxide 
beads and give rise to migrating neuroblasts (Sumner et al., 2009). When the NPC population was 
subjected to ablation by Ara-C after injection of the iron oxide beads, no new migrating neuroblasts 
were generated and no hypointense signal loss was observed in the RMS on MRI images. Both of 
these studies were carried out by injection of a large volume of contrast agent in the ventricles using 
micron-sized iron oxide particles, and imaged at high magnetic field strength. 
In this work we have chosen to focus on Endorem, which is a ferumoxide MRI contrast agent 
composed of dextran-coated superparamagnetic iron oxide nanoparticles (SPIO) with a diameter of 
150 nm, and has FDA approval for MRI contrast imaging in humans. Endorem has been used in vitro 
for  cell  labelling  and  tracking  using  multiple  cell  types:  NPC,  mesenchymal,  hematopoeitic,  and 
embryonic stem cells (Kustermann et al., 2008; Suzuki et al., 2007; Ben-Hur et al., 2007; Modo et al., 
2002;  Arbab  et  al.,  2004).  It  is  well  tolerated  by  labelled  cells  and  does  not  interfere  with  cell 
metabolism, cell division or differentiation (Arbab et al., 2005). Furthermore we have used Protamine 
sulphate, which is a transfection agent used to enhance cell labelling with Endorem in in vitro systems, 
to form the FePro complex (Arbab et al., 2005).   
The aim of our study was to develop and optimize a methodology for endogenous cell labeling with 
future applications for tracking neuroblast migration in the normal and pathological brain. In Chapter 
4,  we  demonstrated  that  the  FePro  complex  could  efficiently  label  cells  in  vitro  at  lower 
concentrations  and  with  greater  iron  oxide  uptake  per  cell  than  labeling  with  Endorem.  Our 
hypothesis was that using a SPIO such as Endorem or the FePro particle would increase labeling 
efficiency at the SVZ with a smaller injection volume of SPIO than has been required in previous 
studies  with  the  Bangs  MION  particles.  In  this  study,  the  aim  was  to  label  the  endogenous 
population of NPC by stereotactic injection of Endorem or FePro into the lateral ventricles adjacent 
to the SVZ, and to visualise neuroblast migration in the RMS in the normal brain. We observed that 
while intraventricular injection of Endorem resulted in its distribution throughout the ventricular 
system and into the periventricular space, the FePro complex was localised to the lateral ventricle. 
Brains imaged 28 days following injection identified the FePro complex in the RMS using both low 
(2.35T) and high (9.4T) magnetic field strength systems. Histology confirmed that the FePro complex 
was localised to the SVZ and RMS, and that neuroblasts within the RMS were labelled with the 
FePro complex.   
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6.2.  Materials and Methods 
6.2.1.  Intraventricular injections 
Twenty six adult male 220g Sprague-Dawley rats (Charles Rivers, UK) were used. Animals were 
stereotactically injected with either Endorem (Guerbet Laboratories Ltd, UK; n=5), FePro (n=18), or 
PBS control (n=3) into the left lateral ventricle. Animals were anaesthetised with 2% isofluorane and 
100%  O2  and  their  head  secured  and  aligned  in  a  stereotactic  frame.  Body  temperature  was 
maintained at 37ºC by use of a rectal thermometer probe and heating mat. Animals were injected 
with 2.5 µl at 0.2 µl min-1 Endorem, FePro, or a control injection of PBS. In two animals, an 
injection volume of 20 µl FePro was used. The coordinates used were AP -0.08, ML +0.14; DV -
0.38. To form the FePro complex, Endorem was mixed with 1mg/ml protamine sulphate (CellTech, 
UK) in a ratio of 9 µl : 5 µl and incubated for 10 minutes prior to injection. All procedures were in 
accordance with the UK Animals (Scientific) Procedures Act of 1986, and approved by the UCL 
Research Ethics Committee. All reagents supplied by Sigma-Aldrich UK unless stated otherwise.   
6.2.2.  In vivo and ex vivo MRI 
MRI animal studies were performed using a 2.35T horizontal magnet with a 120 mm bore (Oxford 
Instruments Eynsham,UK), interfaced to a Surrey Medical Imaging Systems (SMIS, UK) console. A 
volume coil (60 mm length) was used to transmit radiofrequency excitation pulses. The magnetic 
resonance  signals  were  detected  using  a  passively  decoupled,  single  loop,  surface  coil  of  2  cm 
diameter  positioned  on  the  dorsal  aspect  of  the  head.  Animals  were  anaesthetised  with  2% 
isofluorane and 100% O2, and secured on a stereotactic probe for imaging. Body temperature was 
maintained at 37oC. Animals were imaged at 48 hours or four weeks post-injection. The 2D T2-
weighted spin echo images were acquired with the following parameters: TR = 3000 ms, TE = 28 
ms, FOV 30 mm, slice thickness 1 mm, matrix 128 x 128 voxels , 2342 µm in-plane resolution, 4 
averages; or TR = 1500 ms TE =120 ms, FOV 30 mm, slice thickness 1 mm, matrix 128 x 64 voxels, 
in plane resolution 234 µm x 469 µm, 16 averages.. The 3D gradient echo sequence was performed 
using the following parameters: TR = 80 ms, TE = 25 ms, FOV 25 mm, matrix 192 x 192 x 146 
voxels, resolution 130 µm x 130 µm x 171 µm.. Following MRI, animals were transcardially perfused 
fixed  with  0.9%  saline  at  4oC  followed  by  4%  paraformaldehyde  (PFA;  Sigma-Aldrich,  UK)  in 
phosphate buffered saline (PBS) containing 1 mM Gd-DTPA for ex vivo MRI. Perfuse-fixed whole 
brains including the olfactory bulb were removed from the skull after fixation and transferred to a 50 
ml Falcon tube containing PFA. In some animals (n=4) the brains were used for ex vivo imaging 
before freezing for histology. Ex vivo imaging was also performed using a 9.4T horizontal 20 cm 
bore Varian VNMRS system using a 39 mm RF coil (RAPID Biomedical GmbH, Germany) and a 
3D gradient-echo sequence with the following parameters: 2.563 cm FOV, 512 x 512 x 512 matrix 
(256 mm3), TR=70 ms, TE=10 ms, flip angle 30o, 2 averages.  
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6.2.3.  Cellular MRI 
CD133+ cells were isolated from peripheral blood of donors stimulated with GCSF using 
CD133 microbeads (Miltenyi Biotech). CD133+ cells were labelled with Endorem at day 9 of 
culturing using 0.5 mg Fe/ml of growth medium and were washed twice in 15ml 1xPBS. These 
cells  contained  on  average  3.9  pg  iron  oxide,  as  measured  by  superconducting  quantum 
interference device (SQUID), and approximately 75% of cells contained. For differential cell 
labelling (DfL), suspension CD133+ cells were separated from adherent CD133+ cells, and 
labelled for 22 or 23 hours, followed by additional labelling for 2 hours with the adherent 
fraction. Labelled cells were washed twice in 15ml 1xPBS and used in experiments as described 
below.    SPIO,  as  measured  by  isolation  through  a  magnetic  column  (Miltenyi  Biotech). 
Labelled-labelled (DfL) CD133+ cells were embedded in low melting point agarose (0.5%, 
37oC) at the following concentrations of: 745, 165, 49.5, 16.5 and 0 cells (0.5%, 37 x103/ml in 
250 µl eppendorf tubes) and were rapidly cooled prior to horizontal alignment in a 4% agarose 
phantom in a 9.4T horizontal bore Varian system. Tubes were scanned in a single 0.5 mm slice 
at the RF isocentre of a 3935 mm coil (RAPID Biomedical GmbH, Germany). T2* weighted 
images were acquired using a gradient echo sequence (TE=25ms, TR=200ms, FA=30, 5122 
matrix) and T2* maps were obtained from 20 echo times (TE 2.5-30ms, TR=200, FA=30, 2562 
matrix) using the ImageJ MRI Analysis Calculator plugin (Schmidt, K., ImageJ, U. S. National 
Institutes of Health, Bethesda, MA USA.) 
6.2.4.  Histology 
For immunohistochemistry and histology, fixed brains were left in 1% PFA overnight, transferred to 
30% sucrose solution and left at 4oC for 2 days, then frozen and stored at -80oC. Coronal brain 
sections  of  30  or  15  µm  thickness  were  taken  on  a  cryostat.  Prussian  blue  stain  for  iron  was 
performed  with  nuclear  fast  red  counterstain  or  hematoxylin  eosin  staining.  For  Prussian  blue 
staining, sections were incubated in 6% hydrochloric acid and 4% potassium ferrocyanide (Sigma-
Aldrich, UK) for 20 minutes, then washed in PBS. Sections were then stained with nuclear fast red or 
hematoxylin eosin stain, and deyhydrated in 95 then 100% ethanol. Sections were transferred to 
Histoclear for 5 minutes, and mounted using DPX mountant. For immunohistochemistry, sections 
were incubated in 10% foetal calf serum with 0.1% Triton-X for 30 minutes, followed by goat anti-
doublecortin  (1:50,  Santa  Cruz  Biotechnology)  mouse  anti-nestin  (1:50;  rat401,  Developmental 
Biology  Hybridoma  Bank)  or  rabbit  anti-GFAP  (1:1000;  Chemicon)  overnight  at  4oC.  For 
immunofluorescence staining, sections were washed in PBS and incubated in secondary antibody for 
one hour. Sections were washed in PBS and mounted with mountant medium (Citifluor Ltd). For 
immunoperoxidase  staining,  sections  were  incubated  in  3%  hydrogen  peroxide  for  10  minutes, 
followed by biotinylated anti-goat (1: 500, Dako) for one hour, and streptavidin-HRP (1:500, Dako) 
for one hour, with a 10 minute PBS wash between each incubation. Sections were then stained for  
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Prussian blue and nuclear fast red counterstain. Sections were dehydrated in ethanol and histoclear, 
and mounted in DPX mountant. For fluorescence microscopy, sections were incubated in cy3 anti-
goat, cy3 anti-mouse, or FITC anti-rabbit with Hoescht nuclear stain, and mounted using Citifluor 
mounting  medium.  Sections  were  photographed  using  a  Zeiss  Axiophot  microscope,  OpenLab 
imaging  software  and  Jenoptik  digital  camera,  or  a  Leica  TCS  SP2  confocal  microscope  for 
fluorescence imaging. Confocal reflectance microscopy was used to detect iron oxide in the Endorem 
nanoparticles.  The 488nm excitation laser was used and the light acquisition was adjusted to +/- 10 
nm of the excitation wavelength to detect signal reflected by magnetite crystals in the nanoparticles. 
This method has been described to detect submicroscopic magnetite particles in large volumes of 
tissue (Green et al, 2001).All reagents supplied by Sigma-Aldrich UK unless stated otherwise.   
 
6.3.  Results 
6.3.1.  Distribution of  Endorem following intraventricular injection.   
Endorem was injected into the left lateral ventricle, which resulted in a hypointensity in ventricles 
ipsi-  and  contralateral  to  the  injection  site,  as  well  as  in  the  periventricular  area  medial  to  the 
ventricles, on 2.35T MRI spin echo images at 48 hours post-injection. Figure 6.3.1.1A is a coronal 
section at the level of the lateral ventricles, in which a dark appearance due to the paramagnetic effect 
of the iron oxide can be observed throughout the lateral ventricles and periventricular area. The inset 
shows a coronal section at the same level in a sham-injected animal. Multislice imaging demonstrated 
that  the  hypointensity  extended  from  1  mm  anterior  and  6  mm  posterior  to  the  slice  shown, 
extending to the third ventricle.  
Prussian blue histology was performed to detect the distribution of iron within and around the 
ventricles. Prussian blue iron detection on histological sections was compatible with in vivo MRI 
images,  which  demonstrated  that  Endorem  was  present  in  the  anatomical  areas  displaying 
hypointensity on MRI images. Figures 6.3.1.1B-D show that Endorem is present in the ventricles as 
well as in the ventricular ependymal cell layer, the choroid plexus and the periventricular area. Within 
the lateral ventricle, Endorem was predominantly present in the medial wall, but was also detected in 
the lateral wall and the choroid plexus. Unexpectedly, the Prussian blue stain extended out from the 
medial, but not lateral, ependymal layer. Endorem was detected in the periventricular space medial to 
the lateral ventricles, but not in the striatum lateral to the ventricles. Endorem distribution in the 
septum appeared heterogeneous, where iron was observed in the dorsal nuclei – the triangular and 
lateral  septal  nuclei,  septohippocampal  and  ventrohippocampal  nuclei,  and  the  fornix  (Figure 
6.3.1.1C, and data not shown). In addition, Endorem in the medial periventricular space was present 
both as dense clusters, as well as diffuse particles, which may indicate intracellular and extracellular 
iron, respectively (Figure 6.3.1.1D). Some Endorem was present along the injection tract. Endorem  
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was observed outside of the lateral in all animals with intraventricular administration of Endorem. 
 
Figure 6.3.1.1 Endorem injection into the left lateral ventricle. A, 2D coronal MRI image at the level of 
the lateral ventricles.Hypointensity  is  seen in  the ventricles and in the  periventricular space medial to the 
ventricles, which indicates that Endorem is outside of the lateral ventricle. Inset: control, PBS-injection. No 
hypointensity  is  observed.  C,  2D  coronal  MRI  image  1mm  anterior  to  the  SVZ  slice,  showing  Endorem 
distribution in both ventricles and in the medial periventricular space. E, 2D coronal MRI image 1mm rostral 
to the SVZ slice, showing Endorem distribtion in the medial periventricular space. B, D, F Prussian blue (PB) 
histology staining for iron, coronal sections.  B, PB present in the periventricular space between left and right 
ventricles (arrow). D, PB in the corpus callosum (CC), lateral septal nucleus (LSN), fornix (F), and medial wall 
of the lateral ventricle (black arrow).  Scale bar, 100um. F, high magnification view of medial wall of lateral 
ventricle (LV) and periventricularventricular space. Scale bar, 30um.   
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6.3.2.  Localization of  the FePro complex following intraventricular injection 
In contrast to our observations following intraventricular microinjection of Endorem, injection of 
the FePro complex into the left lateral ventricle generated hypointensity in 2.35T MRI spin echo 
images in the left lateral ventricle only, in all animals. Hypointense contrast was absent from the 
periventricular  area  or  the  right  lateral  ventricle,  at  48  hours  post-injection.  Figure  2A  shows  a 
coronal section at the level of the lateral ventricles 48 hours following intraventricular injection, 
demonstrating that the FePro is restricted to the left lateral ventricle only (Figure 6.3.2.1A, arrow). 
No hypointensity was observed in the right lateral ventricle, or in the periventricular space between 
the ventricles.  
The Prussian blue histological stain for iron was compatible with in vivo MRI images, and confirmed 
that FePro was detected in the medial and lateral walls of the left lateral ventricle, and in the choroid 
plexus (not shown), but absent from the periventricular spaces medial and lateral to the ventricles 
(Figure  6.3.2.1B).  In  contrast  to  intraventricular  injection  of  Endorem,  FePro  labelling  was 
predominantly localised to the ependymal and subependymal layers of the medial and lateral walls of 
the ventricle.   
Confocal  reflectance  microscopy  analysis  indicated  that  cell  incorporation  of  the  FePro  contrast 
agent was predominantly in Nestin+ progenitor cells and ependymal cells of the SVZ (6.3.2.1C), as 
well as the GFAP+ astrocyte population in the SVZ (Figure 6.3.2.1D).  At the 48 hour timepoint, no 
FePro-labelled Doublecortin+ neuroblasts were observed in the SVZ or RMS in sections analysed.    
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Figure 6.3.2.1 FePro injection into the left lateral ventricle. A, 2D coronal MRI image at the level of 
the lateral ventricles.Contrast is seen in the left ventricle only (white arrow) and not in the periventricular 
space medial to the ventricles, indicating that the contrast agent is retained within the ventricle. B, Prussian 
blue histology staining for iron shows iron restricted to the medial and lateral walls of the left lateral 
ventricle (LV). No PB is observed in the periventricular spaces medial (M) or lateral (L) to the ventricle.  
C, D, Immunohistochemistry and reflectance mode confocal microscopy for the detection of iron show 
Nestin-positive (C, red) and GFAP-positive (D, green) cells in the SVZ labelled with the FePro contrast 
agent (yellow), indicating that the FePro contrast agent is incorporated by NPC and astrocytes in the SVZ.  
Scale bars: B, 30 µm; C, 30 µm; D, 50 µm.  
 
6.3.3.  Analysis of  the FePro complex in the RMS and OB 
Twenty eight days following intraventricular injection, in vivo and ex vivo 3D gradient echo images 
were  acquired  on  the  2.35T  system.  Figure  3  shows in  vivo  and  ex  vivo  sagittal  view  of  the  left 
hemisphere in two separate animals. Hypointensity was still observed in the left lateral ventricle on in 
vivo MRI images (Figure 6.3.3.1A, B), and remained absent from the periventricular space medial to 
the ventricles and from the right lateral ventricle, suggesting that up to this timepoint the FePro  
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remains restricted to the left lateral ventricle. Hypointensity was detected in the rostral migratory 
stream  on  in  vivo  and  ex  vivo  images  at  low  magnetic  field  strength  (2.35T;  Figure  6.3.3.1C-F).  
Hypointensity was also observed along the injection tract and in the subarachnoid space. However, 
little or no hypointense contrast was observed in the olfactory bulb at 28 days post-injection at low 
field  strength.  At  this  timepoint,  neuroblasts  would  be  expected  to  have  migrated  from  the 
subventricular zone through the rostral migratory stream and arrived at the olfactory bulb. 
 
 
Figure 6.3.3.1 FePro labelling of the SVZ: MRI.  A, B: coronal T2-weighted image at low magnetic field 
strength (2.35T) of FePro-injected left ventricle at 28 days post-injection in two separate animals. Contrast is 
seen in the left ventricle only, and no hypointensity is visible in the contralateral ventricle or septum. Arrows 
indicate hypointensity in the left ventricle.. C, D: in vivo T2*-weighted sagittal image of FePro-injected animals. 
E,  F:  ex  vivo  T2*-weighted  sagittal  image  of  separate  animals  after  perfuse  fixation.  Arrows  denote 
hypointensity in the RMS. G-N, 2D coronal T2-weighted images of 2 separate FePro-injected animals (G-J and 
K-N), showing FePro distribution 1mm anterior (G, K), 1mm posterior (I, M) and 2mm posterior (J, N) to the 
SVZ section (H, L). FePro is restricted to the left ventricle throughout the brain. Arrows denote FePro in the 
ventricles.    
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Perfused-fixed  brains  were  also  imaged  on  a  9.4T  experimental  system  at  the  28  day  timepoint 
(Figure  6.3.3.2).  On  the  high  field  system,  increased  spatial  resolution  and  signal  to  noise  was 
achieved compared to the low field 2.35T system, as well as increased sensitivity to the local field 
inhomogeneities  associated  with  the  iron  oxide  in  the  FePro  complex.  We  observed  greater 
susceptibility effects at the injection site of the lateral ventricles at 9.4T compared to 2.35T, as well as 
a ‘blooming’ effect that extended the hypointense contrast beyond the ventricles. In two animals 
injected with a larger volume of contrast agent, 20 µl FePro, the susceptibility effects extended into 
the ipsilateral striatum and cortex, the contralateral hemisphere, third and fourth ventricles, and the 
RMS (Figure 6.3.3.2A, inset). The high field data was in agreement with that observed at low field: 
hypointense  contrast  was  detected  in  the  left  lateral  ventricle  and  RMS.  Additionally,  some 
hypointense voxels were observed in the anterior RMS and at the OB (Figure 6.3.3.2B-E), in contrast 
to our data at low magnetic field strength.   
Prussian blue stain for iron was performed to assess the distribution of the FePro complex in the 
brain. In all animals, Prussian Blue histology was compatible with in vivo and ex vivo MRI images. 
FePro-labelled cells were observed in the SVZ, RMS and OB granule cell layer, as well as in the 
choroid plexus and subarachnoid space (Figure 6.3.3.3). FePro-labelled cells were observed in the 
OB, despite no hypointensity being observed on in vivo or ex vivo MRI images at the OB at low field 
strength, but in agreement with our data at high field strength (Figure 6.3.3.3A, B). An average of 180 
FePro-labelled  cells  were  counted  per  RMS.  The  estimated  total  volume  of  the  RMS  from  the 
anterior SVZ to the OB is 0.24 mm3, based on histological quantification of mean RMS area and 
stereotactic calculation of total RMS length.2.4 X 104 µm3. Our data therefore indicate that there are 
approximately 750 labelled cells per mm3 in the RMS. To assess whether FePro-labelling provided 
adequate  MR  contrast  for  in  vivo  imaging  at  these  concentrations,  cells  labelled  with  Endorem, 
containing 3.9 pg of iron oxide per cell, were suspended in agarose and imaged in an Eppendorf 
phantom using the 9.4T MRI system. Cells were clearly visible as signal voids due to the SPIO-
induced decrease in T2*. At a concentration of 7508 cells/mm3 suspended in agarose there was a 
84% decrease in T2* compared to control unlabelled cells . Cells were detectable at dispersions of 8 
cells/mm2 due to the SPIO-induced decrease in T2* (T2* values: unlabelled cells = 107 100ms; 
labelled cells 2872 ms) and in corresponding signal intensity in T2*-weighted images indicating the 
detection of cells at these at high-field even at low numbers.   
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Figure 6.3.3.2 FePro labelling of the SVZ: high field 9.4T MRI. A, Ex vivo T2*-weighted coronal image 
of FePro-injected lateral ventricle at 28 days post-injection. B-E, coronal sections of the olfactory bulb. Arrows 
indicate punctate regions of hypointensity. 
Prussian blue staining of coronal sections at 28 days post-injection did not detect FePro in the 
periventricular space or outside of the RMS. Doublecortin+ FePro-labelled cells were observed in 
the SVZ by confocal reflectance microscopy, and in the RMS by immunoperoxidase and horseradish 
peroxidase immunohistochemistry with Prussian blue staining, indicating that neuroblasts in the RMS 
are labelled with the FePro contrast agent (Figure 6.3.3.3E-H).    
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Figure 6.3.3.3 A-D. Prussian blue histology at 28 day timepoint.  Prussian blue stain for iron oxide with 
nuclear  fast  red  counterstain  showing  FePro-labelled  cells  in  the  rostral  migratory  stream  (RMS),  and 
olfactory bulb (OB) at 4 weeks post-injection.  Scale bar, 200 µm.  Blue box indicates area of adjacent high 
resolution insert.  Arrows denote labelled cells. Scale bar, 40 µm. E, F. FePro-labelled cells in the RMS co-
label with doublecortin. Brown, doublecortin positive neuroblasts (HRP) at 28 days post-FePro injection. 
Blue,  FePro-labelled  cells  (prussian  blue  stain  for  iron).  Arrows  indicate  FePro-labelled  doublecortin-
positive  cells.  Scale  bar,  40  µm.  G,  H  Immunofluorescent  staining  and  reflectance  mode  confocal 
microscopy show Doublecortin-positive (red) FePro-labelled (yellow) cells in the SVZ (G) and RMS (H) at 
28 days post-injection.  Scale bars: A, C, 100 µm; B, D–F, 30 µm; G, 50 µm; H, 30 µm.  
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6.4.  Discussion  
In this study we demonstrate that NPC and neuroblasts can be labelled with MRI contrast agents at 
the SVZ, and migrating neuroblasts can be visualised using MRI in the RMS at low magnetic field 
strength. Two MRI contrast agent cell labelling approaches – using Endorem or and the FePro 
complex  –  were  compared,  and  were  shown  to  have  very  different  distributions  in  the  brain 
following intraventricular injection. Endorem injection resulted in its distribution throughout the 
ventricular system as well as in the periventricular space medial to the lateral ventricles. Therefore, 
Endorem may offer the potential to investigate the in vivo properties of the cerebrospinal fluid barrier 
in the brain and the transport of solutes throughout the brain using MRI, with potential applications 
for drug targeting. In contrast to Endorem, the FePro complex was restricted to its injection site, the 
left lateral ventricle. Furthermore, the FePro complex was detected in the SVZ and RMS at low and 
high magnetic field strength 28 days following intraventricular injection, and histology confirmed that 
neuroblasts within the RMS were labelled with the FePro complex. These results may facilitate the 
study of neuroblast migration by establishing a methodology for in vivo labelling and monitoring of 
the endogenous population.   
 
6.4.1.  Endorem distribution may reflect solute transport in the brain 
Due to the observation of Endorem outside of the ventricle following intraventricular injection, 
Endorem  was  not  a  suitable  MRI  contrast  agent  for  endogenous  cell  tracking.  Endorem  was 
observed within the lateral ventricles and in the periventricular space medial to the ventricles. It has 
previously been reported that CSF flow created by the ciliated ependymal cells within the ventricles is 
responsible for circulation of substances throughout the ventricular system (Sawamoto et al., 2006), 
and may account for the distribution of Endorem we observed throughout the ventricular system. 
We observed that Endorem moved more readily into the septum than into the striatum lateral to the 
ventricles, however the mechanism of this transport is not known. Endorem movement into the 
medial  periventricular  space  may  occur  via  transcytosis  through  ependymal  cells  –-  as  has  been 
reported with horseradish peroxidase (Ueno et al., 2000)– via a paracellular route, or both. Endorem 
was detected in ependymal cells of the medial and lateral walls of the lateral ventricle, which would 
support active transcellular transport, but does not exclude the possibility of a paracellular route. 
Endorem particles in the periventricular space may be intracellular, extracellular, or both. Ferric iron, 
such  as  the  iron  oxide  in  Endorem,  stored  in  the  cellular  compartment  has  been  described  as 
appearing as dense conglomerates of Prussian blue stain on histological sections, whereas free ferric 
iron appears pale faint blue (Schenck and Zimmerman, 2004). Within the periventricular space, in the 
septal nuclei between the ventricles, both types of Prussian blue staining was observed, suggesting  
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that Endorem may be present both extra- and intracellularly.   
6.4.2.  FePro complex does not diffuse into the periventricular space 
Formation  of  the  Endorem-protamine  sulphate  complex  appears  to  inhibit  the  movement  of 
Endorem into the periventricular space. In the absence of protamine sulphate, we have observed that 
Endorem is distributed throughout the periventricular space. This may be due to the larger molecular 
size of the aggregated Endorem particles within the FePro complex, inhibiting paracellular transport. 
Alternatively,  protamine  sulphate  interaction  with  cell  membranes  may  encourage  or  favour 
endocytosis and storage of the FePro complex within cells in contact with the complex. Protamine 
sulphate is a polycationic compound that is commonly used as a transfection agent for viral gene 
transfer. Its action is by aggregation of negatively-charged entities to create a complex, and increasing 
contact of the complex with cell membranes due to its positive charge. Endorem nanoparticles are 
coated with negatively-charged dextran, and protamine sulphate has been used in conjunction with 
Endorem in vitro for cell labelling (Arbab et al., 2005; Arbab et al., 2004). We have found that in vitro, 
protamine  sulphate  can  increase  cell  uptake  of  the  FePro  complex  four-fold  compared  to  cell 
incubation  with  Endorem  alone,  as  supported  by  quantification  of  cell  iron  content  using  the 
superconducting quantum interference device (SQUID, unpublished data). Other in vitro studies are 
in agreement with this data (Arbab et al., 2005). 
 
6.4.3.  FePro allows imaging of  endogenous migrating neuroblasts 
The FePro-labelled  migrating  neuroblasts  produce hypointensity  in  MRI T2-  and  T2*  -weighted 
images, observed in the RMS and OB. The FePro complex was detected in the SVZ, RMS on low 
field MRI images, and in the OB on images acquired at high field strength at 28 days post-injection.s. 
This is consistent with SVZ labelling observed at 2 days post-injection, and subsequent migration of 
labelled neuroblasts from the SVZ, detected later by MRI and Prussian blue staining for FePro. 
Immunohistochemistry  indicates  that  at  48  hours  post-injection,  Nestin+  progenitor  cells  and 
GFAP+ astrocytes in the SVZ, of which a subpopulation are stem cells, have incorporated the FePro 
contrast agent. At later timepoints, we observed Doublecortin+ neuroblasts in the RMS labelled with 
the FePro complex. It is likely that this neuroblast labelling occurred at the lateral ventricles. Our 
hypothesis was that injection of MRI contrast agents into the lateral ventricle would be expected to 
non-selectively label cells in the region: neural stem cells, progenitor cells and neuroblasts, as well as 
ependymal cells and the choroid plexus. The data suggest that FePro-labelled stem or progenitor cells 
gave rise to neuroblasts that retained the FePro label, and migrated through the RMS and towards the 
OB.   
The in vivo imaging of neuroblasts was achieved using a smaller injection concentration of iron oxide 
than previously reported by Shapiro et al, and without the addition of growth factors to promote cell  
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labelling at the SVZ. In this study, 2 µl of FePro complex was injected into the left lateral ventricle, in 
contrast to the 50 µl injection volume of Bangs particles and in some cases together with epidermal 
growth factor (10 µl, EGF)(Shapiro et al., 2006).  The reduced susceptibility effects at the injection 
site, due to the smaller injection volume, will also permit imaging the short distance migration of 
neuroblasts  in  pathological  environments,  for  example,  their  migration  from  the  SVZ  into  the 
striatum following cerebral ischaemia. If there is endogenous neuroblast migration from the SVZ 
following an injury, it should be apparent using this method. In the two previous studies using the 
Bangs  particles,  the  susceptibility  effects  from  the  50ul  injection  of  Bangs  particles  caused  a 
‘blooming  effect’  into  the  striatum  and  cortex,  therefore  short  distance  neuroblast  migration  in 
response  to  brain  injury  is  potentially  obscured.  Similarly  in  our  study,  increasing  the  injection 
volume  to  20  µl  FePro resulted  in susceptibility  effects  extending  into the  striatum,  cortex  and 
contralateral hemisphere. The smaller 2 µl injection volume may also account for the lateralisation we 
observed in the ventricles, where the FePro complex did not diffuse throughout the CSF and into the 
contralateral ventricle, a result which will be of some experimental benefit in future studies. 
This method of endogenous labelling of the SVZ with FePro complex has some limitations in that 
we observed a low number of labelled neuroblasts, particularly at longer distances from the injection 
site. While at 48 hours post-injection the SVZ appeared uniformly and non-selectively labelled with 
the FePro complex, at 28 days post-injection few FePro-labelled neuroblasts were observed in the 
OB on histological sections. FePro-labelled cells were observed throughout the RMS at 28 days post-
injection, although the majority of FePro labelling remained at the SVZ. Given the low number of 
FePro-labelled neuroblasts within the RMS and at the OB, MRI detectability of FePro was good at 
both magnetic field strengths. Labelled neuroblasts at the beginning of the RMS, within the first 
millimeter distance from the anterior SVZ, could be detected at low field strength, and without 
interference from the susceptibility effects of the large concentration of iron oxide at the injection 
site. We were able to observe low cell numbers in the olfactory bulb using a 9.4T system, which was 
corroborated by in vitro phantom experiments.   
Further possible limitations of the method are that the FePro complex persists at the injection site 
after the initial injection. FePro was detected in the SVZ after 28 days following injection. In future 
applications, this may limit the capturing of a time window of migration.,. It will provide, however, a 
cumulative  indication  of  neuroblast  migration  from  the  time  of  injection  onwards.  Finally,  it  is 
possible that resident microglia may take up the FePro complex of neuroblasts if they die, and this 
would be indistinguishable on MRI images. However, the fact that most Prussian blue-positive cells 
in  the  RMS  express  Doublecortin  suggests  that  this  should  not  present  a  major  obstacle.  
Furthermore, immunohistochemical detection of microglia in the RMS with the OX-42 antibody is 
low (data not shown). This is consistent with the finding by Shapiro et al (Shapiro et al., 2006), that 
only a small population of microglial cells contain Bangs particles in the RMS.    
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In conclusion, we have shown that intraventricular injection of Endorem results in its distribution 
throughout the ventricular system and into the periventricular space, whereas the FePro complex 
remains localised to the lateral ventricle. We have demonstrated that neuroblasts can be labelled with 
MRI contrast agents via the SVZ, and migrating neuroblasts can be visualised using MRI in the RMS 
at low and high magnetic field strengths. This novel methodology for in vivo labelling and monitoring 
of  endogenous  neuroblasts  using  MRI  will  be  valuable  for  future  applications  in  investigating 
neurogenesis under pathological conditions.    
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7.  Investigation  of   subventricular  zone  stem  cell  subpopulation contributions to  neuroblast 
migration following cerebral ischaemia by lineage tracing  
7.1.  Introduction 
A population of neural stem cells (NSC) exists in the subventricular zone (SVZ) of the mature brain 
(Reynolds et al., 1992) and generates new neurons throughout adult life. In the normal brain, the 
neural  stem  cells  divide  to  generate  transit-amplifying  daughter  cells,  which  in  turn  generate 
neuroblasts that migrate through the rostral migratory stream (RMS) towards the olfactory bulb 
(OB), where they differentiate into olfactory bulb interneurons (Lledo et al., 2006g; Lledo et al., 
2008). The neural stem cells have been characterised as a subpopulation of SVZ astrocytes, based on 
their expression of the astrocyte marker, glial fibrillary acidic protein (GFAP) (Doetsch et al., 1999a); 
. To date, no markers specific and exclusive to the NSC population have been identified, though they 
express a profile of markers shared by other cells types (GFAP, nestin, sox2, etc). This has made 
identifying stem cells difficult in immunohistochemical analysis, and has prevented the isolation of 
adult neural stem cells for cell culture and analysis. For this reason, few transgenic approaches to 
label NSC for in vivo characterisation have been successful.  
Recent  research  suggests  that  the  SVZ  contains  developmentally  distinct  stem  cell  populations, 
derived separately from the embryonic striatum and the embryonic cortex (Young et al., 2007a). In 
the  study  by  Young  et  al,  transgenic  mice  expressing  Cre-recombinase  under  the  transcription 
promoter of embryonic transcription factors – Gsh2 (expressed in the embryonic striatal germinal 
zone) and Emx1 (expressed in the embryonic cortex) (Fogarty et al., 2005; Kessaris et al., 2006)– 
were  crossed  with  Rosa26-YFP  reporter  mice,  in  order  to  label  the  corresponding  embryonic 
telencephalic  regions  with  YFP.  The  transgenic  mice  were  used  to  investigate  whether  these 
regionally distinct embryonic populations contribute differentially to the neural stem cell population 
in the adult SVZ, and to neurogenesis in the olfactory bulb. Gsh2- and Emx1-derived cells were both 
found  to  populate  the  SVZ,  contribute  to  migratory  neuroblast  generation,  and  generate  new 
olfactory neurons in the adult brain. The SVZ was composed predominantly of Gsh2-derived cells at 
the lateral wall and dorsolateral corner, with Emx1-derived cells also contributing to NSC in the 
dorsolateral corner (Figure 1.1).  
Using a bromodeoxyuridine (BrdU) pulse to label newly dividing cells, Young et al demonstrated that 
the distinct stem cell populations made differential contributions to olfactory interneuron subtypes. 
Embryonic striatum-derived stem cells contribute disproportionately to the number of all newborn 
cells in the OB, in particular by generating all new Calbindin-positive and most Tyrosine hydroxylase-
positive  olfactory  interneurons,  whereas  the  cortex-derived  stem  cells  generated  the  majority  of 
Calretinin-positive  interneurons.  Additionally,  it  was found  that  embryonic  cortex-  and striatum- 
derived stem cells maintain expression of the Emx1 and Gsh2 throughout life, respectively (Young et  
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al.,  2007a).  Expression  of  these  markers  in  adulthood  can  be  further  exploited  through  the 
development  of  tamoxifen-inducible  Gsh2-Cre/R26-YFP  ERt2  or  Emx1-Cre/R26-YFP  ERt2 
transgenic mice, for further characterisation of these stem cell populations.  
 
Figure 7.1.1. Emx1-Cre/R26-GFP  and Gsh2-Cre/R26-GFP  transgenic lines (from Young et al., 
2007).  A,  Schematic  depicting  the  different  embryonic  neuroepithelial  domains  and  their  relative 
contribution to generating the adult SVZ. F-K In situ hybridization for endogenous Gsh2 (f) or Cre (g) in 
E12.5 Gsh2-Cre/R26-GFP  mice, and b-galactosidase enzymatic labeling (h) in Gsh2- Cre/ Rosa26R-lacZ 
embryos. In situ hybridization for endogenous Emx1 (i) or Cre (j) in E11.5 Emx1-Cre/R26-GFP  mice 
and activation of the GFP reporter gene (k) in Emx1-Cre/R26-YFP / Rosa26R-GFP embryos. Scale bar, 
400 µm. B,C, GFP-positive cells were detected by immuno-labeling in sections from Gsh2-Cre/R26-YFP  
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/Rosa26R-GFP mice (B) or Emx1-Cre/R26-YFP /Rosa26R-GFP mice (C). Each region of the embryonic 
neuroepithelium contributedpreferentially to distinct regions of the adult SVZ.  L, Many GFP-positive 
cells were found in the SVZ in Gsh2-Cre/R26-YFP /R26-GFP mice. M, Significant numbers of GFP-
labeled  cells  are  present  in  the  dorsal  part  of  the  SVZ  in  Emx1-Cre/R26-YFP  /R26-GFP  mice.  N, 
Generation of new interneurons by distinct subpopulations of SVZ stem cells. Triple immunolabelling for 
BrdU (blue), GPF (green), and either Parvalbumin (A, B), Tyrosine Hydroxylase (TH) (C, D), Calretinin 
(Crt) (E, F) or Calbindin (Cb) (G, H) (red), four weeks after BrdU administration.  P, Gsh2- and Emx1-
derived  stem  cells  generate  different  proportions  of  TH-,  Crt-  and  Cb-positive  neurons.  Cb-positive 
neurons were exclusively Gsh2 (LGE)-derived.  
This study and others (Willaime-Morawek et al, 2006) demonstrate that developmentally distinct 
subpopulations of neural stem cells populate the SVZ and contribute differentially to normal 
neurogenesis at the olfactory bulb. NSC at the SVZ are known to contribute to neurogenesis 
post-ischaemia, by the migration of neuroblasts into the ischaemic striatum and differentiation 
into  striatal  interneurons  (Chopp  et  al.,  2007;  Dempsey  and  Kalluri,  2007;  Hou  et  al.,  2008; 
Kokaia and Lindvall, 2003; Kokaia et al., 2006; Ohab et al., 2006; Thored et al., 2006; Thored et 
al., 2007). Fewer studies have demonstrated neurogenesis in the ischaemic cortex, and the origin 
of  the  newborn  cells  is  not  confirmed  (Magavi  et  al.,  2000;  Rakic,  2002).  It  is possible  that 
differential contribution of NSC subpopulations at the SVZ determines the differential response 
to ischaemia in the stritatum and cortex. This study aims to determine the contribution of Gsh2-
derived and Emx1-derived neural stem cell populations to the neurogenic response following 
ischaemia.  Their  contribution  to  the  interneuron  subpopulations  in  the  normal  striatum  and 
cortex is also investigated as a baseline control measure.  
The aim of this study was to investigate the contribution of these two neural stem cell populations 
– Gsh2- or Emx1-derived – to the ischaemic response, and to examine the in vivo behaviour of 
each neural stem cell population and their relative contributions to brain repair, using Gsh2-
Cre/R26-GFP  and  Emx1-Cre/R26-GFP  transgenic  mice.  To  investigate  this  we  used  BrdU 
administration and the Cre-lox fate mapping approach in transgenic mice to determine which 
types of new cells are produced by the embryonic striatum-derived stem cells (in Gsh2-Cre/R26-
YFP  mice)  or  embryonic  cortex-derived  stem  cells  (Emx1-Cre/R26-YFP  mice)  at  three 
timepoints following ischaemic injury – 1 week, 3 weeks and 5 weeks post-ischaemia. We found 
that both Gsh2- and Emx1-derived NSC proliferate and generate neuroblasts in the striatum but 
not in the cortex following ischaemia.  
Oligodendrocyte precursor cells (OLPs) represent an additional population of proliferating cells in 
the adult brain, and are known to proliferate throughout adult life. The developmental origin of 
OLPs is in the ventricular zone of the developing brain, but they migrate and are distributed 
throughout all regions of the brain, including white matter, the cortex and striatum, by postnatal 
stages.  OLPs  express  PDGFRα  and  NG2  proteoglycan,  which  become  downregulated  when  
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OLPs differentiate into mature oligodendrocytes. It has recently been reported that OLPs can 
also generate forebrain neurons in the normal adult brain in the piriform cortex (Rivers et al,  
2008), and postnatal OLPs can generate astrocytes in vitro  (Figure 7.1.2). In the normal brain, 
OLP contribution to projection neurons in the piriform cortex was found to be approximately 
1.4%, however the function of these cells is unknown.  
 
Figure 7.1.2. OLPs in the adult brain. (From Rivers et al, 2008). A, Schematic depicting the different 
embryonic neuroepithelial domains and their contribution to generating adult OLPs. B, In the corpus 
callosum 8 days after tamoxifen induction of GPF expression, some YFP+ cells expressed CNP in their 
cell bodies and proximal processes (arrows). D, YFP+ NeuN+ cells in the piriform cortex after 210 days 
after tamoxifen induction of GPF expression. Scale bars represent 30 µm. 
   
It is possible that ischaemic damage will not only activate SVZ neural progenitor cells, but will 
additionally activate OLPs to replace oligoendrocytes that are lost or damaged. Some evidence 
suggests that oligodendrocytes are resistant to the initial ischaemic insult, but undergo apoptosis 
24 to 48 hours after a transient ischaemic event (Mabuchi et al., 2000). Oligodendrocytes and 
OLPs have been shown to subsequently accumulate in the corpus callosum and border of the 
ischaemic lesion within 7 days, co-localising with reactive astrocytes and microglia at the infarct 
border (Aguirre and Gallo, 2004; Gottlieb et al., 2000; Mabuchi et al., 2000; Mandai et al., 1997; 
Ohta et al., 2003). It is unclear from these studies whether OLP accumulation after ischaemia is a 
function of OLP proliferation, or migration from other brain areas. It is also unclear whether 
OLP  differentiation  at  later  time  points  contributes  to  glial  scar  formation,  remyelination  or 
neurogenesis.   
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A further aim of this study was to investigate the effect of cerebral ischaemia on the proliferation 
and differentiation of resident oligodendrocyte precursor cells (OLPs) in the cortex, striatum and 
corpus  callosum.  Examining  the  effect  of  ischaemia  on  the  SVZ  stem  cell  population  in 
conjunction with the oligodendrocyte population will help form a more complete understanding 
of  the  activity  of  endogenous  progenitor  cells  following  ischaemia,  and  their  contribution  to 
repair. Furthermore, the finding that OLPs can contribute to neurogenesis in the normal brain 
establishes  oligodendrocyte  precursor  cells  as  a  candidate  cell  type  for  contribution  to 
neurogenesis after ischaemia. The previously generated PDGFRα-CreERt2/R26-YFP transgenic 
line  was  used  to  selectively  label  OLPs  and  trace  their  progeny  and  contribution  to 
oligodendrogenesis after cerebral ischaemia. PDGFRα-CreERt2 mice carrying the Rosa26R-YFP 
allele received Tamoxifen prior to MCAO surgery in order to induce expression of YFP in OLPs 
at the time of ischaemia. We observed an increase in OLP proliferation in the striatum following 
cerebral ischaemia. OLPs contributed to mature oligodendrocyte generation and maintenance of 
the OLP population, but a proportion of OLP-derived cells were of unknown cell type. No OLP-
derived neurons or neuroblasts were observed in the cortex, striatum or corpus callosum. 
 
7.2.  Methods 
7.2.1.  Transgenic mice 
Adult male mice aged 90-120 days and > 25 g were used in this study. The generation of Gsh2-Cre, 
Emx1-Cre, and PDGFRα-CreERt2 mice was described previously (Fogarty et al., 2005;Kessaris et 
al., 2006; Rivers et al. 2008). Each transgenic line was crossed with either of two Cre reporter 
lines: Rosa26-enhanced Green Fluorescent Protein (R26-GFP) (Mao et al., 2001; Jackson Laboratories) 
for Gsh2-Cre and Emx1-Cre, or Rosa26-Yellow Fluorescent Protein (R26-YFP) (Srinivas et al., 2001; 
generously  supplied  by  S.  Srinivas)  for  PDGFRα-CreERt2/R26-YFP.  To  activate  Cre 
recombinase  activity  in  PDGFRα-CreERt2/R26-YFP  transgenics,  tamoxifen  (Sigma)  was 
administered, at a concentration of 50 mg/ml in corn oil. Induction in adult mice was performed 
7 days before MCAO surgery, and was achieved by administering 300 mg/kg Tamoxifen per day 
by gavage on five consecutive days.  
7.2.2.  BrdU labeling 
To identify cells dividing in vivo, BrdU (Sigma) in PBS was administered as four 2 mg intra-
peritoneal doses at a concentration of 20 mg/ml over 48 hours. The first dose of BrdU was 
administered at 48 hours post-MCAO surgery.  
7.2.3.  MCAO surgery 
All procedures were in accordance with the UK Animals (Scientific) Procedures Act of 1986, and  
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approved by the UCL Research Ethics Committee. Forty four animals were used in the study: 
Gsh2-Cre/R26-GFP  1 week (n=5); Gsh2-Cre/R26-GFP  3 weeks (n=5); Gsh2-Cre/R26-GFP  5 
weeks (n=5); Emx1-Cre/R26-GFP  1 week (n=4); Emx1-Cre/R26-GFP  3 week (n=5); Emx1-
Cre/R26-GFP    5  week  (n=6);  PDGFRα-CreERt2/R26-YFP  1  week  (n=5);  PDGFRα-
CreERt2/R26-YFP 3 weeks (n=3); PDGFRα-CreERt2/R26-YFP 5 weeks (n=3). Three animals 
received sham surgery. Mouse MCAO surgery was performed using the Koizumi model (Koizumi 
1986).  Animals  were  anaesthetised  with  2%  isofluorane  and  100%  O2.  Temperature  was 
maintained with a feedback-controlled homeothermic blanket and rectal probe (Hamilton/ADI). 
The right common carotid artery was exposed. For mice, a 7-0 silicon-coated suture (Doccol) was 
inserted into the carotid artery and advance 7mm into the brain to reach the MCA bifurcation 
from the circle of Willis. The MCA was occluded for 30 minutes. Following occlusion, the MCA 
was  reperfused  by  retracting  the  suture  from  the  brain  slowly  over  2  minutes  and  animals 
recovered. Recovered animals were housed individually in clean cages and put on a wet food diet 
for the first 48 hours. For sham surgery, the surgical procedure and post-operative animal care 
was similar to described above, however during surgery the silicon-coated suture did not obstruct 
the MCA bifurcation. In PDGFRα-CreERt2/R26-YFP mice, animals received 5 mg/kg carprofen 
analgesic for 48 hours post-surgery, as prescribed by the UCL vet.   
After  surgery  animals  were  recovered  in  individual  cages  lined  with  soft  tissue  bedding,  and 
housed separately. In the first 48 hours, animals were fed a mixture of soft pellets and jelly, after 
which they were returned to hard pellets.  
7.2.4.  MRI 
MRI  animal  studies  were  performed  using  a  2.35T  horizontal  magnet  with  a  120  mm  bore 
(Oxford Instruments Eynsham, UK), interfaced to a Surrey Medical Imaging Systems (SMIS, UK) 
console. A volume coil (60 mm length) was used to transmit radiofrequency excitation pulses. The 
magnetic resonance signals were detected using passively decoupled, single loop, surface coil of 
1cm diameter positioned on the dorsal aspect of the head. Animals were anaesthetised with 2% 
isofluorane and 100% O2, and secured on a stereotactic probe for imaging. Body temperature was 
maintained  at  37oC.  A  2D  spin  echo  (T2-weighted)  sequence  was  used  with  the  following 
parameters: TR = 1500ms; TE = 120ms; FOV 25 mm; 128 X 128 voxels; slice thickness 1 mm; 
10 averages. Animals were imaged at 7, 21, or 35 days post-MCA occlusion surgery.  
7.2.5.  Tissue preparation 
Following  MRI,  mice  were  anaesthetized  with  pentobarbitone  and  perfused  through  the 
ascending aorta, first with PBS and then with 4% (w/v) paraformaldehyde (PFA, Sigma) in PBS. 
Brains were removed, immersed in fresh 4% PFA and stored at 4°C overnight. Tissue was cryo- 
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protected in 20% sucrose in PBS for 24 hours. All brains were embedded in optimal cutting 
temperature  (OCT)  compound  and  coronal  cryo-sections  (20  µm  nominal  thickness)  were 
collected onto SuperfrostPlus slides (BDH) or floated in PBS. 
7.2.6.  Immunohistochemistry 
Initially, three mice were examined for each transgenic genotype and ischaemic timepoint. From 
each mouse, three coronal brain sections at the anterior SVZ/ MCA region were immunolabeled 
for each antibody staining condition. Sections were washed with PBS and permeabilized with 
blocking  solution  containing  Triton-X100  before  incubating  overnight  with  rabbit  anti-  YFP 
(1:6000) or rat anti-YFP IgG2a (1:1000, Nacalai Tesque Inc.). Sections were washed three times 
with PBS, then incubated with AlexaFluor 488-conjugated anti-rabbit IgG or AlexaFluor 488-
conjugated anti-rat IgG (1:1000; Invitrogen) in blocking solution. Some sections were treated with 
Hoescht 33258 nuclear label (1:1000; Sigma). Floating sections were transferred onto glass slides 
and mounted using Fluoromount (DAKO). Sections were co-stained with either CY3-conjugated 
mouse anti-GFAP (1:3000; Sigma); rabbit anti-GFAP (1:500; Dako); mouse anti-NeuN (1:500, 
Chemicon); rabbit anti-Calbindin (1:1000, Swant); rabbit anti-Calretinin (1:1000, Swant), rabbit 
anti-Parvalbumin (1:1000, Chemicon), guinea-pig anti-doublecortin (1:3000, Chemicon); mouse 
anti-PSA-NCAM IgM (1:1000, Chemicon); and detected with AlexaFluor 568-conjugated anti-
mouse IgG1; AlexaFluor 568-conjugated anti-rabbit IgG; AlexaFluor 568-conjugated anti-mouse 
IgM (Invitrogen, all used at 1:1000;) or CY3-conjugated anti-guinea-pig (1:500, Pierce). 
For BrdU immunohistochemistry, stained floating sections were subsequently collected onto glass 
slides and fixed with 70% ethanol/ 20% glacial acetic acid, then 20 minutes in 70% ethanol at -
20°C. Slides were then washed with PBS / 1% Triton-X100 and treated with 6M HCl / 1% 
Triton X-100 in PBS for 15 minutes. Slides were then washed in PBS and incubated with anti-
BrdU  (1:15,  ATCC  mouse  hybridoma)  overnight  at  4oC.  Slides  were  washed  in  PBS  and 
incubated with AlexaFluor 568-conjugated anti-mouse IgG1 or AlexaFluor 647-conjugated anti-
mouse IgG1 (1:1000, Invitrogen) for one hour at room temperature.  
7.2.7.  Confocal Microscopy 
Images were collected with a confocal microscope (Perkin Elmer). For quantification of cells in 
the PDGFRα-CreERt2/R26-YFP -CreERt2 transgenic line, a minimum of 6 non-overlapping 
fields in the ipsi- and contra-lateral cortex (from cingluate through to motor, somatosensory and 
insular cortex, but excluding the piriform cortex), striatum, and corpus callosum were examined 
per animal. Total YFP+ cells per frame, as well as percentage of NG2+/ CNP+/ NeuN+/ 
GFAP+ or Olig2+ YFP+ double-positive cells were counted. Statistical analysis was performed 
using analysis of variance (ANOVA), with Tukey post-hoc analysis.  
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7.3.  Results:  
7.3.1.  Animal  model  mortality  rates  in  Gsh2-Cre/R26-YFP,  Emx1-Cre/R26-
GFP and PDGFRα-CreERt2/R26-YFP  
Recovery from the MCAO procedure was good; only 2% of animals died during surgery or during 
the recovery period before returning to normal housing. However, a high mortality rate in the 12-60 
hour period after surgery was observed, and some animals died up to 8 days post-surgery. Mortality 
rates were 41.9% for Gsh2-Cre/R26-GFP  and 42.9% for Emx1-Cre/R26-GFP  transgenics. For 
PDGFRα-CreERt2/R26-YFP  -CreERT2  transgenics,  the  initial  mortality  rate  was  very  high  at 
83.3%. Post-operative care was adjusted, as recommended by the UCL vet, to include carprofen 
analgesic  at  5  mg/kg/day  for  48  hours  post-surgery  to  improve  outcome.  Following  this 
modification,  mortality  in  the  PDGFRα-CreERt2/R26-YFP  -CreERT2  transgenic  group  was 
reduced to 50.0%. All animals analysed are from the carprofen-treated group. The mean weight at 
surgery was 27.1 ±2.1 for PDGFRα-CreERt2/R26-YFP -CreERT2, 29.0 ±2.9 for Emx1-Cre/R26-
YFP , and 32.1 ±3.2 for Gsh2-Cre/R26-GFP  mice.  
 
7.3.2.  MRI in Gsh2-Cre/R26-GFP and Emx1-Cre/R26-GFP  transgenic mice.  
Following cerebral ischaemia surgery, animals were imaged at 1 week, 3 weeks or 5 weeks post-
ischaemia, prior to perfusion fixation, for confirmation and assessment of final lesion volume. We 
observed the evolution of hypointensity in the lesion at later timepoints on T2-weighted images, 
consistent with previous reported data (Figure 7.3.2.1A).  
Whole brain total lesion volume and MCA territory lesion volume were assessed. We observed a time 
point effect but no transgenic effect. There was no difference in the total lesion volume, or lesion 
volume at the MCA territory, between Gsh2-Cre/R26-GFP and Emx1-Cre/R26-GFP  transgenics at 
any  timepoint,  but  lesion  volumes between  time  points  were significantly  different  (whole  brain 
ANOVA, p<0.005; MCAO territory ANOVA, p<0.001; Figure 3.2.1B,C). For both whole brain and 
MCA territory lesion volumes, 3-week and 5-week lesion volumes significantly smaller than 1-week 
lesion volumes (Total, p<0.01; MCAO, p<0.001). Lesion volume as a proportion of the ipsilateral 
hemisphere  (lesion  fraction)  was  also  assessed.  We  found  that there  was  no  difference  between 
Gsh2-Cre/R26-GFP and Emx1-Cre/R26-GFP lesion fractions at each time point, but that lesion 
fractions  were  significantly  different  across  timepoints  (ANOVA,  p<0.001;  Figure  3.2.1C).  In 
summary,  no  difference  was  observed  between  Gsh2-Cre/R26-GFP  and  Emx1-Cre/R26-GFP 
transgenics  at  1-week,  3-week  or  5-weeks  post-ischaemia.  Ischaemic  lesions  were  significantly  
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reduced in volume and as a fraction of the ipsilateral hemisphere at 3- and 5-weeks, relative to 1-
week post-ischaemia.  
We also assessed the ratio of contralateral to ipsilateral hemisphere volume at the SVZ level. We 
observed  that  the  ipsilateral  total  hemisphere  volume  decreased  at  3-weeks  and  5-weeks  post-
ischaemia,  relative  to  the  contralateral  hemisphere,  and  compared  to  sham-operated  animals 
(univariate ANOVA, p<0.001; Figure 7.3.2.1E). 
 
Figure 7.3.2.1. A, MRI of Gsh2-Cre/R26-GFP  and Emx1-Cre/R26-GFP  transgenic mice at 1, 3, and 5  
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weeks post-ischaemia.  B-D Whole brain total lesion volume (B), lesion volume at the MCA territory (C) and 
lesion volume as a fraction of ischaemic hemisphere volume at the MCA territory (D) for Gsh2-Cre/R26-GFP  
(yellow) and  Emx1-Cre/R26-GFP  (violet) at 1, 3, and 5  weeks post-ischaemia. E, Ratio  of ipsilateral  to 
contralateral hemisphere volume in Gsh2-Cre/R26-GFP  (yellow), Emx1-Cre/R26-GFP  (violet), and sham-
operated mice (grey).  The ischaemic (ipsilateral) hemisphere decreases in volume over time relative to the non-
ischaemic (contralateral) hemisphere over time. 
 
7.3.3.  Contribution of  Emx1- and Gsh2-derived stem cells to proliferating and migrating 
neuroblasts.  
Next, we assessed the capacity of Gsh2- and Emx1-derived NSC to proliferate, migrate, and generate 
new neurons following cerebral ischaemia by immunohistochemical analysis. NPC proliferation was 
observed  in  the  SVZ  at  1-week  post-ischaemia  in  Gsh-2  animals  (Figure  7.3.3.1).  Preliminary 
observations  indicate  an  increase  in  BrdU+  cells  in  the  ipsilateral  hemisphere  relative  to  the 
contralateral hemisphere, with almost all BrdU+ cells PSA-NCAM+ and all were YFP+, whereas 
fewer BrdU+ cells in the contralateral SVZ were PSA-NCAM+, and some BrdU+YFP- cells were 
observed in this hemisphere (Figure 7.3.3.1). This suggests that following ischaemia, Gsh2-derived 
stem and progenitor cells are activated and respond by the proliferation and generation of neuroblasts.    
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Figure 7.3.3.1. Proliferation at the SVZ at 1 week post-ischaemia in Gsh2-Cre/R26-GFP  mouse. A, 
Schematic of a coronal section of adult brain at the SVZ, with ischaemic lesion demarcated (pink dots). B-E, 
Cell  proliferation  at  the  SVZ  dorsolateral  corner  (B,D)  and  lateral  wall  (C,E)  in  the  ischaemic  (B,C)  and 
contralateral (D,E) hemisphere. Green, GFP; red, PSA-NCAM; blue, BrdU. Arrows denote PSA-NCAM+ 
BrdU+ cells. Scale bars, 50um.  
 
Consistent with other studies, in our preliminary observations we detected Doublecortin+ and PSA-
NCAM+ neuroblasts migrating out from the subventricular zone ipsilateral to the lesion. At 5 weeks 
post-ischaemia,  neuroblast  streams  were  observed  migrating  from  both  the  lateral  wall  and  the 
dorsolateral  corner of  the  ipsilateral  ventricle  into the  striatum  (Figure  7.3.3.2  C,G-I).  No  PSA-
NCAM+ or Doublecortin+ cells were observed in the ipsilateral cortex. No neuroblast migration 
away from the SVZ into the striatum was observed in the contralateral hemisphere (Figure 7.3.3.2 D-
E).  
YFP+ Doublecortin+ BrdU+ cells were observed in Gsh2-Cre/R26-GFP  transgenics, indicating 
that some neuroblasts migrating at 5 weeks originated between 2-4 days post-ischaemia from Gsh2-
derived neural stem cells in the SVZ (Figure 7.3.3.2 J-K). 
Figure 7.3.3.2 A-C shows a whole hemisphere profile of PSANCAM distribution in Gsh2 at 1-week 
(B), 5-week (C), and in the contralateral control hemisphere (A). PSANCAM expression is restricted 
to the SVZ in the contralateral hemisphere and at 1-week post-ischaemia. At 5 weeks post-ischaemia, 
we observed PSANCAM+ neuroblast streams migrating toward the lesion, and at the peri-infarct 
border.  
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Figure 7.3.3.2. Neuroblast migration from the SVZ at 5W post-ischaemia in Gsh2-Cre/R26-GFP 
transgenic  mice.  A-C,  Fluorescent  microscopy  of  GFP  and  PSA-NCAM  immunohistochemistry  in 
contralateral (control) 5W (A), ipsilateral (ischaemic) 1W (B), and ipsilateral 5W (C) whole hemisphere, showing 
neuroblast  migration  from  the  SVZ  toward  the  ischaemic  lesion.  D-I,  higher  magnification  of  SVZ  and 
striatum at 5W post-ischaemia in control contralateral (D-F) and ischaemic ipsilateral (G-I) hemispheres. D,G, 
SVZ dorsolateral corner. E,H, SVZ dorsolateral wall. F,I, striatum.  Arrows denote PSA-NCAM+ migrating  
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neuroblasts. Red, PSA-NCAM. Green, GFP. Blue, Hoescht nuclear dye. J,K, BrdU, GFP, and Doublecortin 
(DCX) at the SVZ dorsolateral corner (J) and dorsolateral migratory streatm (K) in the ipsilateral hemisphere at 
5W post-ischaemia, showing newly-generated Gsh2-derived and non-Gsh2-derived neuroblasts migrating into 
the ischaemic striatum. Arrows denote BrdU+ GFP+ PSA-NCAM+ triple-immunolabelled cells. Scale bars, 
50um.  
 
YFP+ PSA-NCAM+ neuroblasts were observed in both Emx1-Cre/R26-GFP  and Gsh2-Cre/R26-
GFP  transgenics, indicating that both stem cell populations contribute to new neuroblast generation 
in response to ischaemia (Figure 7.3.3.3). In the Emx1-Cre/R26-GFP  mice, YFP+PSA-NCAM+ 
cells  were  predominantly  observed  in  the  dorsolateral  stream  of  neuroblasts  migrating  from  the 
dorsolateral corner of the SVZ, bordering the corpus callosum. No YFP+ neuroblasts were observed 
migrating in the striatum. 
 
Figure 7.3.3.3. GFP and PSA-NCAM immunohistochemistry in Gsh2-Cre/R26-GFP. (A,B) and Emx1-
Cre/R26-GFP    (C,D)  transgenic  mice.  A,C,  SVZ  dorsolateral  corner.  B,D,  dorsolateral  migratory  stream. 
Arrows denote GFP+ PSA-NCAM+ double immunolabelled cells. Scale bars, 50um.  
 
7.3.4.  Contribution  of   Emx1-  and  Gsh2-derived  populations  cortical  and  striatal 
interneurons. 
In order to assess the contribution of Emx1- and Gsh2-derived cells to neurogenesis following  
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ischaemia in the striatum or cortex, we must first assess the extent to which Emx1- and Gsh2-
derived neurons are present in the normal brain. In the current literature this has been assessed at the 
olfactory bulb but not in the cortex or striatum (Young et al, 2007). We used the contralateral, non-
ischaemic  hemisphere  as  a  control,  to  determine  the  normal  contribution  of  Emx1-  and  Gsh2-
derived cells to the interneuron populations in the adult cortex and striatum. In Gsh2-Cre/R26-GFP  
transgenics, both YFP+ and YFP- interneurons were observed to coexpress with NeuN (neuronal), 
Calretinin, Calbindin, Parvalbumin, and NPY in both the striatum and cortex (interneurons; Figure 
7.3.4.1). This is expected as developmentally Gsh2-derived cells are known to contribute to the 
neuronal population in the striatum as well as to give rise to interneuron populations in the cortex. In 
Emx1-Cre/R26-GFP  transgenics,  we  observed  that  Emx1-derived  cells  contributed  to  cortical 
neuron  population,  which  is  consistent  with  findings  demonstrating  that  this  developmental 
population gives rise to neurons in the cortex. We also observed YFP co-expression with NeuN and 
Crt in the striatum, which may indicate that some Emx1-derived cells can give rise to striatal neurons. 
This is an unexpected result and further quantification of these observations is necessary to confirm 
this finding. One other study (Willaime-Morawek et al, 2008) found that Emx1-derived neural stem 
cells give rise to a small proportion of striatal neurons expressing NeuN, Calretinin, Calbindin or 
DARPP32. At 5 weeks post-ischaemia, few or no BrdU+ YFP+ interneurons were observed in 
Gsh2-Cre/R26-GFP transgenics in the ipsilateral cortex or striatum (not shown), suggesting that 
NSC dividing between 2-4 days post-ischaemia do not give rise to mature interneurons.   
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Figure  7.3.4.1.  Contribution  of  Emx1-  and  Gsh2-derived  populations  cortical  and  striatal 
interneurons.  Contralateral (control) striatum and cortex at 5W post-ischaemia. Red, interneuron markers 
(NeuN, neuron; NPY, neuropeptide Y; Crt, calretinin; Cb, calbindin; PV, parvabumin. Green, GFP.  Arrows 
denote  GFP+  interneuron+  cells.  Left,  Gsh2-Cre/R26-GFP    transgenic.  Right,  Emx1-Cre/R26-GFP  
transgenic. Scale bars, 30um.  
 
Very few BrdU+ NeuN+ or interneuron marker-positive (calretinin, calbindin, NPY, parvabumin) 
cells were observed in the peri-infarct region, ipsilateral or contralateral cortex or striatum. Figure  
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3.4.2  A  shows  a  BrdU+  NPY+  GFP-  cell  in  the  ipsilateral  striatum  of  Gsh2-Cre/R26-GFP  
transgenic  at  5-weeks  post-ischaemia.  BrdU+  YFP+  cells  were  also  observed  in  the  cortex  and 
striatum (Figure 7.3.4.2 B). These cells may be proliferating astrocytes or oligodendrocyte precursors 
whose developmental origin was Gsh2 or Emx1 embryonic telencephalic regions. The observed 
BrdU+  YFP-  cells  may  represent  proliferating  microglia.  These  results  may  indicate  that  cells 
proliferating at 2 to 4 days post-ischaemia in the SVZ have a low contribution to post-ischaemia 
neurogenesis, and may have died by the 5 week timepoint. In conclusion, both Gsh2- and Emx1-
derived NPC at the SVZ respond to cerebral ischaemia by proliferation and migration to the lesion 
site by 5 weeks post-ischaemia.  
 
Figure 7.3.4.2. Cell proliferation in the ischaemic hemisphere at 5W post-ischaemia in the Gsh2-
Cre/R26-GFP  transgenic  mouse.  A,  BrdU+  NPY+  double-immunolabelled  interneuron  (arrow)  in  the 
ischaemic striatum. B, GFP+ BrdU+ NeuN- cell in the ischaemic striatum (arrow). Scale bars, 30 um. Insets, 
high magnification of cells. 
 
7.3.5.  MRI and ischaemic lesion in PDGFRα-CreERt2/R26-YFP  mice 
At  1  week  post-ischaemia,  lesions  in  PDGFRα-CreERt2/R26-YFP  animals  were  predominantly 
located in the striatum (Figure 7.3.5.1). At 3 and 5 weeks, lesions were not apparent on MRI images, 
but  could  be  detected  with  hematoxylin-eosin  staining  on  histological  sections  (Figure  7.3.5.1). 
Enlarged  ventricles  in  the  ipsilateral  hemisphere  were  also  observed  on  MRI  images.  These 
differences in lesion size and character may be due to modifications of the experimental protocol to 
include tamoxifen administration prior to MCAO surgery, and are considered in the Discussion 
section.   
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Figure 7.3.5.1. Ischaemic lesion in the PDGFRα-CreERt2/R26-YFP-iCreERT2 transgenic mouse. 
Top row, Coronal spin-echo MRI images of the MCA territory at 1, 3, and 5 weeeks post-ischaemia. Bottom 
row, hematoxylin-eosin histological stain in the contralateral (non-ischaemic) and ipsilateral (ischaemic) cortex. 
Scale bars, 50 um.  
 
7.3.6.  Distribution of  YFP+ cells post-ischaemia 
We assessed the distribution of YFP+ cells in the ipsilateral and contralateral cortex, striatum and 
corpus callosum at 1 week post-ischaemia.  We observed an increase in YFP+ cells in the ipsilateral 
striatum, relative to all other groups: contralateral striatum, contra- and ipsilateral cortex and corpus 
callosum (ANOVA, p<0.001; Figure 7.3.7.1G). We did not observe any difference in YFP+ cell 
distribution between ipsilateral and contralateral hemispheres in the cortex or corpus callosum at 1 
week  post-ischaemia.  This  pattern  of  YFP+  cell  distribution  remained  similar  at  5  weeks  post-
ischaemia. YFP+ cells remained elevated in the ipsilateral striatum relative to the contralateral side, 
cortex and corpus callosum (Fig 7.3.7.1G; ANOVA, p<0.001).  
 
7.3.7.  Fate of  PDGFRα-CreERt2/R26-YFP- expressing cells  
Next, we assessed the fate of YFP+ cells in the ischaemic brain. OLP-derived cells may take a 
number  of  differentiation  pathways  following  ischaemia:  they  may  remain  undifferentiated  (1); 
differentiate into mature oligodendrocytes or neurons (2); or differentiate into astrocytes or another 
unknown cell type (3). We initially assessed the first two scenarios, as previous studies confirm that 
OLPs have the capacity to differentiate into neurons in vivo.   
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We observed that a proportion of YFP+ cells remained undifferentiated OLPs in all brain regions, as 
characterised by NG2 expression. At 1 week post-ischaemia, the proportion of YFP+ NG2+ cells 
was comparatively consistent across brain regions and hemispheres except in the ipsilateral striatum, 
where  we  observed  a  decrease  in  the  percentage  of  YFP+NG2+  cells  (ANOVA,  p<0.005;  Fig 
7.3.7.1). We observed some YFP+NG2+ cells that were also BrdU+, indicating that that these cells 
were generated after the ischaemic event (Fig 7.3.7.2). These results suggest that OLP proliferate in 
response to cerebral ischaemia, but the newly generated cells do not remain as undifferentiated OLP.   
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Figure 7.3.7.1. Distribution of YFP+ cells at 5W post-ischaemia in PDGFRa-CreERT2/R26-YFP 
transgenic mouse. A-F, YFP (green) and NG2 (red) expression in the corpus callosum (CC; A,B), cortex 
(CTX; C,D), and striatum (STR; E,F) in the ischaemic (A,C,E) and contralateral control (B,D,F) hemispheres. 
G, YFP+ cell counts in the ipsilateral ischaemic and contralateral control corpus callosum, cortex, and striatum. 
H, YFP+ NG2+ double immunolabelled cells as a percentage of total YFP+ cells in the ipsi- and contralateral 
corpus callosum, cortex and striatum. Scale bars, 50um.   
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Figure 7.3.7.2. Proliferation of OLPs following cerebral ischaemia. BrdU+ GFP+ NG2+ cells in the 
ischaemic cortex and striatum at 5W post-ischaemia in the PDGFRa-iCreERT2 transgenic mouse. Arrows 
denote triple-immunolabelled cells. Scale bar, 50 um.  
 
We then examined whether the YFP+ cells were differentiated mature oligodendrocytes. CNP is an 
early  marker for  mature  myelinating  oligodendrocytes.  At  1-,  3-  (not shown)  and  5-weeks  post-
ischaemia,  we  observed  both  YFP+  CNP+  and  YFP+CNP-  cells  in  all  brain  regions:  ipsi-  and 
contralateral striatum, cortex and corpus callosum (Figures 7.3.7.3G-L). These results indicate that 
OLPs can contribute to oligodendrogenesis from early stages following cerebral ischaemia.  
We  also  examined  whether  YFP+  cells  differentiated  into  neurons  (Figure  7.3.7.3  A-E).  In  the 
sections studied, we did not observe any YFP+NeuN+ cells at 1 week or 5-weeks post-ischaemia in 
the contralateral or ipsilateral striatum, cortex or corpus callosum, excluding the piriform cortex 
which  was  not  counted.  These  preliminary  results  suggest  that  OLP  do  not  contribute  in  any 
significant amount to neurogenesis outside of the piriform cortex.   
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Figure 7.3.7.3. Identity of YFP+ cells at 5W post-ischaemia. A-F, NeuN and YFP expression in the 
corpus callosum (A,B); cortex (C,D); and striatum (E,F) in the ipsilateral ischaemic (A,C,E) and contralateral 
control (B,D,F) hemispheres. No NeuN+ YFP+ cells were observed. G-L, CNP expression in the corpus 
callosum (G,H); cortex (I,J); and striatum (K,L) in the ipsilateral (G,I,K) and contralateral (H,J,L) hemispheres. 
Arrows denote CNP+ YFP+ double-immunolabelled cells. M, N, PSA-NCAM and GFP expression at the 
SVZ. No PSA-NCAM+ YFP+ cells were observed. Scale bars, 50 um.  
 
7.4.  Discussion:  
In this study, we explore the fate of different populations of endogenous progenitors in the brain 
following cerebral ischaemia: neural stem and progenitors in the SVZ, and oligodendrocyte precursor 
cells (OLPs).  
7.4.1.  Gsh2/Emx1 neural stem and progenitor cells 
In this study, the reduction in ipsilateral hemisphere volume over time may represent secondary, 
delayed neuronal death in the ischaemic hemisphere, lesion compaction, brain reorganisation or a 
combination of these factors  
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Although we only observed neuroblast migration from the SVZ into the striatum and not into the 
cortex after ischaemia, these neuroblasts were a mixed population originating from Gsh2- and Emx1-
derived neural stem cells. The restriction of migration to the striatum following focal middle cerebral 
artery  occlusion  has  been  previously  reported  (Arvidsson,  2002).  Our  results  suggest  that  the 
embryonic lineage of the distinct neural stem cell populations in the SVZ does not restrict their 
capacity to migrate, as we observed both embryonic cortex (Emx1) and embryonic striatum (Gsh2) 
derived neuroblast migration in the striatum. 
Lack of neuroblast migration to the cortex may be a result of several factors. Neuroblasts must cross 
the corpus callosum to reach the cortex from the SVZ. We observed neuroblast migration from the 
dorsolateral corner of the SVZ and along the ventral edge of the corpus callosum where it meets the 
striatum. The corpus callosum may therefore be a barrier to neuroblast migration, or create a barrier 
for chemoattractive cues originating in the ischaemic cortex. In models of cerebral ischaemia where 
the lesion is exclusively in the cortex, neuroblast migration to the lesion boundary has been observed 
(Moorshead),  which  suggests  that  SVZ  neuroblasts  are  able  to  overcome  the  corpus  callosum 
boundary. Alternatively, the inflammatory response in the cortex may be different from that of the 
striatum, and may lack migratory cues for neuroblast recruitment. Finally, there may be a latent 
migration to the cortex that occurs later than neuroblast migration to the striatum, which peaks at 4-5 
weeks post-ischaemia.  
In this study, BrdU was administered between 48 and 96 hours post-ischaemia. We observed BrdU+ 
neuroblasts at the SVZ at 1 week post-ischaemia, but few BrdU+ neurons in the ischaemic striatum 
at  5  weeks  post-ischaemia.  This  suggests  that  the  proliferation  at  the  SVZ  during  this  time 
contributes little to neurogenesis in the lesion. It is possible that SVZ proliferation at later timepoints 
contributes more to neurogenesis post-ischaemia, and there are several options for evaluating this.   
In future studies, a cumulative approach to labelling could be used. BrdU could be administered over 
longer  periods,  for  example  by  adding  BrdU  to  the drinking  water  over several  days  or  weeks. 
Alternatively, additional groups could be included in the study to examine proliferative activity at 7 
days  and  10  days  post-ischaemia  in  Gsh2-Cre/R26-GFP  and  Emx1-Cre/R26-GFP    mice. 
Immunohisochemistry with mitotic markers would also give an indication of cell proliferation at each 
timepoint. 
Caution must be used when interpreting BrdU activity in cell stress environments such as cerebral 
ischaemia. Damaged or degenerating neurons can also express mitotic markers and initiate DNA 
synthesis while undergoing DNA repair or apoptosis (Rakic, 2002). Under normal conditions the 
level of DNA repair in the brain is low (Schmitz et al., 1999), and BrdU immunohistochemistry is not 
sensitive enough to detect this activity. And even after inducing DNA damage by ionising radiation, 
BrdU  has  not  been  detected  by  immunohistochemistry  in  vivo  or  in  vitro  (Taupin,  2007).  The  
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sensitivity may be due to the levels of BrdU incorporation into the cell, where proliferation involves 
the replication of the entire genome, and DNA repair replaces approximately 100 nucleotides per 
repair site  (Taupin,  2007). However,  Pawelczyk  et  al recently  demonstrated  that  BrdU  could  be 
transferred  from  BrdU-labelled  cells  to  macrophages  in  an  in  vitro  Boyden  chamber  model  of 
inflammation, albeit in small quantities (Pawelczyk et al., 2008).  
Immunohistochemistry with mitotic markers are a secondary option for assessing cell proliferation 
and would give an indication of cell proliferation at the time of sacrifice – eg at 1, 3 and 5 weeks 
post-ischaemia. However, some markers of mitosis may also be upregulated during DNA repair. 
PCNA is expressed in the DNA synthesis phase of replication, G1 and S-phase, but under cell stress 
is  involved  in  the  RAD6-dependednt  DNA  repair  pathway.  Phospho-histone  3  is  involved  in 
chromosome  condensation  during  mitosis,  is  not  recruited  into  DNA  repair  pathways,  and  is 
commonly used as a marker for cell proliferation in in vitro DNA damage studies.  Ki-67 is expressed 
in  the  G1,  S  and  G2  phases  of  the  cell  cycle,  and  is  also  used  as  a  marker  in  DNA  damage 
studies(Hall et al., 1993; Iatropoulos and Williams, 1996). 
 
7.4.2.  PDGFRα-CreERt2/R26-YFP  
We observed an increase in proliferation of OLPs in the ischaemic lesion. Few studies have examined 
the  role  of  oligodendrocyte  precursors  after  ischaemia.  Our  results  suggest  that  they  proliferate 
locally in response to ischaemia, however their long-term fate remains unknown. We found that the 
majority of OLPs did not express NG2 at 1 week post-ischaemia, suggesting that by this timepoint 
they  were  undergoing  differentiation.  We  identified  CNP+  cells  at  1  week  and  5  weeks  post-
ischaemia,  however  the  majority  of  GFP+  cells  were  CNP-negative,  suggesting  the  OLP 
differentiation was not predominantly into mature oligodendrocytes. Our results do not suggest that 
OLPs are a contributor to post-ischaemic neurogenesis, although it is possible that a very small 
percentage can differentiate into neurons.  
What  is  the  fate  of  the  OLP  progeny?  Do  the  OLP  progeny  contribute  to  injury  or  repair 
mechanisms after ischaemia? There is scope for the role of the OLPs following ischaemia to be 
further  explored.  It  is  possible  that  while  OLPs  do  not  mature  fully  into  myelinating 
oligodendrocytes after ischaemia, they begin differentiation into an intermediate cell type and retain 
an  oligodendroglial  identity.  Immunohistochemistry  for  oligodendroglial  markers  such  as  Sox10 
could determine if OLPs in the ischaemic lesion exit the oligodendroglial lineage. Similarly, while we 
observed very few NeuN- or interneuron-positive cells at 5 weeks post-ischaemia in the ipsilateral 
striatum  and  cortex,  it  is  possible  that  OLPs  were  differentiating  into  immature  neuronal  cells. 
Immunohistochemistry for early neuronal markers such as β3-tubulin would determine whether a 
larger proportion of OLPs were contributing to neurogenesis. Finally, it is possible that OLPs are  
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differentiating into other glial cell types, for example astrocytes. 
In contrast to the Gsh2-Cre/R26-GFP  and Emx1-Cre/R26-GFP  transgenic lines, the use of the 
inducible PDGFRα-CreERt2/R26-YFP -CreERT2 transgenic allowed us to define the initiation of 
GFP expression, and to selectively label the OLP population immediately prior to cerebral ischaemia. 
Our  data  therefore  represent  the  fate  of  resident  OLP  at  the  time  of  ischaemia.  However,  we 
encountered several limitations in using this model. Induction of GFP expression requires Tamoxifen 
treatment, which we administered by gavage between 7 and 2 days prior to MCAO surgery, allowing 
2 days for wash out. Initially, we observed a high mortality in these animals relative to the Gsh2-
Cre/R26-GFP  and Emx1-Cre/R26-GFP  transgenic lines. Tamoxifen is a selective estrogen receptor 
modulator, and is commonly used in treatment for breast cancer. Its activity on estrogen receptors 
has been exploited in this transgenic line to selectively activate Cre recombinase in cells expressing 
the  estrogen  receptor  2  under  the  PDGFRα-CreERt2/R26-YFP  promotor.  However,  there  are 
several known side effects of Tamoxifen, including the increased risk of blood clotting and stroke, as 
well as fatigue, nausea and pain. Tamoxifen has also been shown to be neuroprotective following 
cerebral ischaemia (Wakade et al., 2008; Zhang et al., 2007b; Zhang et al., 2005b).  
 
7.4.3.  Animal mortality and lesion variability  
We  observed  increased  mortality  in  the  PDGFRα-CreERt2/R26-YFP  -CreERT2  transgenic  line. 
Mortality  resulting  from  the  MCAO  surgery  itself  was  kept  to  a  minimum  (less  than  2%)  by 
minimising  tissue  damage  at  the  neck  area,  minimising  the  surgery  time,  working  in  a  sterile 
environment, and the post-operative care procedure. Tamoxifen treatment has known side effects, 
and additionally mice may have increased stress from extensive handling and gavage. Though the age 
of all mice in the study was 3 to 4 months of age, the mean weight of the PDGFRα-CreERt2/R26-
YFP -CreERT2 mice was the lowest of all groups, suggesting that the mice may have been stressed. 
In future studies, it will be important to weigh mice prior to Tamoxifen treatment as well as at regular 
intervals following ischaemia.  
We also observed a different lesion pathology in the PDGFRα-CreERt2/R26-YFP -CreERT2 mice, 
where  the  lesion  was  restricted  to  the  striatum  at  1  week  post-ischaemia,  and  lesions  were  not 
detectable on MRI at 3- and 5-weeks post-ischaemia. A similar observation was reported by Wegener 
et al, who describe exclusively subcortical infarctions after MCAO surgery, which ‘were characterised 
by a complete resolution of initially increased T1 and T2 relaxation times by 10 weeks (Wegener et 
al., 2006). Consistent with our findings, the authors detected selective neuronal death and gliosis in 
histological lesions.  
It is possible that the vasculature of this transgenic line differs slightly from the Gsh2-Cre/R26-GFP   
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and Emx1-Cre/R26-GFP  mice and could lead to a different lesion type. It is also possible that the 
combined use of carprofen and Tamoxifen conferred neuroprotection to the mice which resulted in a 
reduced lesion volume. There is scope for optimisation of the timing of Tamoxifen administration, 
post-operative care and monitoring will be undertaken to improve mortality rates and lesion volume, 
if possible in future studies.  
 
7.4.4.  Future work   
There is opportunity for further work resulting from our findings. The contribution of Gsh2 and 
Emx1-derived cells to neuroblast generation after stroke can be quantified. Neuroblasts in the rostral 
migratory  stream  may  proliferate  or  exit  the  stream  in  response  to  ischaemia,  and  this  can  be 
characterised. As discussed above, BrdU administration protocols can be modified or extended to 
label more proliferating neural stem cells, and the contribution of Gsh2- and Emx1-derived cells to 
the generation of mature neurons can be further characterised. 
Futher  work  will  include  further  characterisation  of  the  fate  of  the  OLP  progeny,  as  well  as 
investigation of the contribution of OLPs to neurogenesis in the piriform cortex. Finally, MRI was 
performed at the final timepoint on a 2.35T system, for quantification of lesion volume. In future 
studies, longitudinal data may be acquired in mice up to the final timepoint, to assess the evolution of 
lesion volume. In this study we observed a decrease in mean lesion volume at later timepoints. 
However, due to the high mortality rate, it is unclear whether mice surviving have smaller lesion 
volumes, or whether, consistent with other studies and our findings in the rat, lesion size decreases in 
individual animals at later timepoints. In vivo imaging using high-field system will increase spatial 
resolution, and imaging of physiological parameters such as cerebral blood flow and oedema could 
further characterise the infarct core and penumbra (Weber et al., 2005).  
These experiments will provide essential knowledge into possible targets for the directed exploitation 
of SVZ stem cell populations in order to enhance endogenous brain repair. This study will also 
determine the contribution of each stem cell population to neurogenesis following injury. Better 
understanding of these issues will contribute to our knowledge of CNS injury, and may identify 
therapeutic targets.  
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8.  Discussion 
This thesis investigated methods of labeling and tracking of endogenous or grafted neural progenitor cells 
using MRI contrast agents, and their potential application to in vivo imaging of NPC migration after cerebral 
ischaemia. Cell labelling with iron oxide MRI contrast agents was optimised, and novel gadolinium-based 
MRI contrast agents were characterized. Labelled cells could be imaged in vivo in a model of cerebral 
ischaemia, but endogenous, pathological sources of iron oxide were also observed, and confounded cellular 
imaging. A method of in situ labelling of endogenous NPC with MRI contrast agents was developed and 
optimised, and endogenous NPC migration following cerebral ischaemia was investigated by transgenic 
lineage tracing. In the future, these approaches could be combined to longitudinally track subpopulations of 
SVZ NPC after cerebral ischamia.  
 
First, an iron oxide-based MRI contrast agent and labelling method was investigated and optimized in vitro 
in a fetal NPC cell culture model. The FePro contrast agent labelling method maximised iron oxide uptake 
by cells, relative to incubation with Endorem alone, and generated hypointense contrast on MRI images. In 
addition, the FePro contrast agent was non-toxic to NPC, did not alter labelled cell metabolism relative to 
control cells, and did not interfere with NPC neurosphere formation or differentiation. In vivo cell tracking 
of FePro-labelled cells was then investigated in a model of cerebral ischaemia, where grafted cells were 
imaged over four weeks after cerebral ischaemia. Grafted cells were identified at the lesion site on MRI 
images, but an endogenous hypointense contrast was also observed to evolve over time within the lesioned 
tissue, in all animals. Endogenous ferric iron was observed in the lesion on histological sections. In addition 
to investigating the source of endogenous iron following ischaemia, there is scope to optimise other study 
parameters to increase graft survival and migration after ischaemia. These can include the timepoint and 
location of the graft, and the use of immunosuppressant drugs.  
This study raises important issues surrounding the use of MRI and MRI contrast agents for longitudinal cell 
tracking studies in models of injury, where the evolution of endogenous contrast over time within lesioned 
tissue  can  be  a  source  of  uncertainty  in  image  interpretation.  Blood  brain  barrier  breakdown, 
microhemorrhage and iron dysregulation after ischaemia, leading to iron accumulation in the lesion, are 
possible causes of the evolution of T2 hypointensity, and delayed neuronal death. Brain iron accumulation 
after the ischaemic event may contribute to the development of a neurotoxic environment that leads to 
delayed neuronal death. The sources of iron are likely from both the degradation of blood products as a 
consequence  of  BBB  breakdown  or  microhemorrhages  following  the  ischaemic  insult,  as  well  as 
endogenous brain iron stores which may contribute to, and exacerbate, free radical damage after ischaemia. 
Together, the studies described above confirm our observation that the evolution of the ischaemic lesion is 
a dynamic process occurring over several weeks following cerebral ischaemia, and delayed neuronal death 
may reshape the lesion at later time points.  
Next, we considered the development of gadolinium-based MRI contrast agents for cellular labeling and  
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tracking, as an alternative to the iron oxide-based agents, in collaboration with Imperial College chemistry 
department. Monomeric and polymeric Gd-DOTA chelates were synthesized and designed for maximal r1 
relaxivity,  and  their  relaxivity  and  effects  on  cell  viability  were  assessed.  Through  this  approach,  we 
identified a number of candidate polymeric Gd-DOTA chelates with high relaxivity and low cytotoxicity for 
use in cellular imaging and tracking studies.  
For monomers, r1 and r2 relaxivity were lower than Gd-DOTA or Gd-DTPA, at 2.35T and 9.4T. For all 
monomers, r1 and r2 relaxivity were lower at 9.4T than 2.35T. Cell viability for monomer-labelled cells was 
not different than control cells, and cells could be labelled and imaged using MRI. While T1-weighted 
positive contrast was observed in monomer 56, hypointense contrast was observed in monomers 60 or 72, 
possibly due to T2 effects of these monomer becoming dominant within labelled cells. Electron microscopy 
analysis will be necessary to determine the internal localisation of the contrast agents. The chemistry of the 
monomer branching arms appears to have a significant effect on cell labelling, and T1 and T2.  
Although the mean number of monomer units in the polymers was lower than expected, several partially-
loaded polymers has greater r1 relaxivity than the monomer from which it was synthesized, whereas this 
was not observed with any of the 100%-loaded polymers. Optimising the synthesis reaction to obtain higher 
molecular weight polymers with greater monomer units per polymer may lead to a further increase in r1 
relaxivity. Cell viability was reduced for polymers, relative to control cells and gadolinium monomers, and 
viability assays were confirmed with microscopy. Monomer 72, the ligand from which the polymer was 
synthesised, did not affect cell viability in Alamar Blue or MTT assays, so the viability effects may be due to 
the  polymer  size  or  the  presence  of  diazides.  This  must  be  further  investigated  for  polymers  to  be 
considered candidate contrast agents for cellular imaging. For optimal contrast agent design, compound 
chemistry, relaxivity, and cytotoxicity must all be considered at early stages of design. 
To investigate the endogenous NPC population, a method of in situ labeling of endogenous NPC with the 
MRI contrast agent FePro was developed. In this study we demonstrate that NPC and neuroblasts can be 
labelled with MRI contrast agents at the SVZ, and migrating neuroblasts can be visualised using MRI in the 
RMS at low magnetic field strength. Histology confirmed that neuroblasts within the RMS were labelled 
with the FePro complex. These results may facilitate the study of neuroblast migration by establishing a 
methodology for in vivo labelling and monitoring of the endogenous population.   
The in vivo imaging of neuroblasts was achieved using a smaller injection concentration of iron oxide than 
previously reported, and without the addition of growth factors to promote cell labelling at the SVZ. The 
reduced susceptibility effects at the injection site, due to the smaller injection volume, will also permit 
imaging  the  short  distance  migration  of  neuroblasts  in  pathological  environments,  for  example,  their 
migration from the SVZ into the striatum following cerebral ischaemia. If there is endogenous neuroblast 
migration from the SVZ following an injury, it should be apparent using this method.  
This method of endogenous labelling of the SVZ with FePro complex has some limitations in that we 
observed a low number of labelled neuroblasts, particularly at longer distances from the injection site. These  
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studies demonstrate that MRI contrast agents offer the potential for in vivo, longitudinal tracking of NPC 
migration, in both grafted and endogenous NPC populations. Coupled with transgenic lineage tracing, and 
used in animal models of CNS injury such as cerebral ischaemia, labeling and tracking the migration of NSC 
with  MRI  contrast  agents  can  contribute  to  our  understanding  of  NPC  biology  in  pathological 
environments.   
We use transgenic lineage tracing to explore the fate of different populations of endogenous progenitors in 
the  brain  following  cerebral  ischaemia:  neural  stem  and  progenitors  in  the  SVZ,  and  oligodendrocyte 
precursor cells (OLPs). We observed neuroblast migration from the SVZ into the striatum after ischaemia, 
and these neuroblasts were a mixed population originating from Gsh2- and Emx1-derived neural stem cells. 
Further  assessment  of  the  contribution  of  neuroblasts  to  neurogenesis  and  newborn  neurons  after 
ischaemia is the subject of future studies.   
We also observed an increase in proliferation of OLPs at the ischaemic lesion. We found that the majority 
of OLPs did not express the OLP marker NG2 at 1 week post-ischaemia, suggesting that by this timepoint 
they were undergoing differentiation. We identified CNP+ myelin-producing oligodendrocyte cells at 1 
week and 5 weeks post-ischaemia, however the majority of GFP+ cells were CNP-negative, suggesting the 
OLP differentiation was not predominantly into mature oligodendrocytes. The fate of proliferating OLPs 
after ischaemia remains uncertain, and is the subject of future studies. Our results do not suggest that OLPs 
are a contributor to post-ischaemic neurogenesis, although it is possible that a very small percentage can 
differentiate into neurons.  
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